var title_f18_7_18544="Screening mammography";
var content_f18_7_18544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Type of information average-risk women should have when participating in shared decision making about screening mammography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 607px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chances among 1000 women who undergo annual screening mammography for 10 years: (A) of experiencing a false-positive mammogram, undergoing a breast biopsy, and developing breast cancer, and (B) being cured of breast cancer regardless of screening, being diagnosed with noninvasive breast ductal carcinoma in situ because of screening, and averting death from breast cancer because of screening mammography.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher RH, Fletcher SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18544=[""].join("\n");
var outline_f18_7_18544=null;
var title_f18_7_18545="Esophageal perforation buttressed with intercostal muscle flap";
var content_f18_7_18545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal perforation buttressed with intercostal muscle flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 465px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the repair of an esophageal perforation with an intercostal muscle patch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18545=[""].join("\n");
var outline_f18_7_18545=null;
var title_f18_7_18546="Patient information: Preserving fertility after cancer treatment in children (The Basics)";
var content_f18_7_18546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83955\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"         Male reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"          Female reproductive anatomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/50/31523\">",
"         Patient information: Hodgkin lymphoma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/40/24194\">",
"         Patient information: Leukemia in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/1/30738\">",
"         Patient information: Normal sexual development (puberty) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/preserving-fertility-after-cancer-treatment-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H196197934\">",
"      <span class=\"h1\">",
"       What is fertility?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Fertility is the term doctors use to describe a woman&rsquo;s ability to get pregnant or a man&rsquo;s ability to father a child. &ldquo;Preserving fertility after cancer treatment&rdquo; involves taking steps before or during cancer treatment to help people&rsquo;s chances of having children after cancer treatment.",
"     </p>",
"     <p>",
"      It might seem strange to think about your child&rsquo;s fertility when he or she is young. But it&rsquo;s important to think about this issue before your child starts cancer treatment. That&rsquo;s because some types of cancer treatments can cause fertility problems, even years later.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196197949\">",
"      <span class=\"h1\">",
"       Which cancer treatments can cause fertility problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer treatments that can cause fertility problems include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation involves getting high doses of X-rays.",
"       </li>",
"       <li>",
"        Surgery &ndash; If the sex organs are removed or damaged during treatment, girls won&rsquo;t be able to get pregnant or will have trouble getting pregnant later in life. Or boys won&rsquo;t be able to father a child or will have trouble fathering a child later in life. The sex organs include the testicles (in boys) and the ovaries and uterus (in girls) (",
"        <a class=\"graphic graphic_figure graphicRef68075 \" href=\"UTD.htm?21/43/22194\">",
"         figure 1",
"        </a>",
"        and",
"        <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Both chemotherapy and radiation can damage cells in the male and female sex organs.",
"     </p>",
"     <p>",
"      But not everyone who gets chemotherapy or radiation will have fertility problems. With chemotherapy, it depends on the medicine and dose a person gets. With radiation, it depends on the dose and part of the body treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196198009\">",
"      <span class=\"h1\">",
"       What should I do if I want to preserve my child&rsquo;s fertility?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should talk with your child&rsquo;s doctor",
"      <strong>",
"       BEFORE",
"      </strong>",
"      your child starts cancer treatment. Treatments that have a lower chance of affecting future fertility might be available.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196198024\">",
"      <span class=\"h1\">",
"       Are there other ways to preserve fertility?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. They depend on your child&rsquo;s sex and whether he or she has gone through puberty.",
"     </p>",
"     <p>",
"      For boys and girls who have not yet gone through puberty, the main way to preserve fertility is to shield the sex organs during radiation treatment. This involves wearing a special type of shield on the outside of the body. The shield covers and protects the sex organs, so they aren&rsquo;t damaged by the radiation.",
"     </p>",
"     <p>",
"      For boys who have gone through puberty, ways of preserving fertility can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Shielding the testicles during radiation treatment",
"       </li>",
"       <li>",
"        Sperm banking &ndash; This involves collecting and freezing sperm before cancer treatment starts. To collect the sperm, your child will need to ejaculate. If he can&rsquo;t, or if there is no sperm in the semen, the doctor can do a procedure to remove sperm from the testicle. After the sperm is collected, it is frozen and stored until needed.",
"       </li>",
"       <li>",
"        Freezing and storing small pieces of tissue from the testicle &ndash; Doctors are still testing this procedure to see if it works.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For girls who have gone through puberty, ways of preserving fertility can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Shielding the ovaries or uterus during radiation treatment",
"       </li>",
"       <li>",
"        Moving the ovaries &ndash; If a girl&rsquo;s ovaries are in the path of the radiation, the doctor can move them slightly to keep them from getting damaged.",
"       </li>",
"       <li>",
"        Freezing and storing eggs or small pieces of tissue from the ovary",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196198039\">",
"      <span class=\"h1\">",
"       How do I decide which option is right for my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The best way to preserve your child&rsquo;s fertility depends on your child&rsquo;s cancer, treatment, age, and individual situation. Talk with your child&rsquo;s doctor about the possible choices. To make your decision, you might want to think about:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The benefits and downsides of the choices",
"       </li>",
"       <li>",
"        How well the doctor thinks they will work",
"       </li>",
"       <li>",
"        How much they cost &ndash; For example, it costs money to collect, freeze, and store sperm. Health insurance sometimes pays for these things.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196198056\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/50/31523?source=see_link\">",
"       Patient information: Hodgkin lymphoma in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/40/24194?source=see_link\">",
"       Patient information: Leukemia in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=see_link\">",
"       Patient information: Normal sexual development (puberty) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/7/18546?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83955 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18546=[""].join("\n");
var outline_f18_7_18546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196197934\">",
"      What is fertility?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196197949\">",
"      Which cancer treatments can cause fertility problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196198009\">",
"      What should I do if I want to preserve my child&rsquo;s fertility?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196198024\">",
"      Are there other ways to preserve fertility?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196198039\">",
"      How do I decide which option is right for my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196198056\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83955\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"      Male reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"       Female reproductive anatomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/50/31523?source=related_link\">",
"      Patient information: Hodgkin lymphoma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/40/24194?source=related_link\">",
"      Patient information: Leukemia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_7_18547="Patient information: Vaccines for children age 7 to 18 years (The Basics)";
var content_f18_7_18547=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15742\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?14/38/14956\">",
"         Recommended vaccine schedule for children age 7 to 18 years (United States, 2013)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/13/16594\">",
"         Patient information: Genital warts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/22/5475\">",
"         Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/43/3763\">",
"         Patient information: Meningitis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/38/36450\">",
"         Patient information: Whooping cough (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/18/37156\">",
"         Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/42/18084\">",
"         Patient information: Why does my child need vaccines? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaccines-for-children-age-7-to-18-years-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1482996907\">",
"      <span class=\"h1\">",
"       What are vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vaccines are treatments used to prevent certain serious or deadly infections. These infections can strike at any time in life. Vaccines work by preparing the body to fight the germs that cause the infections.",
"     </p>",
"     <p>",
"      Vaccines usually come in shots, but some come in nose sprays or medicines that children swallow. Vaccines are also called &ldquo;vaccinations&rdquo; or &ldquo;immunizations.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482996914\">",
"      <span class=\"h1\">",
"       Why should my child get vaccinated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Getting vaccinated can help keep your child from getting sick. If your child does get sick, being vaccinated can keep him or her from getting severely ill. Plus, being vaccinated helps protect the people around your child from getting sick.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482996921\">",
"      <span class=\"h1\">",
"       What vaccines do children age 7 to 18 get?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors recommend that children age 7 to 18 get vaccines to prevent the following infections:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Influenza (flu) &ndash; The flu can cause fever, chills, muscle aches, cough, or sore throat.",
"       </li>",
"       <li>",
"        Diphtheria, tetanus, and pertussis &ndash; Vaccines to prevent these 3 different diseases are usually grouped together in one shot. Diphtheria can cause a thick covering in the back of the throat that can lead to breathing problems. Tetanus causes the muscles to work abnormally. Pertussis, also called &ldquo;whooping cough,&rdquo; can cause a severe cough.",
"       </li>",
"       <li>",
"        Human papillomavirus (HPV) &ndash; HPV infection can lead to cancer of the cervix in women. It can also cause genital warts in men and women. Both girls and boys can get the HPV vaccine.",
"       </li>",
"       <li>",
"        Meningococcus &ndash; Meningococcus is a germ that can cause a serious body-wide infection of the blood or the tissues around the brain.",
"       </li>",
"       <li>",
"        Pneumococcus &ndash; Pneumococcus is a germ that can cause infections of the lungs, ears, blood, or tissues around the brain. Most children age 7 to 18 do not need this vaccine. But children who have certain medical conditions might need it.",
"       </li>",
"       <li>",
"        Hepatitis A &ndash; Hepatitis A does not usually cause problems in children, but it can cause severe liver disease in adults. Children who get the",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?10/58/11169?source=see_link\">",
"         hepatitis A vaccine",
"        </a>",
"        help prevent the adults around them from getting the infection. If your child never got this vaccine at a younger age, he or she might need to get it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some children will need other vaccines, such as scheduled vaccines they did not get when younger.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482996928\">",
"      <span class=\"h1\">",
"       How many vaccine doses does my child need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each vaccine is different. Some vaccines work after just one dose. Others need two or more doses to prevent an infection. Vaccines usually take a few weeks to start working.",
"     </p>",
"     <p>",
"      Some vaccines prevent an infection for the rest of your life. Others stop working well after some time. A &ldquo;booster&rdquo; is a vaccine dose given after a number of years. It reminds the body how to prevent an infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482996935\">",
"      <span class=\"h1\">",
"       At what ages will my child get vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different vaccines are given at different ages. Most healthy children follow a set vaccine schedule (",
"      <a class=\"graphic graphic_table graphicRef73404 \" href=\"UTD.htm?14/38/14956\">",
"       table 1",
"      </a>",
"      ). Even though doctors follow a set schedule, different children can get doses at different times. For example, many girls get the HPV vaccine at age 11 or 12. But they can get it any time from age 9 to 26.",
"     </p>",
"     <p>",
"      Children might not follow the usual vaccine schedule if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have certain medical problems",
"       </li>",
"       <li>",
"        Started getting their vaccines later than usual",
"       </li>",
"       <li>",
"        Started getting their vaccines on time, but then missed doses and fell behind schedule",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or nurse will recommend a vaccine schedule that is right for your child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482996942\">",
"      <span class=\"h1\">",
"       What side effects can vaccines cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Often, vaccines cause no side effects. When they do cause side effects, they can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Redness, mild swelling, or soreness where the shot was given",
"       </li>",
"       <li>",
"        A mild fever",
"       </li>",
"       <li>",
"        A mild rash",
"       </li>",
"       <li>",
"        Headache or body aches",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Vaccines also sometimes cause more serious side effects, such as severe allergic reactions. But serious side effects are rare.",
"     </p>",
"     <p>",
"      Ask your doctor or nurse what side effects to expect each time your child gets a vaccine. If your child has a reaction or a problem after a vaccine, let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482996949\">",
"      <span class=\"h1\">",
"       What if my child has an egg allergy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child has an egg allergy, let your doctor or nurse know. Some vaccines have egg in them because of how they are made. Your doctor or nurse will tell you which vaccines are safe to get.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482996956\">",
"      <span class=\"h1\">",
"       Should I keep track of my child&rsquo;s vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to keep a list of the vaccines your child gets and when he or she gets them. Many schools and camps need this information before they let a child in. You can keep your list up to date by bringing it to your check-ups.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482996963\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"       Patient information: Genital warts (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=see_link\">",
"       Patient information: Meningitis in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=see_link\">",
"       Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=see_link\">",
"       Patient information: Whooping cough (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       Patient information: Why does my child need vaccines? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/7/18547?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15742 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18547=[""].join("\n");
var outline_f18_7_18547=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482996907\">",
"      What are vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482996914\">",
"      Why should my child get vaccinated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482996921\">",
"      What vaccines do children age 7 to 18 get?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482996928\">",
"      How many vaccine doses does my child need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482996935\">",
"      At what ages will my child get vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482996942\">",
"      What side effects can vaccines cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482996949\">",
"      What if my child has an egg allergy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482996956\">",
"      Should I keep track of my child&rsquo;s vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482996963\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/38/14956\">",
"      Recommended vaccine schedule for children age 7 to 18 years (United States, 2013)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=related_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=related_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=related_link\">",
"      Patient information: Whooping cough (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_7_18548="Nasal packing posterior";
var content_f18_7_18548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Packing to control posterior epistaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prior to the availability of balloon catheters, tamponade was achieved by means of cotton packing. This process involves: A) feeding a small caliber rubber hose through the nose, retrieving it from the oropharynx, and attaching a cotton pack; B) the hose is then retracted through the nose, while digitally guiding the pack posteriorly, until it lodges against the posterior choana; C) a second cotton pack or gauze roll is secured against the nares to secure the hose. Balloon catheters are preferable. A foley catheter may be used (image D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Smelzter, SC, Bare, BG. Textbook of Medical-Surgical Nursing, 9th Ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2000. Copyright &copy;2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18548=[""].join("\n");
var outline_f18_7_18548=null;
var title_f18_7_18549="Cetirizine: Pediatric drug information";
var content_f18_7_18549=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cetirizine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"    see \"Cetirizine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/28/28100?source=see_link\">",
"    see \"Cetirizine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      All Day Allergy [OTC];",
"     </li>",
"     <li>",
"      ZyrTEC&reg; Allergy [OTC];",
"     </li>",
"     <li>",
"      ZyrTEC&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      ZyrTEC&reg; Children's Hives Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aller-Relief [OTC];",
"     </li>",
"     <li>",
"      Apo-Cetirizine&reg; [OTC];",
"     </li>",
"     <li>",
"      Extra Strength Allergy Relief [OTC];",
"     </li>",
"     <li>",
"      PMS-Cetirizine;",
"     </li>",
"     <li>",
"      Reactine [OTC];",
"     </li>",
"     <li>",
"      Reactine&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"      see \"Cetirizine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 months: 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 12-23 months: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-5 years: 2.5 mg/day; may be increased to a maximum of 5 mg/day given either as a single dose or divided into 2 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years to Adults: 5-10 mg/day as a single dose or divided into 2 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal or hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;6 years: Cetirizine use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-11 years: &lt;2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     11-31 mL/minute, hemodialysis, or hepatic impairment: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;11 mL/minute, not on dialysis: Cetirizine use not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid gel, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 5 mg/5 mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 5 mg/5 mL (5 mL, 118 mL, 120 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Children's Allergy: 5 mg/5 mL (118 mL) [contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Children's Allergy: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Children's Hives Relief: 5 mg/5 mL (118 mL) [contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     All Day Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as hydrochloride: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     All Day Allergy: 5 mg, 10 mg [fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Children's Allergy: 5 mg, 10 mg [grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes liquid gel capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect syrup from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms associated with perennial and seasonal allergic rhinitis; treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F148846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyrTEC&reg; may be confused with Lipitor&reg;, Serax, Xanax&reg;, Zantac&reg;, Zerit&reg;, Zocor&reg;, ZyPREXA&reg;, ZyrTEC-D&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyrTEC&reg; (cetirizine) may be confused with ZyrTEC&reg; Itchy Eye (ketotifen)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F148844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, fatigue, insomnia, malaise, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dry mouth, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, epistaxis, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggressive reaction, anaphylaxis, angioedema, ataxia, chest pain, confusion, convulsions, depersonalization, depression, edema, fussiness, hallucinations, hemolytic anemia, hepatitis, hypertension, hypotension (severe), irritability, liver function abnormal, nervousness, ototoxicity, palpitation, paralysis, paresthesia, photosensitivity, rash, suicidal ideation, suicide, taste perversion, tongue discoloration, tongue edema, tremor, visual field defect, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cetirizine, hydroxyzine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects including death have been reported. The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient.  Doses &gt;10 mg/day may cause significant drowsiness.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F148834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F148782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal use of cetirizine has not been associated with an increased risk of major malformations. The use of antihistamines for the treatment of rhinitis during pregnancy is generally considered to be safe at recommended doses. Although safety data is limited, cetirizine may be a preferred second generation antihistamine for the treatment of rhinitis during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cetirizine, a metabolite of hydroxyzine, competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the GI tract, blood vessels, and respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.5-0.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Exact fate is unknown, limited hepatic metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 6.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 7.4-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with mild-moderate renal failure: 19-21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% to 70% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: &lt;10% removed during hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/28/28100?source=see_link\">",
"      see \"Cetirizine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13141 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-D201336892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18549=[""].join("\n");
var outline_f18_7_18549=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148795\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148796\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057209\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057203\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148773\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148758\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057213\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057206\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057212\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148846\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148844\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057217\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057202\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057201\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148834\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148767\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148782\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057200\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057215\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057216\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057208\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13141\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13141|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=related_link\">",
"      Cetirizine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/28/28100?source=related_link\">",
"      Cetirizine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_7_18550="The orbital septum";
var content_f18_7_18550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    The orbital septum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram showing the proximity of the periosteum in relation to the orbital septum. Orbital cellulitis arises posterior to the orbital septum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18550=[""].join("\n");
var outline_f18_7_18550=null;
var title_f18_7_18551="Clinical manifestations and diagnosis of diabetic polyneuropathy";
var content_f18_7_18551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of diabetic polyneuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18551/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18551/contributors\">",
"     Eva L Feldman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18551/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18551/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18551/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18551/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/7/18551/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many forms of diabetic neuropathy including symmetric polyneuropathy, autonomic neuropathy, radiculopathies, mononeuropathies, and mononeuropathy multiplex (",
"    <a class=\"graphic graphic_table graphicRef59626 \" href=\"UTD.htm?7/11/7357\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=see_link\">",
"     \"Epidemiology and classification of diabetic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of diabetic polyneuropathy, also referred to as diabetic neuropathy, will be reviewed here. The pathogenesis and treatment of this disorder and the characteristics of the other forms of diabetic neuropathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=see_link\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=see_link\">",
"     \"Treatment of diabetic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic polyneuropathy is primarily a symmetrical sensory polyneuropathy, initially affecting the distal lower extremities. Ten to 18 percent of patients have evidence of nerve damage at the time their diabetes is diagnosed, suggesting that even early impairment of glucose handling, classified as prediabetes, is associated with neuropathy. With disease progression, sensory loss ascends and, when reaching approximately mid-calf, appears in the hands. This gradual evolution causes the typical \"stocking-glove\" sensory loss. This pattern reflects preferential damage according to axon length; the longest axons are affected first. Motor involvement with frank weakness occurs in the same pattern, but only later and in more severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest signs of diabetic polyneuropathy probably reflect the gradual loss of integrity of both large myelinated and small myelinated and unmyelinated nerve fibers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of vibratory sensation and altered proprioception reflect large-fiber loss",
"     </li>",
"     <li>",
"      Impairment of pain, light touch and temperature is secondary to loss of small fibers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decreased or absent ankle reflexes occur early in the disease, while more widespread loss of reflexes and motor weakness are late findings.",
"   </p>",
"   <p>",
"    Patients with prediabetes (defined by the American Diabetes Association as a fasting glucose of 100 to 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.6 to 6.9",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or a two-hour serum glucose between 140 and 199",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7.8 and 11.0",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    on an oral glucose tolerance test) may present with intensely painful feet. Patients with frank diabetic polyneuropathy may also present with pain, paresthesias, or dysesthesias of their feet. Some patients, however, have few complaints but the physical examination reveals mild to moderately severe sensory loss [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic polyneuropathy is frequently insidious in onset and can lead to formation of foot ulcers and muscle and joint disease. Progressive sensory loss predisposes to ulcer formation. Foot ulcers are usually classified into two groups: acute ulcers secondary to dermal abrasion from poorly fitting shoes; and chronic plantar ulcers occurring over weight-bearing areas. Chronic ulceration is probably multifactorial, due to a combination of diabetic neuropathy (with decreased pain sensation), autonomic dysfunction and vascular insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link\">",
"     \"Evaluation of the diabetic foot\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distal motor axonal loss results in atrophy of intrinsic foot muscles and an imbalance between strength in toe extensors and flexors. This ultimately leads to chronic metatarsal-phalangeal flexion (claw-toe deformity) which shifts weight to the metatarsal heads [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/3\">",
"     3",
"    </a>",
"    ]. This weight shift results in formation of calluses that can fissure, become infected and ulcerate. There may also be other arthropathic changes including collapse of the arch of the midfoot and bony prominences, leading to Charcot arthropathy, fragmentation and sclerosis of bone, new bone formation, subluxation, dislocation, and stress fractures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=see_link\">",
"     \"Diabetic neuropathic arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for regular monitoring (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Monitoring'",
"    </a>",
"    below) is the observation that the incidence of diabetic neuropathy (and other microvascular and macrovascular complications) increases over time. This was illustrated by a study from Finland that evaluated the natural history of peripheral neuropathy in patients with newly diagnosed type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/3\">",
"     3",
"    </a>",
"    ]. Polyneuropathy was diagnosed on the basis of both clinical (pain and paresthesia) and electrodiagnostic (nerve conduction velocity and response-amplitude values) criteria. The prevalence of definite or probable polyneuropathy progressively increased from 8.3 percent at baseline to 41.9 percent at 10 years; comparable values in normal subjects were 2.1 and 5.8 percent, respectively.",
"   </p>",
"   <p>",
"    In a later population-based study from Australia that evaluated patients with type 2 diabetes who had an average disease duration of about eight years, the prevalence of painful diabetic polyneuropathy was 26.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CRITERIA FOR DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discussion that follows regarding the diagnosis of diabetic polyneuropathy applies primarily to patients with an established diagnosis of diabetes mellitus. An overview of the diagnostic approach to suspected polyneuropathy in patients without diabetes or in those who have not yet been evaluated for diabetes is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of polyneuropathy\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, the diagnosis of diabetic polyneuropathy was based on subjective interpretation of a constellation of symptoms and signs such as loss of vibratory or light touch sensation and reduced or absent ankle reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/5\">",
"     5",
"    </a>",
"    ]. In 1988, a group of diabetologists and neurologists proposed a comprehensive set of criteria, the San Antonio Consensus statement, to diagnose and monitor diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/6\">",
"     6",
"    </a>",
"    ]. Using similar symptom scores, quantitative examination and electrophysiologic measurements, investigators at the Mayo Clinic placed patients in one of three classes of diabetic neuropathy.",
"   </p>",
"   <p>",
"    In 2005, an expert panel developed a case definition of distal symmetric polyneuropathy; most of the supporting evidence came from studies involving patients with diabetic polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/7\">",
"     7",
"    </a>",
"    ]. This polyneuropathy definition is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of polyneuropathy\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A third consensus panel convened in Toronto in 2009 and advocated that, for controlled clinical trials and epidemiologic studies of diabetic neuropathy, nerve conduction studies are needed for accurate assessment, and are coupled with assessments of symptoms and signs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Screening tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The San Antonio Consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/6\">",
"     6",
"    </a>",
"    ], the Mayo Clinic criteria and the Toronto criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/8\">",
"     8",
"    </a>",
"    ] are thorough and appropriate for research purposes. However, they are not practical in routine clinical practice. The need to identify simplified criteria has resulted in the development of several simple screening tests. Two will be discussed: one from the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/9\">",
"     9",
"    </a>",
"    ] and one which we developed at Michigan [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/10\">",
"     10",
"    </a>",
"    ]. These simple tools used to diagnose diabetic neuropathy do",
"    <strong>",
"     not",
"    </strong>",
"    include electrodiagnostic assessments with nerve conduction studies or quantitative sensory testing. These are discussed later. (See",
"    <a class=\"local\" href=\"#H114901971\">",
"     'Electrodiagnostic tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Accurate assessment of symptoms in diabetic polyneuropathy is known to be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/2\">",
"     2",
"    </a>",
"    ]. In developing the Michigan Neuropathy Screening Test described below, we hoped to assess both the symptoms as well as the key signs of diabetic neuropathy. A 15-item,",
"    <span class=\"nowrap\">",
"     yes/no",
"    </span>",
"    questionnaire which included 13 questions relevant to diabetic neuropathy, one to general asthenia and one to peripheral vascular disease was administered to all patients. We found that a similar number of patients with and without neuropathy answered positively on up to six questions, demonstrating that symptoms do not always indicate underlying neuropathy.",
"   </p>",
"   <p>",
"    Similarly, in the Rochester Diabetic Neuropathy Study, assessment of symptoms by either the Neuropathy Symptom Score or the Neuropathy Symptom Profile was poorly reproducible, and significant differences in judging symptom severity occurred even among highly trained neurologists [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/11\">",
"     11",
"    </a>",
"    ]. We therefore now rely on clinical signs to diagnose diabetic neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     United Kingdom screening test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United Kingdom, investigators have developed a two-part diagnostic test, consisting of a simple symptom score and physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the sensation felt? Burning, numbness, or tingling in the feet (2 points); fatigue, cramping, or aching (1 point). Maximum is 2 points.",
"     </li>",
"     <li>",
"      What is the location of symptoms? Feet (2 points); calves (1 point); elsewhere (0 points). Maximum is 2 points.",
"     </li>",
"     <li>",
"      Have the symptoms ever awakened you at night? Yes (1 point).",
"     </li>",
"     <li>",
"      What is the timing of symptoms? Worse at night (2 points); present day and night (1 point); present only during the day (0 points). Maximum is 2 points.",
"     </li>",
"     <li>",
"      How are symptoms relieved? Walking around (2 points); standing (1 point); sitting or lying or no relief (0 points). Maximum is 2 points.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The total symptom score can then be determined:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 2 points: Normal",
"     </li>",
"     <li>",
"      3 to 4 points: Mild neuropathy",
"     </li>",
"     <li>",
"      5 to 6 points: Moderate neuropathy",
"     </li>",
"     <li>",
"      7 to 9 points: Severe neuropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar quantitative score can be made for the physical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the Achilles tendon reflex? Absent (2 points for each foot); present with reinforcement (1 point for each foot).",
"     </li>",
"     <li>",
"      What is vibration sense? Absent or reduced (1 point for each foot).",
"     </li>",
"     <li>",
"      What is pin prick sensation? Absent or reduced (1 point for each foot).",
"     </li>",
"     <li>",
"      What is temperature sensation? Reduced (1 point for each foot).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The neurologic signs score can then be determined:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 2 points: Normal",
"     </li>",
"     <li>",
"      3 to 5 points: Mild neuropathy",
"     </li>",
"     <li>",
"      6 to 8 points: Moderate neuropathy",
"     </li>",
"     <li>",
"      9 to 10 points: Severe neuropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Peripheral neuropathy is considered to be present if there are moderate or severe signs (&ge;6 points), even in the absence of symptoms, or if there are at least mild signs (&ge;3 points) in the presence of moderate symptoms (&ge;5 points). A neurologic sign score of 8 or more indicates that the patient's feet are at high risk for ulceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Michigan Neuropathy Screening Instrument",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have designed a simple screening test to diagnose diabetic neuropathy in outpatient clinics (",
"    <a class=\"graphic graphic_figure graphicRef65776 \" href=\"UTD.htm?20/51/21310\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/10\">",
"     10",
"    </a>",
"    ]. We use this test to screen large numbers of patients for the presence of diabetic neuropathy. In this simple examination the following questions are addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do the feet show dry skin, callus, fissure, infection or deformities? The presence of any of these indicators of neuropathy is scored as one point and an additional point is added if an ulcer is present.",
"     </li>",
"     <li>",
"      What is the vibration sense on the dorsum of the great toes? Reduced (0.5 points); absent (1 point).",
"     </li>",
"     <li>",
"      What is the Achilles tendon reflex? Absent (1 point); present with reinforcement (0.5 points).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This test was standardized against the San Antonio Consensus criteria. A score greater than 2 indicated neuropathy with both a high specificity (95 percent) and sensitivity (80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/10\">",
"     10",
"    </a>",
"    ]. The Michigan Neuropathy Screening Instrument can be administered by any health care professional involved in the treatment of diabetic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Tuning fork test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple test using a 128 Hz tuning fork to examine vibration perception can be used to screen for diabetic polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H76#H76\">",
"     \"The detailed neurologic examination in adults\", section on 'Vibration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 128 Hz tuning fork is placed on the interphalangeal joint of the right hallux.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The score is 2 points if the patient feels no vibration.",
"      <br/>",
"      <br/>",
"      When the patient feels vibration at the hallux, the still vibrating tuning fork is immediately placed at the dorsal wrist, and the patient is asked to compare the strength of vibration at the two sites.",
"     </li>",
"     <li>",
"      The score is 1 point if the vibration feels stronger at the wrist.",
"     </li>",
"     <li>",
"      The score is 0 points if the vibration feels no different at the wrist.",
"     </li>",
"     <li>",
"      A normal score is 0 points, a mild to moderate deficit is 1, and a severe deficit is 2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This tuning fork test has widespread utility in clinical practice because it is simple, brief, valid and reliable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114901971\">",
"    <span class=\"h2\">",
"     Electrodiagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic testing is necessary when the clinical presentation of neuropathy is atypical for diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/14\">",
"     14",
"    </a>",
"    ]. Atypical presenting features suggesting a cause other than diabetes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymmetry of symptoms or signs",
"     </li>",
"     <li>",
"      Initial presentation with weakness more than sensory loss",
"     </li>",
"     <li>",
"      Proximal greater than distal signs and symptoms",
"     </li>",
"     <li>",
"      Rapidly progressive disease course",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A patient with any constellation of these atypical presenting symptoms or signs requires electrodiagnostic testing for an accurate diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Staging test",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Michigan Diabetic Neuropathy Score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Michigan Diabetic Neuropathy Score consists of a quantitative neurologic examination that assesses sensory impairment (vibratory threshold perception, pain, and light touch), muscle strength, and reflexes (",
"    <a class=\"graphic graphic_table graphicRef50683 \" href=\"UTD.htm?5/31/5630\">",
"     table 2",
"    </a>",
"    ), and a set of five nerve conduction studies (sural, peroneal motor, median sensory and motor, and ulnar sensory) that are graded separately [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/10\">",
"     10",
"    </a>",
"    ]. This score provides a means of diagnosing and staging diabetic neuropathy for clinical trials and epidemiologic studies that is simpler and less time consuming than the San Antonio criteria. In a study of 8757 diabetic patients in Italy, 32 percent screened positively on the Michigan Neuropathy Screening Instrument (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Michigan Neuropathy Screening Instrument'",
"    </a>",
"    above), and these patients were administered the Michigan Diabetic Neuropathy Score:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      16 percent had no neuropathy by this assessment: Score &le;6 and abnormal conduction in no or one nerve.",
"     </li>",
"     <li>",
"      41 percent had mild neuropathy: Score &le;12 and abnormal conduction in two nerves.",
"     </li>",
"     <li>",
"      29 percent had moderate neuropathy: Score &le;29 and abnormal conduction in three or four nerves.",
"     </li>",
"     <li>",
"      13 percent severe neuropathy: Score &ge; 29 and abnormal conduction in all five nerves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In each case, severity of neuropathy correlated with disease duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating diabetic patients with neuropathy, it is important to appreciate that there are other causes of neuropathy (",
"    <a class=\"graphic graphic_table graphicRef76476 \" href=\"UTD.htm?20/18/20781\">",
"     table 3",
"    </a>",
"    ). These should be considered if there is any aspect of the history or clinical presentation suggesting features atypical of diabetic neuropathy (eg, signs of a systemic disease such as vasculitis).",
"   </p>",
"   <p>",
"    Certain forms of neuropathy (other than diabetic neuropathy) occur more frequently in patients with diabetes than in the general population and should be excluded. These include chronic inflammatory demyelinating polyneuropathy (CIDP) and neuropathy due to vitamin B12 deficiency, hypothyroidism, and uremia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute painful diabetic neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon, there are several types of acute painful diabetic neuropathy syndromes. These are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment-induced diabetic neuropathy (also called insulin neuritis) that presents in the setting of rapid glycemic control [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/15-17\">",
"       15-17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetic neuropathy that occurs in the setting of unintended severe weight loss (diabetic neuropathic cachexia) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetic neuropathy that is seen with intentional weight loss (diabetic anorexia) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, these conditions are characterized by severe neuropathic pain, autonomic dysfunction, and a reversible course that may last for many months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic neuropathy should be suspected in any patient with type 1 diabetes of more than five years' duration and in all patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. In addition, neuropathy due to prediabetes should be suspected in any patient presenting with \"idiopathic\" painful neuropathy. Both epidemiological and case-controlled studies show that 40 to 50 percent of patients with idiopathic neuropathy have prediabetes compared with 14 percent of the age-matched general population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the potentially severe complications, including amputation for infected, nonhealing ulcers, early detection of diabetic polyneuropathy is important. Early detection, if followed by therapeutic interventions including patient education, regular foot surveillance, and improved glycemic control, can decrease the morbidity of diabetic neuropathy.",
"   </p>",
"   <p>",
"    Our recommendations are in agreement with those of the American Diabetes Association practice statement published in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with diabetes should be screened for neuropathy at diagnosis of type 2 diabetes and five years after diagnosis of type 1 diabetes.",
"     </li>",
"     <li>",
"      After initial screening, all patients should be screened at least annually by examining sensory function in the feet and checking ankle reflexes. One or more of the following tests can be used to assess sensory function:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pinprick",
"     </li>",
"     <li>",
"      Temperature",
"     </li>",
"     <li>",
"      Vibration perception (using a 128 Hz tuning fork)",
"     </li>",
"     <li>",
"      Pressure sensation (using a 10 g monofilament pressure sensation at the distal halluces)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete history and clinical examination focusing on symptoms and signs of peripheral neuropathy should be performed annually. Any history of neuropathic symptoms should be elicited. A careful clinical examination of the feet and lower limbs should be performed.",
"     </li>",
"     <li>",
"      At each diabetes care clinic visit, the feet should be examined for neuropathic deformities, infection and ulceration, and the footwear should be inspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link\">",
"       \"Evaluation of the diabetic foot\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient should carefully inspect his or her feet daily [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18551/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All patients with neuropathy, including those who are asymptomatic, should receive foot care education and consideration for podiatric referral.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=see_link\">",
"       \"Patient information: Nerve damage caused by diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"       \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5749282\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic neuropathy is primarily a symmetrical sensory polyneuropathy, initially affecting the distal lower extremities. The earliest signs of diabetic neuropathy probably reflect the gradual loss of integrity of both large myelinated and small myelinated and unmyelinated nerve fibers (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Loss of vibratory sensation and altered proprioception reflect large-fiber loss",
"     </li>",
"     <li>",
"      Impairment of pain, light touch, and temperature is secondary to loss of small fibers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic neuropathy is frequently insidious in onset and can lead to formation of foot ulcers and muscle and joint disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of diabetic neuropathy (and other microvascular and macrovascular complications) increases over time. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the diagnosis of diabetic polyneuropathy, both the San Antonio Consensus and the Mayo Clinic criteria are thorough and appropriate for research purposes. However, they are not practical in routine clinical practice. Simplified criteria have been developed for clinical use (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Criteria for diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Michigan Neuropathy Screening Instrument (",
"      <a class=\"graphic graphic_figure graphicRef65776 \" href=\"UTD.htm?20/51/21310\">",
"       figure 1",
"      </a>",
"      ) was designed to diagnose diabetic neuropathy in outpatient clinics. Additional useful screening assessments include the United Kingdom screening test and the tuning fork test. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Michigan Neuropathy Screening Instrument'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Michigan Diabetic Neuropathy Score (",
"      <a class=\"graphic graphic_table graphicRef50683 \" href=\"UTD.htm?5/31/5630\">",
"       table 2",
"      </a>",
"      ), which consists of a quantitative neurologic examination and nerve conduction studies, is useful for diagnosing and staging diabetic neuropathy for clinical trials and epidemiologic studies. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Michigan Diabetic Neuropathy Score'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other causes of neuropathy (",
"      <a class=\"graphic graphic_table graphicRef76476 \" href=\"UTD.htm?20/18/20781\">",
"       table 3",
"      </a>",
"      ) should be considered if there is any aspect of the history or clinical presentation suggesting features atypical of diabetic neuropathy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetic neuropathy should be suspected in any patient with type 1 diabetes of more than five years duration and in all patients with type 2 diabetes. In addition, neuropathy due to prediabetes should be suspected in any patient presenting with \"idiopathic\" painful neuropathy. Because of the potentially severe complications, including amputation for infected, nonhealing ulcers, early detection of diabetic polyneuropathy is important. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/1\">",
"      Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/2\">",
"      Franse LV, Valk GD, Dekker JH, et al. 'Numbness of the feet' is a poor indicator for polyneuropathy in Type 2 diabetic patients. Diabet Med 2000; 17:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/3\">",
"      Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/4\">",
"      Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/5\">",
"      MULDER DW, LAMBERT EH, BASTRON JA, SPRAGUE RG. The neuropathies associated with diabetes mellitus. A clinical and electromyographic study of 103 unselected diabetic patients. Neurology 1961; 11(4)Pt 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/6\">",
"      Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 1988; 11:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/7\">",
"      England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/8\">",
"      Dyck PJ, Albers JW, Andersen H, et al. Diabetic Polyneuropathies: Update on Research Definition, Diagnostic Criteria and Estimation of Severity. Diabetes Metab Res Rev 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/9\">",
"      Young MJ, Boulton AJ, MacLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/10\">",
"      Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/11\">",
"      Dyck PJ, Kratz KM, Lehman KA, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991; 41:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/12\">",
"      Meijer JW, Smit AJ, Lefrandt JD, et al. Back to basics in diagnosing diabetic polyneuropathy with the tuning fork! Diabetes Care 2005; 28:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/13\">",
"      Kanji JN, Anglin RE, Hunt DL, Panju A. Does this patient with diabetes have large-fiber peripheral neuropathy? JAMA 2010; 303:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/14\">",
"      Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/15\">",
"      Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996; 39:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/16\">",
"      Dabby R, Sadeh M, Lampl Y, et al. Acute painful neuropathy induced by rapid correction of serum glucose levels in diabetic patients. Biomed Pharmacother 2009; 63:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/17\">",
"      Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010; 67:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/18\">",
"      Archer AG, Watkins PJ, Thomas PK, et al. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983; 46:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/19\">",
"      Ellenberg M. Diabetic neuropathic cachexia. Diabetes 1974; 23:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/20\">",
"      Castellanos F, Mascias J, Zabala JA, et al. Acute painful diabetic neuropathy following severe weight loss. Muscle Nerve 1996; 19:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/21\">",
"      Steel JM, Young RJ, Lloyd GG, Clarke BF. Clinically apparent eating disorders in young diabetic women: associations with painful neuropathy and other complications. Br Med J (Clin Res Ed) 1987; 294:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/22\">",
"      Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008; 120:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18551/abstract/23\">",
"      Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol 2005; 7:33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5272 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18551=[""].join("\n");
var outline_f18_7_18551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5749282\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CRITERIA FOR DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Screening tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - United Kingdom screening test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Michigan Neuropathy Screening Instrument",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Tuning fork test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114901971\">",
"      Electrodiagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Staging test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Michigan Diabetic Neuropathy Score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute painful diabetic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5749282\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5272\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5272|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/51/21310\" title=\"figure 1\">",
"      Neuropathy screening instrument",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5272|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/11/7357\" title=\"table 1\">",
"      Classification diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/31/5630\" title=\"table 2\">",
"      Diabetic neuropathy score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/18/20781\" title=\"table 3\">",
"      Diff dx diabetic neuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=related_link\">",
"      Diabetic neuropathic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=related_link\">",
"      Epidemiology and classification of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=related_link\">",
"      Pathogenesis and prevention of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=related_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=related_link\">",
"      Patient information: Nerve damage caused by diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=related_link\">",
"      Treatment of diabetic neuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_7_18552="The difficult airway in adults";
var content_f18_7_18552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The difficult airway in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18552/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18552/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18552/contributors\">",
"     Michael F Murphy, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18552/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18552/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18552/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/7/18552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most emergency department (ED) endotracheal intubations are performed on an emergent basis (ie, intubation cannot be delayed or avoided). The universal emergency airway management algorithm&copy; provides the recommended approach to emergency intubation (",
"    <a class=\"graphic graphic_algorithm graphicRef76711 \" href=\"UTD.htm?41/28/42445\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef63518 \" href=\"UTD.htm?33/39/34430\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This approach is based on two key assessments of the patient prior to intubation.",
"   </p>",
"   <p>",
"    The first assessment is to determine if the patient has a \"crash\" airway (ie, presenting in extremis with little or no cardiovascular or respiratory activity, and unlikely to respond to insertion of a laryngoscope). If so, the crash airway algorithm&copy; is used (",
"    <a class=\"graphic graphic_algorithm graphicRef73509 \" href=\"UTD.htm?24/20/24910\">",
"     algorithm 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the patient is not a crash airway, the next step is to determine if the patient presents a difficult airway. This requires assessment of specific patient attributes to predict the likelihood of difficulty in performing any of the major procedures in airway management: direct laryngoscopy and intubation, bag-mask ventilation, surgical airway management, and ventilation using an extraglottic airway.",
"   </p>",
"   <p>",
"    If the patient is felt to be neither a crash nor a difficult airway, then rapid sequence intubation is the recommended method for managing the airway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision that the patient presents with a difficult airway is a critical determinant of the best approach to intubation. This topic review will discuss assessment and management of the difficult airway in adults. Other aspects of airway management, including pediatric airway management, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence of difficult intubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A difficult ED intubation can be defined as one that requires multiple attempts, multiple operators, multiple devices, excessive lifting force, external laryngeal manipulation, or is performed with an inadequate glottic view. The precise incidence of difficult intubation in the emergency department (ED) is unknown. The multicenter National Emergency Airway Registry (NEAR) project analyzed over 8900 ED intubations and found that in approximately 5 percent of cases, the airway ultimately was secured by a means other than the first method chosen. Approximately 0.9 percent of airway encounters required a surgical airway. Using these data, one would estimate the incidence of failed airway in the ED at approximately 5 percent. The incidence of difficult airway would necessarily be somewhat higher than this [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An earlier analysis of NEAR data found that intubation by residents in emergency medicine was successful 83 percent of the time on the first attempt and 90 percent of the time within three attempts. The intubation success rate improved as residents progressed through training. Also, 90 percent of patients were intubated successfully by the first operator. This suggests that approximately 10 percent of ED intubations could be considered difficult using a definition of requiring more than one intubator or more than three intubation attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2002 review estimated the incidence of difficult ED intubation at 30 percent, but variations in clinician expertise and experience greatly influence the subjective impression of intubation difficulty, and the need for additional equipment or operators [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/5\">",
"     5",
"    </a>",
"    ]. Furthermore, virtually all concepts of difficult ED intubation are predicated on difficulty obtaining an adequate glottic view using a direct laryngoscope and blade. A retrospective study of emergency intubations performed by anesthesiologists outside the operating room reported that 351 of 3423 intubations (10.3 percent) were difficult (Cormack-Lehane grade 3 or 4) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/6\">",
"     6",
"    </a>",
"    ]. The concept of difficult intubation will change radically as video laryngoscopes, now widely used, replace traditional direct laryngoscopes for emergency intubation.",
"   </p>",
"   <p>",
"    Difficult direct laryngoscopy correlates with the best view of the glottis, as defined by the Cormack-Lehane scale, in which a grade 1 view connotes a full view of the entire glottic aperture, grade 2 represents a partial glottic view, grade 3 represents visualization of the epiglottis only, and grade 4 represents inability to visualize even the epiglottis (",
"    <a class=\"graphic graphic_figure graphicRef55034 \" href=\"UTD.htm?34/2/34863\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the operating room, the incidence of grade 3 laryngoscopy is approximately 5 percent and true grade 4 laryngoscopy occurs in less than 1 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/8\">",
"     8",
"    </a>",
"    ]. These data are derived from selected cases, as patients with difficult airways are usually identified in advance and have planned airway interventions. In the ED, the incidence of grade 3 and 4 laryngoscopic views is likely to be much higher.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence of difficult bag-mask ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Difficult bag-mask ventilation (BMV) has been studied extensively in the operating room but not in the emergency department (ED) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. Researchers in one prospective observational study of 1502 operating room patients defined difficult BMV as the inability of a single clinician to maintain oxygen saturation above 92 percent or provide adequate ventilation. They found BMV to be difficult in about 5 percent of patients, and impossible in only a single patient [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/9\">",
"     9",
"    </a>",
"    ]. These findings were validated in subsequent, larger studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/10,15\">",
"     10,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the selected patients studied in the operating room, the combined presence of the inability to intubate and the inability to perform BMV occurs in only 1 in 5000 to 1 in 10,000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/16\">",
"     16",
"    </a>",
"    ]. This likely represents a reasonable estimate of the incidence of unexpected difficulty in the ED (ie, patients without identifiable characteristics associated with difficulty but for whom intubation and BMV are difficult). This observation underscores the safety of an approach to airway management that includes a preintubation assessment for difficult intubation and difficult BMV. In the absence of markers of difficult intubation or difficult BMV, the clinician is extremely unlikely to encounter a patient who is both impossible to intubate and impossible to ventilate with a bag-mask. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link&amp;anchor=H12#H12\">",
"     \"Basic airway management in adults\", section on 'Bag-mask ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence of difficult cricothyrotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of difficult surgical cricothyrotomy in the emergency department (ED), where the procedure is most often performed, or in the operating room (OR) is not known. Cricothyrotomy is not a technically difficult procedure in most patients, but infrequency of performance, lack of regular training, and the anxiety accompanying airway failure undoubtedly play key roles in any difficulty encountered.",
"   </p>",
"   <p>",
"    Several case series of emergency surgical cricothyrotomies have reported success rates approaching 100 percent, with complication rates of 5 to 14 percent. Difficulty related to the procedure, including cases requiring excessive time to secure the airway, is not properly captured in these retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incidence of difficult extraglottic airways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraglottic airways are most often used as rescue devices in the emergency department (ED). These include the supraglottic airways (ie, laryngeal mask airways), designed to sit just above the glottis, and the retro-glottic airways, designed to be inserted into the esophagus, and which provide proximal (oropharyngeal) and distal (esophageal) seals to permit \"side-stream\" ventilation (eg, Combitube&trade;, King LT Airway&trade;, and others).",
"   </p>",
"   <p>",
"    The incidence of difficult insertion is not known for most of these devices. Disposable and reusable laryngeal mask airway devices have been shown to permit effective ventilation in 92 and 97 percent, respectively, of anesthetized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/19\">",
"     19",
"    </a>",
"    ]. Emergency medical technicians (EMT) have used the Combitube&trade; in the prehospital setting, obtaining ventilation rates ranging from 79 to 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. One retrospective review of 162 patients managed by EMTs reported a success rate of only 70 percent with a 27 percent complication rate using the Combitube&trade; [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Success rates for retroglottic airways used in the ED are unknown. Analysis of data from the NEAR registry showed extraglottic airways were seldom used as rescue devices and never used as a primary airway in 7712 ED patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with disrupted upper airway anatomy are poor candidates for a supraglottic or retroglottic airway device, as both rely on creating a seal between an inflatable cuff and the patient's mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF THE DIFFICULT AIRWAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to identify, in advance, characteristics associated with difficult intubation or ventilation is one of the leading causes of a failed airway in the operating room [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This concept likely extends to emergency airway management outside the operating room. Difficult airway assessment requires determination of the potential for difficulty with bag-mask ventilation, laryngoscopy and intubation, cricothyrotomy, and extraglottic airway insertion.",
"   </p>",
"   <p>",
"    Multiple studies have attempted to identify patient characteristics predictive of difficult laryngoscopy and intubation. Not all markers of difficulty are applicable to emergency department (ED) patients, and many are too complex or require evaluation (eg, MRI) that is not feasible in the emergency situation. Researchers in emergency airway management have developed mnemonics for evaluation of the difficult airway in the ED, based upon these studies and their practical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The mnemonic LEMON&copy; is discussed below (",
"    <a class=\"graphic graphic_table graphicRef64336 \" href=\"UTD.htm?0/46/747\">",
"     table 1",
"    </a>",
"    ). A prospective observational study of 156 patients undergoing intubation in the ED found the LEMON&copy; evaluation accurately stratified patients according to the risk of difficult intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, the LEMON mnemonic was adopted by the American College of Surgeons&rsquo; Advanced Trauma Life Support Course&trade;. The LEMON mnemonic applies to direct laryngoscopy, not to video laryngoscopy, although some of the attributes (eg, obesity) are likely to have some validity for video laryngoscopy as well. However, it will be challenging to develop predictors of difficult intubation using a video laryngoscope, as these instruments almost universally provide grade 1 or 2 views",
"    <span class=\"nowrap\">",
"     (400/400",
"    </span>",
"    grade 1 or 2 in one study of the Glidescope&trade; [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/30\">",
"     30",
"    </a>",
"    ] and",
"    <span class=\"nowrap\">",
"     60/60",
"    </span>",
"    in a study using the Storz C-MAC&trade; [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/31\">",
"     31",
"    </a>",
"    ]). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     The LEMON&copy; approach to difficult airway assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LEMON&copy; rule uses a series of physical evaluations to determine whether difficult laryngoscopy is anticipated. Each step is described:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     L: Look externally",
"    </span>",
"    &nbsp;&mdash;&nbsp;This refers to the clinician's general impression that the airway will be difficult. Does the patient have abnormal facies or body habitus, unusual anatomy, or facial trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], any of which can be expected to create difficulty? A general impression of airway difficulty is reasonably specific, but not particularly sensitive. If an operator observes the patient and anticipates difficulty, that assessment likely is correct. Conversely, absence of obvious external markers of airway difficulty does not ensure success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     E: Evaluate (3-3-2 rule)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size of the mandible, the distance between the mentum and the hyoid bone, and the extent of mouth opening are all important geometric determinants of the success of direct laryngoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/34\">",
"     34",
"    </a>",
"    ]. These relationships are represented by the 3-3-2 rule (",
"    <a class=\"graphic graphic_picture graphicRef60507 \" href=\"UTD.htm?37/23/38256\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The rule describes three measurements found in normal patients (ie, patients in whom difficult laryngoscopy is",
"    <strong>",
"     NOT",
"    </strong>",
"    expected).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      3: This assessment indicates the ease of access to the airway. A normal patient can open his mouth sufficiently to permit three of his own fingers to be placed between the incisors. Adequate mouth opening facilitates both insertion of the laryngoscope and obtaining a direct view of the glottis.",
"     </li>",
"     <li>",
"      3: This assessment provides an estimate of the volume of the submandibular space. A normal patient is able to place three of his fingers along the floor of the mandible between the mentum and the",
"      <span class=\"nowrap\">",
"       neck/mandible",
"      </span>",
"      junction (near the hyoid bone).",
"     </li>",
"     <li>",
"      2: This assessment identifies the location of the larynx relative to the base of the tongue. A normal patient is able to place two fingers in the superior laryngeal notch (ie, the space between the superior notch of the thyroid cartilage and the",
"      <span class=\"nowrap\">",
"       neck/mandible",
"      </span>",
"      junction, near the hyoid bone). If the larynx is too high in the neck, direct laryngoscopy is difficult or impossible because of the angles that have to be negotiated to permit visualization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Variations in patient size are accommodated by using the patient's fingers as the standard for measurement. Since the ED patient is often uncooperative or unable to perform the required steps, size is estimated by comparing the examiner's fingers with the patient's. The examiner's fingers are then used to estimate the proportions involved. Failure to achieve these three dimensions predicts difficulty visualizing the glottis during direct laryngoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     M: Mallampati score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Mallampati classification is a simple scoring system to help predict difficult intubation (",
"    <a class=\"graphic graphic_figure graphicRef75229 \" href=\"UTD.htm?2/36/2626\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. It has been prospectively validated in several studies, although not as a solitary (ie, sufficient) predictor of difficult intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The Mallampati class, ranging from I to IV, relates the amount of mouth opening to the size of the tongue, and provides an estimate of space for oral intubation by direct laryngoscopy. In general, Mallampati class I or II predicts easy laryngoscopy, class III predicts difficulty, and class IV predicts extreme difficulty.",
"   </p>",
"   <p>",
"    Many ED patients are unable to cooperate with a Mallampati assessment. In such cases, the examiner should gently open the mouth if possible and use a direct laryngoscope blade in the manner of a conventional tongue blade to assess the size of the tongue compared with that of the oropharynx. If this assessment reveals a large tongue to oropharynx ratio or it cannot be done, the clinician should assume that direct laryngoscopy will be difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     O: Obstruction/Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of upper airway obstruction interferes with both laryngoscopy and intubation. A supraglottic mass or infection, trauma with hematoma, injury with disruption of the upper airway, and vocal cord masses (eg, tumor), among other conditions, can obstruct the view of the glottis, block access for tube insertion by narrowing the airway, or both. The redundant tissues in the upper airway of the obese patient make visualization of the glottis by direct laryngoscopy more difficult, and an oversize laryngoscope blade may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     N: Neck mobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, the patient is placed in the sniffing position for intubation. The sniffing position is achieved by flexing the neck forward on the body (thoracic spine) and elevating the head. Thus, decreased cervical spine mobility compromises the direct laryngoscopic view [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Proper positioning for direct laryngoscopy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28906?source=see_link&amp;anchor=H12#H12\">",
"     \"Direct laryngoscopy and tracheal intubation in adults\", section on 'Positioning the patient'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medical conditions, such as psoriatic or rheumatoid arthritis, or ankylosing spondylitis, or simply the degenerative joint disease that accompanies aging, can greatly reduce neck mobility. In uncooperative,",
"    <strong>",
"     non",
"    </strong>",
"    trauma patients, neck mobility can be assessed by passively extending the neck.",
"   </p>",
"   <p>",
"    Blunt trauma patients require in-line stabilization of the cervical spine during intubation, which also limits glottic view. Most trauma patients, although identified as difficult airways because they require in-line cervical spine stabilization, can nonetheless be intubated successfully orally, unless other difficult airway markers are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Difficult bag-mask ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment for difficult bag-mask ventilation (BMV) is performed immediately after the LEMON&copy; evaluation for difficult intubation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'L: Look externally'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Difficult BMV has been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/9,10,15\">",
"     9,10,15",
"    </a>",
"    ] and the predictors of difficulty are summarized by the mnemonic MOANS&copy; (",
"    <a class=\"graphic graphic_table graphicRef73627 \" href=\"UTD.htm?0/39/635\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/27\">",
"     27",
"    </a>",
"    ]. There is no clear correlation between each of these attributes and the degree of difficulty, but assessment of all the attributes helps to determine whether difficulty with BMV is likely.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       M: mask seal &ndash;",
"      </strong>",
"      Mask seal requires reasonably normal anatomy, absence of facial hair, lack of interfering substances, such as excessive vomitus or bleeding, and the ability to apply pressure to the face with the mask.",
"     </li>",
"     <li>",
"      <strong>",
"       O:",
"       <span class=\"nowrap\">",
"        Obstruction/Obesity",
"       </span>",
"       &ndash;",
"      </strong>",
"      Obstruction of the upper airway, although not widely studied, will make BMV more difficult, as increased pressures will be required to ensure that gas flows past the obstruction in both directions. Obesity (BMI&gt;26) is an independent marker of difficult BMV. Redundant upper airway tissue and the combination of chest wall weight and resistance from abdominal contents all impede airflow. Late third trimester pregnancy is a surrogate for obesity with respect to BMV, as it creates many of the same problems. Placing the bed at an angle with the head higher than the feet (ie, reverse Trendelenburg) may reduce impedance to airflow from abdominal weight.",
"     </li>",
"     <li>",
"      <strong>",
"       A: Age &ndash;",
"      </strong>",
"      In one study, age &gt;55 years was a marker of difficult BMV [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/9\">",
"       9",
"      </a>",
"      ]. Most likely the general loss of elasticity of tissues and the increased incidence of restrictive or obstructive pulmonary disease make ventilation more difficult. Fifty-five years is not a distinct cut-off, but as patients age, or appear to be physiologically aged, it is reasonable to assume that BMV difficulty will increase.",
"     </li>",
"     <li>",
"      <strong>",
"       N: No teeth &ndash;",
"      </strong>",
"      Edentulousness creates difficulty with BMV. Teeth provide a framework against which the mask sits and support the cheeks, enhancing mask seal. If a patient has dentures, they should be left in situ during BMV, where they are of benefit, then removed for direct laryngoscopy, where they are detrimental [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       S: Stiffness &ndash;",
"      </strong>",
"      &ldquo;Stiffness&rdquo; is used to connote resistance to ventilation that occurs in conditions that increase the required inspiratory pressure to ventilate the lungs and include asthma, chronic obstructive pulmonary disease (COPD), pulmonary edema, widespread infiltrates, and any other condition that decreases pulmonary compliance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Difficult cricothyrotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment for difficult cricothyrotomy is performed after the LEMON&copy; evaluation for difficult intubation and the MOANS&copy; evaluation for difficult bag-mask ventilation. &nbsp;",
"   </p>",
"   <p>",
"    Difficult cricothyrotomy is caused by difficult access to the anterior neck, inability to identify landmarks, distortion of the anatomy, or abnormalities of the tissues, and is assessed using the mnemonic SMART &copy; (",
"    <a class=\"graphic graphic_table graphicRef67468 \" href=\"UTD.htm?2/49/2843\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/27\">",
"     27",
"    </a>",
"    ]. Evaluation for difficult cricothyrotomy requires palpating the structures overlying the larynx, identifying the cricothyroid membrane, and identifying potential problems with surgical access. Identification of the cricothyroid membrane is more difficult in the obese and in women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Difficult extraglottic airway placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of a rescue device (eg, laryngeal mask airway) can be difficult if mouth opening is limited, if the airway is disrupted or distorted (eg, by swelling), or if debris such as teeth or bone fragments are present (",
"    <a class=\"graphic graphic_table graphicRef71383 \" href=\"UTD.htm?0/8/136\">",
"     table 4",
"    </a>",
"    ). Increased airway resistance can prevent effective ventilation via an extraglottic airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     THE DIFFICULT AIRWAY ALGORITHM&copy;",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a difficult airway is identified using the LEMON&copy; criteria, the difficult airway algorithm&copy; is used (",
"    <a class=\"graphic graphic_algorithm graphicRef58510 \" href=\"UTD.htm?21/54/22382\">",
"     algorithm 4",
"    </a>",
"    ). Predictors of airway difficulty when using a video laryngoscope remain to be fully defined; pending that, it is reasonable to apply the same principles of airway assessment and decision making, regardless of whether a traditional direct or a video laryngoscope will be used. Although the difficult airway algorithm&copy; appears complex, it is really a series of simple questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is there sufficient time? If not, this is a failed airway, and the failed airway algorithm&copy; should be used (",
"      <a class=\"graphic graphic_algorithm graphicRef73112 \" href=\"UTD.htm?12/9/12446\">",
"       algorithm 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Is rapid sequence intubation (RSI) a reasonable approach, even though the airway has been identified as difficult?",
"     </li>",
"     <li>",
"      If RSI is not reasonable, what can be learned from an awake look at the glottis?",
"     </li>",
"     <li>",
"      Is there still sufficient time? If so, a number of alternatives remain. If not, the situation represents a failed airway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Applying the algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiating the steps in the difficult airway algorithm&copy;, the first action is to obtain any necessary assistance (personnel, equipment, airway devices) at the earliest opportunity (",
"    <a class=\"graphic graphic_algorithm graphicRef58510 \" href=\"UTD.htm?21/54/22382\">",
"     algorithm 4",
"    </a>",
"    ). As this is being done, the stepwise management of the difficult airway can proceed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Is there time?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first determination is whether the patient's oxygenation is adequate. Adequate oxygenation is defined as the ability to maintain the patient's oxyhemoglobin saturation (SpO2), as measured by a pulse oximeter, at 90 percent or higher. A patient with chronically low, but stable, oxygenation might be considered to have adequate oxygenation at a lower threshold value, but the risk of rapid desaturation is much higher [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18552/abstract/43\">",
"     43",
"    </a>",
"    ]. Adequate SpO2 allows the clinician time to plan and implement a stepwise approach to airway management.",
"   </p>",
"   <p>",
"    If oxygenation is inadequate, attempts are made to improve it with supplemental oxygen, or bag-mask ventilation (or assisted ventilation). If there is insufficient time to plan a methodical approach to the airway because adequate SpO2 cannot be maintained, the airway is considered to be a failed airway (",
"    <a class=\"graphic graphic_algorithm graphicRef73112 \" href=\"UTD.htm?12/9/12446\">",
"     algorithm 5",
"    </a>",
"    ). The combination of an anticipated difficult intubation and inability to maintain SpO2 at adequate levels is a surrogate for the \"can't intubate, can't ventilate\" failed airway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18228?source=see_link\">",
"     \"The failed airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Is RSI reasonable?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many difficult airways are managed using RSI. The presence of a difficult airway does not preclude use of RSI, but requires the operator to ask two key questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Am I confident I could oxygenate the patient using a bag and mask or an extraglottic device? &nbsp;",
"     </li>",
"     <li>",
"      Am I confident I can intubate?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RSI is not a prudent option if the operator is not confident the patient can be ventilated adequately with a bag and mask or an extraglottic device, in which case an awake technique is advised. Even if bag-mask ventilation is deemed possible, RSI is not advisable unless the clinician believes oral intubation will likely be successful. RSI can be performed (using the universal emergency airway algorithm&copy;) if the clinician answers yes to both key questions (",
"    <a class=\"graphic graphic_algorithm graphicRef76711 \" href=\"UTD.htm?41/28/42445\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef63518 \" href=\"UTD.htm?33/39/34430\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Often, a double set-up is used when RSI is planned in the setting of a potentially difficult airway. Double set-up means the alternative (ie, back-up) airway device and approach (often a surgical airway) are identified and readied, before beginning the intubation sequence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Awake technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Awake&rdquo; is an imprecise term that connotes direct examination of the upper airway, facilitated by light to moderate sedation and topical anesthesia, using a direct laryngoscope, flexible endoscope, or rigid fiberoptic or video laryngoscope. The term is imprecise, because it refers to a number of different approaches, having only in common that each is done while the patient is breathing on their own and, although technically awake, is sedated as for a painful procedure to permit laryngoscopy.",
"   </p>",
"   <p>",
"    The patient receives procedural sedation and topical anesthesia (depending upon their clinical condition) to permit laryngoscopy, and intubation if indicated. The laryngoscopy may identify barriers that preclude oral intubation, and mandate cricothyrotomy, or, conversely, may identify a straightforward upper airway amenable to RSI. The patient may simply be inspected, then a decision made to proceed with an intubation plan, or may be intubated during the awake look, depending upon the circumstances, likelihood of deterioration, and the judgment of the operator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the awake examination identifies that RSI is not advisable, and the patient cannot be intubated during laryngoscopy (eg, glottis cannot be visualized during awake look), a number of airway management options remain, provided an adequate SpO2 is maintained. The goal with the difficult airway, as with any emergency intubation, is to place a cuffed endotracheal tube in the trachea. A number of devices can be used to accomplish this end.",
"   </p>",
"   <p>",
"    An intubating laryngeal mask airway may be placed, then an endotracheal tube passed through it. A fiberoptic or video device, such as a flexible bronchoscope or a rigid fiberoptic intubating stylet, may be used. A video laryngoscope likely will achieve a glottic view superior to that of a standard laryngoscope, enabling intubation. A fiberoptic or video intubating stylet may be used. Primary cricothyrotomy (ie, cricothyrotomy as a planned airway intervention, rather than a rescue) may be indicated if oral access or the supraglottic region of the airway is anatomically disrupted. Blind nasotracheal intubation may rarely have a role, but is best reserved for situations in which no other device is available or felt to be appropriate (eg, massive hemorrhage obscuring vision). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/55/25466?source=see_link\">",
"     \"Devices for difficult emergency airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Failed airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;If, at any time during the evaluation or management of the difficult airway, an SpO2 cannot be maintained at 90 percent, or at least held stable in a viable range, the difficult airway becomes a failed airway, and the failed airway algorithm&copy; is followed (",
"    <a class=\"graphic graphic_algorithm graphicRef73112 \" href=\"UTD.htm?12/9/12446\">",
"     algorithm 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18228?source=see_link\">",
"     \"The failed airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the clinician perform a difficult airway assessment, to determine the difficulty of intubation, bag-mask ventilation (BMV), extra-glottic device placement, and cricothyrotomy, before undertaking rapid sequence intubation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Failure to recognize and plan for a difficult intubation is a leading factor contributing to a failed airway. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Identification of the difficult airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attributes predictive of difficult direct laryngoscopy and intubation can be identified using the LEMON&copy; mnemonic: Look, Evaluate (3:3:2), Mallampati,",
"      <span class=\"nowrap\">",
"       Obstruction/Obesity,",
"      </span>",
"      Neck mobility. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'The LEMON&copy; approach to difficult airway assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Difficult bag-mask ventilation can be predicted using the MOANS&copy; mnemonic: Mask seal,",
"      <span class=\"nowrap\">",
"       Obstruction/Obesity,",
"      </span>",
"      Age over 55, No teeth, Stiff lungs. &nbsp;(See",
"      <a class=\"local\" href=\"#H14\">",
"       'Difficult bag-mask ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The difficult airway is managed according to the difficult airway algorithm&copy; (",
"      <a class=\"graphic graphic_algorithm graphicRef58510 \" href=\"UTD.htm?21/54/22382\">",
"       algorithm 4",
"      </a>",
"      ). The first action is to obtain all necessary assistance (personnel, equipment, airway devices). The key determination is whether the patient's oxygenation is adequate (ie, SpO2 &gt; 90 percent). If oxygenation is inadequate, attempts are made to improve it with supplemental oxygen or bag-mask ventilation. If adequate SpO2 cannot be maintained, the airway is considered to be a failed airway and is managed accordingly (",
"      <a class=\"graphic graphic_algorithm graphicRef73112 \" href=\"UTD.htm?12/9/12446\">",
"       algorithm 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18228?source=see_link\">",
"       \"The failed airway in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the clinician anticipates intubation to be difficult, and doubts whether the patient can be successfully ventilated using a bag-mask, we suggest neuromuscular blockade be avoided and an awake technique used to manage the airway (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Awake technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1476369\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Walls RM. The emergency airway algorithms. In: Manual of Emergency Airway Management, 4th, Walls RM, Murphy MF.  (Eds), Lippincott Williams and Wilkins, Philadelphia 2012. p.24.",
"    </li>",
"    <li>",
"     The airway management algorithms cited in this review are reproduced with permission from: The Difficult Airway Course&trade;: Emergency, and Walls RM, Murphy MF. Manual of Emergency Airway Management,  Lippincott Williams &amp; Wilkins, Philadelphia 2008, and 4th ed, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/3\">",
"      Walls RM, Brown CA 3rd, Bair AE, et al. Emergency airway management: a multi-center report of 8937 emergency department intubations. J Emerg Med 2011; 41:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/4\">",
"      Sagarin MJ, Barton ED, Chng YM, et al. Airway management by US and Canadian emergency medicine residents: a multicenter analysis of more than 6,000 endotracheal intubation attempts. Ann Emerg Med 2005; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/5\">",
"      Orebaugh SL. Difficult airway management in the emergency department. J Emerg Med 2002; 22:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/6\">",
"      Martin LD, Mhyre JM, Shanks AM, et al. 3,423 emergency tracheal intubations at a university hospital: airway outcomes and complications. Anesthesiology 2011; 114:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/7\">",
"      Cormack RS, Lehane J. Difficult tracheal intubation in obstetrics. Anaesthesia 1984; 39:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/8\">",
"      Burkle CM, Walsh MT, Harrison BA, et al. Airway management after failure to intubate by direct laryngoscopy: outcomes in a large teaching hospital. Can J Anaesth 2005; 52:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/9\">",
"      Langeron O, Masso E, Huraux C, et al. Prediction of difficult mask ventilation. Anesthesiology 2000; 92:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/10\">",
"      Kheterpal S, Han R, Tremper KK, et al. Incidence and predictors of difficult and impossible mask ventilation. Anesthesiology 2006; 105:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/11\">",
"      El-Orbany M, Woehlck HJ. Difficult mask ventilation. Anesth Analg 2009; 109:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/12\">",
"      Salem MR, Ovassapian A. Difficult mask ventilation: what needs improvement? Anesth Analg 2009; 109:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/13\">",
"      Gautam P, Gaul TK, Luthra N. Prediction of difficult mask ventilation. Eur J Anaesthesiol 2005; 22:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/14\">",
"      Yildiz TS, Solak M, Toker K. The incidence and risk factors of difficult mask ventilation. J Anesth 2005; 19:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/15\">",
"      Kheterpal S, Martin L, Shanks AM, Tremper KK. Prediction and outcomes of impossible mask ventilation: a review of 50,000 anesthetics. Anesthesiology 2009; 110:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/16\">",
"      Rose DK, Cohen MM. The airway: problems and predictions in 18,500 patients. Can J Anaesth 1994; 41:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/17\">",
"      Bair AE, Panacek EA, Wisner DH, et al. Cricothyrotomy: a 5-year experience at one institution. J Emerg Med 2003; 24:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/18\">",
"      Wright MJ, Greenberg DE, Hunt JP, et al. Surgical cricothyroidotomy in trauma patients. South Med J 2003; 96:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/19\">",
"      Shafik MT, Bahlman BU, Hall JE, Ali MS. A comparison of the Soft Seal disposable and the Classic re-usable laryngeal mask airway. Anaesthesia 2006; 61:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/20\">",
"      Ochs M, Vilke GM, Chan TC, et al. Successful prehospital airway management by EMT-Ds using the combitube. Prehosp Emerg Care 2000; 4:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/21\">",
"      Lefran&ccedil;ois DP, Dufour DG. Use of the esophageal tracheal combitube by basic emergency medical technicians. Resuscitation 2002; 52:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/22\">",
"      Davis DP, Valentine C, Ochs M, et al. The Combitube as a salvage airway device for paramedic rapid sequence intubation. Ann Emerg Med 2003; 42:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/23\">",
"      Calkins TR, Miller K, Langdorf MI. Success and complication rates with prehospital placement of an esophageal-tracheal combitube as a rescue airway. Prehosp Disaster Med 2006; 21:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/24\">",
"      Bair AE, Filbin MR, Kulkarni RG, Walls RM. The failed intubation attempt in the emergency department: analysis of prevalence, rescue techniques, and personnel. J Emerg Med 2002; 23:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/25\">",
"      American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology 2003; 98:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/26\">",
"      Apfelbaum JL, Hagberg CA, Caplan RA, et al. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology 2013; 118:251.",
"     </a>",
"    </li>",
"    <li>",
"     Murphy M, Walls RM. Identification of the difficult and failed airway. In: Manual of Emergency Airway Management, Walls RM, Murphy MF, Luten RC.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.70.",
"    </li>",
"    <li>",
"     The mnemonics for difficult airway identification cited in this review are reproduced with permission from The Difficult Airway Course&trade;: Emergency.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/29\">",
"      Reed MJ, Dunn MJ, McKeown DW. Can an airway assessment score predict difficulty at intubation in the emergency department? Emerg Med J 2005; 22:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/30\">",
"      Tremblay MH, Williams S, Robitaille A, Drolet P. Poor visualization during direct laryngoscopy and high upper lip bite test score are predictors of difficult intubation with the GlideScope videolaryngoscope. Anesth Analg 2008; 106:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/31\">",
"      Cavus E, Kieckhaefer J, Doerges V, et al. The C-MAC videolaryngoscope: first experiences with a new device for videolaryngoscopy-guided intubation. Anesth Analg 2010; 110:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/32\">",
"      Lundstr&oslash;m LH, M&oslash;ller AM, Rosenstock C, et al. High body mass index is a weak predictor for difficult and failed tracheal intubation: a cohort study of 91,332 consecutive patients scheduled for direct laryngoscopy registered in the Danish Anesthesia Database. Anesthesiology 2009; 110:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/33\">",
"      Juvin P, Lavaut E, Dupont H, et al. Difficult tracheal intubation is more common in obese than in lean patients. Anesth Analg 2003; 97:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/34\">",
"      Naguib M, Scamman FL, O'Sullivan C, et al. Predictive performance of three multivariate difficult tracheal intubation models: a double-blind, case-controlled study. Anesth Analg 2006; 102:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/35\">",
"      Mallampati SR, Gatt SP, Gugino LD, et al. A clinical sign to predict difficult tracheal intubation: a prospective study. Can Anaesth Soc J 1985; 32:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/36\">",
"      Samsoon GL, Young JR. Difficult tracheal intubation: a retrospective study. Anaesthesia 1987; 42:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/37\">",
"      Lee A, Fan LT, Gin T, et al. A systematic review (meta-analysis) of the accuracy of the Mallampati tests to predict the difficult airway. Anesth Analg 2006; 102:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/38\">",
"      Lundstr&oslash;m LH, Vester-Andersen M, M&oslash;ller AM, et al. Poor prognostic value of the modified Mallampati score: a meta-analysis involving 177 088 patients. Br J Anaesth 2011; 107:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/39\">",
"      Crosby ET. Considerations for airway management for cervical spine surgery in adults. Anesthesiol Clin 2007; 25:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/40\">",
"      Crosby ET. Airway management in adults after cervical spine trauma. Anesthesiology 2006; 104:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/41\">",
"      Conlon NP, Sullivan RP, Herbison PG, et al. The effect of leaving dentures in place on bag-mask ventilation at induction of general anesthesia. Anesth Analg 2007; 105:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/42\">",
"      Aslani A, Ng SC, Hurley M, et al. Accuracy of identification of the cricothyroid membrane in female subjects using palpation: an observational study. Anesth Analg 2012; 114:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18552/abstract/43\">",
"      Benumof JL, Dagg R, Benumof R. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology 1997; 87:979.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 275 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-B12D491B22-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18552=[""].join("\n");
var outline_f18_7_18552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence of difficult intubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence of difficult bag-mask ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence of difficult cricothyrotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incidence of difficult extraglottic airways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IDENTIFICATION OF THE DIFFICULT AIRWAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      The LEMON&copy; approach to difficult airway assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - L: Look externally",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - E: Evaluate (3-3-2 rule)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - M: Mallampati score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - O: Obstruction/Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - N: Neck mobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Difficult bag-mask ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Difficult cricothyrotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Difficult extraglottic airway placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      THE DIFFICULT AIRWAY ALGORITHM&copy;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Applying the algorithm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Is there time?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Is RSI reasonable?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Awake technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Alternatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Failed airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1476369\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/275|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/28/42445\" title=\"algorithm 1\">",
"      Universal airway management algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?33/39/34430\" title=\"algorithm 2\">",
"      Main airway management algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/20/24910\" title=\"algorithm 3\">",
"      Crash airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/54/22382\" title=\"algorithm 4\">",
"      Difficult airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?12/9/12446\" title=\"algorithm 5\">",
"      Failed airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/275|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/2/34863\" title=\"figure 1\">",
"      Cormack Lehane laryngoscopy grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/36/2626\" title=\"figure 2\">",
"      Modified Mallampati airway classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/275|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/23/38256\" title=\"picture 1\">",
"      3 3 2 rule for identifying a difficult airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/275|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/46/747\" title=\"table 1\">",
"      LEMON mnemonic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/39/635\" title=\"table 2\">",
"      MOANS mnemonic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/49/2843\" title=\"table 3\">",
"      SMART mnemonic for difficult cricothyrotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/8/136\" title=\"table 4\">",
"      RODS mnemonic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/55/25466?source=related_link\">",
"      Devices for difficult emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28906?source=related_link\">",
"      Direct laryngoscopy and tracheal intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18228?source=related_link\">",
"      The failed airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_7_18553="Closure of skin wounds with sutures";
var content_f18_7_18553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Closure of skin wounds with sutures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18553/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18553/contributors\">",
"     David deLemos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18553/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18553/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18553/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18553/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/7/18553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic principles of laceration repair have not changed significantly in the last century, but the therapeutic options now available are more innovative and rigorously studied. The development of topical anesthetics, tissue adhesives, and fast-absorbing sutures has made the management of lacerations less traumatic for the patient. In addition, the use of procedural sedation for difficult lacerations or for the extremely anxious child has made the experience more tolerable for the patient, family, and physician.",
"   </p>",
"   <p>",
"    The goals of wound management are simple: to avoid wound infection, assist in hemostasis, and to provide an esthetically pleasing scar [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of studies now are focusing on the esthetic nature of wound healing rather than infection rates, because infection rates remain low, regardless of management.",
"   </p>",
"   <p>",
"    Laceration repair with sutures will be discussed here. Information concerning wound preparation and irrigation, topical and infiltrative anesthesia, and tissue adhesive and staples is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33124?source=see_link\">",
"     \"Closure of minor skin wounds with staples\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"     \"Minor wound preparation and irrigation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=see_link\">",
"     \"Superficial wound repair with tissue adhesives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WOUND PHYSIOLOGY AND HEALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidermis, dermis, subcutaneous layer, and deep fascia are the tissue layers of concern in wound closure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The epidermis and dermis are tightly adhered and clinically indistinguishable, and together constitute the skin. Dermal approximation provides the strength and alignment of skin closure.",
"     </li>",
"     <li>",
"      The subcutaneous layer is mainly comprised of adipose tissue. Nerve fibers, blood vessels, and hair follicles are located here. Although this layer provides little strength to the repair, sutures placed in the subcutaneous layer may decrease the tension of the wound and improve the cosmetic result.",
"     </li>",
"     <li>",
"      The deep fascial layer is intermixed with muscle and occasionally requires repair in deep lacerations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The healing process of skin occurs in several stages [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coagulation begins immediately following the injury. Vasospasm as well as platelet aggregation and fibrous clot formation occur. During the inflammatory phase, proteolytic enzymes released by neutrophils and macrophages break down damaged tissue.",
"     </li>",
"     <li>",
"      Epithelialization occurs in the epidermis, which is the only layer capable of regeneration. Complete bridging of the wound occurs within 48 hours after suturing.",
"     </li>",
"     <li>",
"      New blood vessel growth peaks four days after the injury.",
"     </li>",
"     <li>",
"      Collagen formation is necessary to restore tensile strength to the wound. The process begins within 48 hours of the injury and peaks in the first week. Collagen production and remodeling continue for up to 12 months.",
"     </li>",
"     <li>",
"      Wound contraction occurs three to four days following the injury, and the process is poorly understood. The full wound thickness moves toward the center of the wound, which may affect the final appearance of the wound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic disturbances can influence wound healing. These host factors include renal insufficiency, diabetes mellitus, nutritional status, obesity, chemotherapeutic agents, corticosteroids, and anticoagulant or antiplatelet adhering drugs. Disorders of collagen synthesis, such as Ehlers-Danlos syndrome and Marfan's syndrome, can also affect wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H8#H8\">",
"     \"Minor wound preparation and irrigation\", section on 'Risks for poor outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local disturbances are more common contributors to abnormal wound healing. These factors include temperature, ischemia, tissue trauma, denervation, and infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temperature, blood supply, and ischemia are interrelated. The higher the temperature of the anatomic area, the greater the blood supply and resultant oxygen delivery. The skin temperature of the face can be up to nine degrees Fahrenheit warmer than that of the foot, thus allowing for sutures to remain for shorter periods of time and also allowing for lower infection rates. Different suturing techniques can contribute to tissue ischemia, in particular the vertical mattress suture. Vertical mattress sutures have been shown in animal studies to cause more ischemia than continuous or simple interrupted sutures [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Vertical mattress'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Infection can occur in any traumatic wound, and all acute wounds are contaminated to a certain degree. An infection occurs when there is an imbalance between host resistance (systemic or local) and bacterial inoculum. The mechanism of injury and the time from injury to potential repair are important considerations. Crush injuries may cause extensive cellular necrosis and higher infection rates than shear injuries due to the greater energy distributed over a larger area [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/4\">",
"       4",
"      </a>",
"      ]. An injury heavily contaminated with dirt, gravel, or other debris also has a higher infection risk. The length of time between the injury and the evaluation also affects infection risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H3#H3\">",
"       \"Minor wound preparation and irrigation\", section on 'Age of injury'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WOUND ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of minor lacerations begins with assessment and preparation of the wound. Wound assessment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determination of the mechanism of the injury",
"     </li>",
"     <li>",
"      Age of the injury",
"     </li>",
"     <li>",
"      Identification of possible contamination or foreign body",
"     </li>",
"     <li>",
"      Assessment of extent of the wound",
"     </li>",
"     <li>",
"      Assessment for neurovascular compromise or tendon injury in the surrounding area",
"     </li>",
"     <li>",
"      Need for tetanus prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Identification of risk factors that might affect healing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H2#H2\">",
"     \"Minor wound preparation and irrigation\", section on 'Assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31004258\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sutures are appropriate when the depth of the wound will lead to excess scarring if the wound edges are not properly opposed. Typically this is true whenever the laceration extends through the dermis. Clean, uninfected lacerations on any part of the body in healthy patients may be closed primarily for up to 18 hours following the injury without a significant increase in the risk of wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/1\">",
"     1",
"    </a>",
"    ]. Facial wounds may be closed primarily up to 24 hours following the injury, and in select cases up to 48 to 72 hours if there are no signs of infection, the patient has no risk factors for infection, and the wound edges can be approximated easily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31004266\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern about wound infection is the main reason not to close a wound primarily [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;Wounds that have been grossly contaminated with foreign debris that cannot be completely removed, infected tissue,&nbsp;or noncosmetic wounds that have come to medical attention late should be allowed to heal by granulation (secondary intention) after appropriate cleansing.&nbsp;In addition, patients with risk factors for proper wound healing (eg, immunocompromise, peripheral arterial disease, diabetes mellitus) may warrant delayed primary closure depending upon the age of the wound (eg, &gt;6 hours old) or wound site (eg, hands or feet). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=see_link\">",
"     \"Wound healing and risk factors for non-healing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other situations in which closure with sutures may not be appropriate include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H10#H10\">",
"     \"Minor wound preparation and irrigation\", section on 'Type of closure'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Animal bites, especially in noncosmetic areas (eg, hand, foot). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link&amp;anchor=H20#H20\">",
"       \"Initial management of animal and human bites\", section on 'Primary closure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Deep puncture wounds in which effective irrigation cannot occur.",
"     </li>",
"     <li>",
"      Wounds in which suturing will cause too much tension across the suture line. In this instance, healing by secondary intention with later scar revision may be a better approach.",
"     </li>",
"     <li>",
"      Wounds that are actively bleeding, especially if the source is arterial (with the exception of scalp wounds). The clinician should establish hemostasis so that a subcutaneous hematoma does not collect and create a potential nidus for infection as well as impede proper healing.",
"     </li>",
"     <li>",
"      Superficial wounds that would be expected to heal without significant scarring, such as lacerations or abrasions that only involve the epidermis. Suturing in these wounds will potentially cause increased scar formation and risk for infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WOUND PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound irrigation, foreign body removal, and necrotic tissue debridement are the main preventative measures against tissue infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H17#H17\">",
"     \"Minor wound preparation and irrigation\", section on 'Irrigation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surfactant cleaners, such as the nonionic surfactant poloxamer 188 (ShurClens), are also safe and useful for wound decontamination. They possess no antibacterial activity, but decrease the mechanical trauma of scrubbing while reducing bacterial load and incidence of infection. A high-porosity sponge (Optipore) is typically used in conjunction to limit local trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/1\">",
"     1",
"    </a>",
"    ]. This system is ideal for scrubbing large surface areas like \"road rash\" or burns.",
"   </p>",
"   <p>",
"    Debridement has been considered by many to be equally or more important than irrigation in the management of the contaminated wound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H14#H14\">",
"     \"Minor wound preparation and irrigation\", section on 'Debridement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUTURE MATERIALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of terms are used to describe the properties of various types of sutures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The physical configuration of a suture describes whether it is monofilamentous (Prolene or Ethilon) or multifilamentous (silk). Multifilamentous sutures come in braided and twisted types. Braided types are usually easier to handle and tie, but can harbor bacteria between strands and cause higher infection rates.",
"     </li>",
"     <li>",
"      Tensile strength is defined as the amount of weight required to break a suture divided by its cross sectional area. The designation for suture strength is the number of zeros. The higher the number of zeros (1-0 to 10-0), the smaller the size and the lower the strength.",
"     </li>",
"     <li>",
"      Knot strength is the measure of the amount of force required to cause a knot to slip and is directly proportional to the coefficient of friction for a given material.",
"     </li>",
"     <li>",
"      Elasticity refers to the suture's intrinsic ability to hold its original form and length after being stretched. This allows the suture to expand with wound edema or to retract and maintain wound edge apposition during wound contraction. Plasticity refers to a material that, when stretched, does not return to original length.",
"     </li>",
"     <li>",
"      Memory is closely related to plasticity and elasticity. It refers to the inherent ability of a material to return to its former shape after being manipulated, and is often a reflection of its stiffness. A suture with a high level of memory is stiffer, more difficult to handle, and more susceptible to becoming untied than a suture with low memory. Polypropylene (Prolene) is a good example of a suture with a high level of memory [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Absorbable sutures",
"    </span>",
"    &nbsp;&mdash;&nbsp;An absorbable suture is generally defined as one that will lose most of its tensile strength within 60 days after implantation beneath the skin surface [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/6\">",
"     6",
"    </a>",
"    ]. The most commonly used today are the synthetic sutures (polyglactin 910 [Vicryl], polyglycolic acid [Dexon], polydioxanone [PDS], and polytrimethylene carbonate [Maxon]) (",
"    <a class=\"graphic graphic_table graphicRef51741 \" href=\"UTD.htm?32/22/33132\">",
"     table 2",
"    </a>",
"    ). Catgut is still used frequently in pediatric wound closures. Fast Absorbing Gut is ideal for percutaneous facial closures and Chromic Gut can be used for laceration repair under splints or casts.",
"   </p>",
"   <p>",
"    The ideal absorbable suture has low tissue reactivity, high tensile strength, slow absorption rates, and reliable knot security. Classically, absorbable sutures were only used for deep sutures. However, many have advocated the use of absorbable sutures for percutaneous closure of wounds in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fast-absorbing gut for percutaneous closure of some facial lacerations is reasonable, particularly if suture removal will be traumatic. Subcutaneous sutures with a synthetic absorbable suture may improve wound tension and provide support to the healing wound once the gut has dissolved.",
"     </li>",
"     <li>",
"      Vicryl Rapide or Chromic Gut is ideal for percutaneous closure of lacerations underneath casts or splints, but is limited for facial use due to their longer absorption times.",
"     </li>",
"     <li>",
"      Chromic gut or Vicryl works well for single or layered closure of tongue or oral mucosa lacerations.",
"     </li>",
"     <li>",
"      Vicryl or Monocryl is ideal for dermal closure of deep facial lacerations.",
"     </li>",
"     <li>",
"      Nail bed closure is best done with chromic gut or Vicryl.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Catgut",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catgut is a natural product derived from sheep or cattle intima. Plain catgut retains significant tensile strength for only five to seven days. Chromic gut is treated with chromium salts to resist body enzymes, thus delaying absorption time. Chromic gut retains tensile strength for 10 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main use of chromic gut is to close lacerations in the oral mucosa. Chromic gut is more rapidly absorbed in the oral cavity than most synthetic sutures, making it ideal for this environment. Chromic Gut is also used at our institution for skin closure on fingertip lacerations with or without concurrent nail bed injuries. It is less optimal for use in dermal (subcutaneous) and muscle layer closures because of increased tissue reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fast-absorbing gut is a newer material not treated with chromic salts. It is heat-treated to accelerate tensile strength loss and absorption. It is used primarily for epidermal suturing, where sutures are only required for five to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/12\">",
"     12",
"    </a>",
"    ]. The use of this fast-absorbing suture was studied in 654 wounds during plastic surgery procedures. The suture was adequately dissolved in the majority of cases during follow-up visits at four to six days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/8\">",
"     8",
"    </a>",
"    ]. Fast-absorbing gut is ideal for suturing facial lacerations when tissue adhesives cannot be used or suture removal will be difficult. However, care must be taken to be gentle with tying knots when using the smaller (6-0) fast-absorbing gut, due to its low tensile strength. It is reasonable to reinforce this suture with skin tapes. The use of 5-0 fast absorbing gut is reasonable for facial closures due to improved tensile strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Polyglactin 910 (Vicryl)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Introduced in 1974, Vicryl is a lubricated, braided synthetic material with excellent handling and smooth tie-down properties. It retains significant tensile strength for three to four weeks. Complete absorption occurs in 60 to 90 days. It has decreased tissue reactivity compared with catgut as well as improved tensile strength and knot strength [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/5\">",
"     5",
"    </a>",
"    ]. Vicryl is an ideal choice for subcutaneous sutures.",
"   </p>",
"   <p>",
"    A newer form of Vicryl, Vicryl Rapide, has properties similar to fast-absorbing gut. It is the fastest absorbing synthetic suture and is indicated only for use in superficial soft tissue approximation of the skin and mucosa. All of its tensile strength is lost by 10 to 14 days, and the suture begins to \"fall off\" in 7 to 10 days as the wound heals. It is ideal for skin closure in patients in whom suture removal would be difficult or for closure of lacerations under casts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/12\">",
"     12",
"    </a>",
"    ]. The longer absorption time may limit its usefulness in some facial closures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Poliglecaprone 25 (Monocryl)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monocryl is a monofilament suture that has superior pliability for easier handling and tying of knots. Its monofilament quality gives it a theoretical advantage over braided sutures for contaminated wounds requiring deep sutures. This suture is often used by plastic surgeons at our institution for facial lacerations closed with subcuticular running sutures. All of its tensile strength is lost by 21 days postimplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Polglycolic acid (Dexon)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Introduced in 1970, polyglycolic acid was the first synthetic absorbable suture to become available. It is a braided polymer, is less reactive than gut sutures, and has excellent knot security. It maintains at least 50 percent of its tensile strength for 25 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"     13",
"    </a>",
"    ]. The main drawback is a high friction coefficient causing \"binding and snagging\" when wet. Newer forms of this suture have been developed, Dexon Plus and Dexon II, which have an added synthetic coating to improve handling properties while maintaining knot security [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Polydiaxanone (PDS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;PDS is a synthetic monofilament polymer marketed as having improved tensile strength compared with Vicryl. It retains the majority of its tensile strength at five to six weeks. Because it is a monofilament, it has the theoretical advantage of creating a lower potential for infection. In addition, it appears to have a lower friction coefficient and better knot security than Vicryl. A disadvantage of using PDS is that it is more difficult to use than the braided synthetics because of intrinsic stiffness. In addition, it costs about 14 percent more than either Dexon or Vicryl [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Polytimethylene carbonate (Maxon)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maxon is a synthetic monofilament. It was developed to combine the excellent tensile strength of PDS with improved handling properties. The majority of its tensile strength is present at five to six weeks. It has minimal tissue reactivity, excellent first-throw holding capacity, and smoother knot tie-down than Vicryl. The only disadvantage is the approximate 7 percent increased cost compared with Vicryl or Dexon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonabsorbable sutures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knot security, tensile strength, tissue reactivity, and workability of the various nonabsorbable sutures used for skin closure are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef63622 \" href=\"UTD.htm?36/14/37099\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Silk",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Silk is a natural product that is renowned for its ease to handle and tie. It has the lowest tensile strength of any nonabsorbable suture. It is rarely used for suturing of minor wounds because stronger synthetic materials are now available.",
"     </li>",
"     <li>",
"      <strong>",
"       Nylon (Dermalon, Ethilon)",
"      </strong>",
"      &ndash; Nylon was the first synthetic suture introduced; it is popular due to its high tensile strength, excellent elastic properties, minimal tissue reactivity, and low cost. Its main disadvantage is prominent memory that requires an increased number of knot throws (3 to 4) to hold a suture in place [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Polypropylene (Surgilene, Prolene)",
"      </strong>",
"      &ndash; Polypropylene is a plastic, synthetic suture that has low tissue reactivity and high tensile strength similar to nylon. It is slippery and requires extra throws to secure the knot (4 to 5). Prolene is especially noted for its plasticity, allowing the suture to stretch to accommodate wound swelling. When wound swelling recedes, the suture will remain loose. The cost of Prolene is approximately 13 percent more than nylon [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/5\">",
"       5",
"      </a>",
"      ]. Prolene can be purchased in a blue color, which can be advantageous in localizing sutures in the scalp and dark-skinned individuals.",
"     </li>",
"     <li>",
"      <strong>",
"       Polybutester (Novafil)",
"      </strong>",
"      &ndash; Polybutester suture is composed of a monofilament synthetic copolymer with tensile strength and healing properties similar to nylon and polypropylene [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/14\">",
"       14",
"      </a>",
"      ]. Polybutester also handles well but has greater elasticity than either nylon or polypropylene. Its use may be associated with decreased potential for suture marks because of its ability to expand if wound edema occurs [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NEEDLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choosing the proper needle can be confusing because of varying nomenclature. The two most prominent manufacturers of suture, Ethicon and Davis and Geck, use different nomenclature for their needles [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/5\">",
"     5",
"    </a>",
"    ]. The basic anatomy of a needle remains the same, however:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The eye is the end of the needle attached to the suture. All sutures used for acute wound repair are swaged (ie, the needle and suture are connected as a continuous unit).",
"     </li>",
"     <li>",
"      The body of the needle is the portion that is grasped by the needle holder during the procedure. The body determines the shape of the needle and is curved for cutaneous suturing. The curvature may be one-fourth, three-eighths, one-half, or five-eighths circle. The most commonly used curvature is the three-eighths circle, requiring only minimal pronation of the wrist for large and superficial wounds. The one-half and five-eighths circles were devised for suturing in confined spaces, such as the oral cavity.",
"     </li>",
"     <li>",
"      The point of the needle extends from the extreme tip to the maximum cross section of body. For soft tissue and fascia, the taper needle, round in cross section, is ideal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Needle points are also available in cutting, conventional cutting, or reverse cutting form:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutting &ndash; Cutting needles have at least two opposing cutting edges. Cutting needles are ideal for skin sutures that must pass through dense, irregular, and relatively thick dermal connective tissue.",
"     </li>",
"     <li>",
"      Conventional cutting &ndash; Conventional cutting needles have a third cutting edge on the inside concave curvature of the needle. This needle type may be prone to cutout of tissue because the inside cutting edge cuts toward the edges of the incision or wound.",
"     </li>",
"     <li>",
"      Reverse cutting &ndash; Reverse cutting needles have a third cutting edge located on the outer convex curvature of the needle, which theoretically reduces the danger of tissue cutout [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/12\">",
"       12",
"      </a>",
"      ]. Reverse cutting needles should be used for thick skin like the palm and soles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Standard skin needles (FS series, CE series) are suitable for the scalp, trunk, and extremities. Finer sutures on the face require a smaller and more sharply honed needle (P, PS, PC, and PRE series) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUTURING TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Percutaneous skin closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The simple interrupted suture is used to close most uncomplicated wounds. For proper healing, the edges of the wound must be everted. This is best accomplished using the following technique (",
"    <a class=\"graphic graphic_figure graphicRef60681 \" href=\"UTD.htm?9/34/9775\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74454 \" href=\"UTD.htm?35/31/36340\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The needle should penetrate the skin surface at a 90 degree angle.",
"     </li>",
"     <li>",
"      The suture loop should be at least as wide at the base as it is at the skin surface.",
"     </li>",
"     <li>",
"      The width and depth of the suture loop should be the same on both sides of the wound.",
"     </li>",
"     <li>",
"      The width and depth of the suture loop should be similar to the thickness of the dermis and will therefore differ from wound to wound, according to the anatomic location.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The number of sutures needed to close a wound varies depending upon the length, shape, and location of the laceration. In general, sutures are placed just far enough from each other so that no gap appears in the wound edges. A useful guideline is that the distance between sutures is equal to the bite distance from the wound edge [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dermal closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dermal or buried suture approximates the dermis just below the dermal-epidermal junction, which minimizes skin tension and closes dead space. Removing tension from a wound allows percutaneous sutures to be tied loosely and removed sooner, thereby improving the cosmetic result.",
"   </p>",
"   <p>",
"    Absorbable suture material must be used for dermal or buried sutures. The knot should be buried away from the skin surface of the wound so that it will not interfere with epidermal healing. This can be accomplished by inverting the suture loop using the following technique (",
"    <a class=\"graphic graphic_figure graphicRef75042 \" href=\"UTD.htm?31/22/32097\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The needle should be inserted in the dermis and directed toward the skin surface, exiting near the dermal-epidermal junction on the same side.",
"     </li>",
"     <li>",
"      The needle should then be inserted on the opposite side of the wound near the dermal-epidermal junction, directly across from the point of exit.",
"     </li>",
"     <li>",
"      The suture loop should be completed in the dermis, directly opposite the origin of the loop, and the knot tied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dermal sutures do not increase the risk of infection in clean, noncontaminated lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/16\">",
"     16",
"    </a>",
"    ]. However, animal studies suggest that deep sutures should be avoided in highly contaminated wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/17\">",
"     17",
"    </a>",
"    ]. There should be no more than three knots per suture and the fewest number of sutures possible should be placed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Alternative suture techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Running suture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A running suture is used for rapid percutaneous closure of longer wounds. It provides even distribution of tension along the length of the wound, preventing excess tightness in any one area. This technique is best reserved for wounds at low risk of infection with edges that align easily.",
"   </p>",
"   <p>",
"    The closure is started with the standard technique of a percutaneous simple interrupted suture, but the suture is not cut after the initial knot is tied. The needle is then used to make repeated bites, starting at the original knot by making each new bite through the skin at an angle of 45 degrees to the wound direction. The cross stays on the surface of the skin will be at an angle of 90 degrees to the wound direction. The final bite is made at an angle of 90 degrees to the wound direction to bring the suture out next to the previous bite. The final bite is left in a loose loop, which acts as a free end for tying the knot. A disadvantage to this suture is if the stitch breaks or if the physician wants to remove only a few sutures at a time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Subcuticular running suture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subcuticular running suture is often used by plastic surgeons to close straight lacerations on the face. An absorbable suture, such as Monocryl or Vicryl, is used. The suture is anchored at one end of the laceration and then a plane is chosen in the dermis or just deep to the dermis in the superficial subcutaneous fascia (",
"    <a class=\"graphic graphic_figure graphicRef71747 \" href=\"UTD.htm?19/28/19908\">",
"     figure 4",
"    </a>",
"    ). Mirror image bites are taken horizontally in this plane for the full length of the laceration. The final bite leaves a trailing loop of suture so a final knot can be tied. The wound is then reinforced with adhesive tape [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Vertical mattress",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vertical mattress suture is recommended for wounds under tension and for those with edges that tend to invert (fall or fold into the wound). It acts as a deep and superficial closure all in one suture. The first portion of the suture loop (far-far) approximates the dermal structures. The second portion (near-near) closes the wound and everts the edges.",
"   </p>",
"   <p>",
"    A vertical mattress suture is traditionally placed using the following technique (",
"    <a class=\"graphic graphic_figure graphicRef69848 \" href=\"UTD.htm?19/1/19473\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The needle is initially inserted at a distance from the wound edge, crossing through the dermal tissue and exiting through the skin on the opposite side at an equal distance from the wound edge. This is the far-far portion.",
"     </li>",
"     <li>",
"      The needle is then rotated 180 degrees in the needle holder and the direction of the suture loop is reversed (backhanded).",
"     </li>",
"     <li>",
"      On the return, small bites are taken at the",
"      <span class=\"nowrap\">",
"       epidermal/dermal",
"      </span>",
"      edges, which become approximated when the knot is tied. This near-near portion of the suture loop closes and everts the edges of the wound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, in the shorthand vertical mattress technique, the small backhand bites at the wound edges are completed first, followed by the deeper, wider forehand bites. In one trial that compared repair time and wound healing for patients randomized to receive either the traditional or the shorthand technique, wounds were repaired in one-half the time using the shorthand technique [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/18\">",
"     18",
"    </a>",
"    ]. There was no difference between the two groups with respect to wound healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Horizontal mattress",
"    </span>",
"    &nbsp;&mdash;&nbsp;A horizontal mattress suture can also be used to achieve wound eversion in areas of high skin tension. The needle is introduced into the skin in the usual manner and brought out on the opposite side of the wound. A second bite is taken along the opposite side, approximately 0.5 cm from the first exit site, and is brought back to the original starting side, also 0.5 cm from the initial entry point.",
"   </p>",
"   <p>",
"    The half-buried horizontal mattress suture combines elements of the horizontal mattress suture with a dermal closure. It can be used to approximate the corner of a flap (",
"    <a class=\"graphic graphic_figure graphicRef51901 \" href=\"UTD.htm?9/52/10063\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"     13",
"    </a>",
"    ]. The needle is introduced through the skin in the nonflap portion of the wound. In the dermal (or buried) portion of the suture, the corner of the flap is picked up horizontally through the dermis. The suture loop is completed by bringing the needle out through the skin on the opposite side of the nonflap portion. The knot is tied on the nonflap portion of the wound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SPECIFIC WOUND SITES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lip",
"      </strong>",
"      &ndash; The major consideration in lip lacerations is the integrity of the vermilion border. The casual observer can notice a misalignment as small as 1 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"       13",
"      </a>",
"      ]. The first suture should be placed through both edges of the divided vermilion border (",
"      <a class=\"graphic graphic_figure graphicRef55006 \" href=\"UTD.htm?34/14/35055\">",
"       figure 7",
"      </a>",
"      )",
"      <br/>",
"      <br/>",
"      An infraorbital nerve block for the upper lip and a mental nerve block for the lower lip are ideal for local anesthesia. Injection of local anesthesia directly into the wound should be avoided since it may distort the anatomic landmarks necessary to approximate the vermilion border.",
"      <br/>",
"      <br/>",
"      While the skin and vermilion border virtually always require sutures, the mucosal surface of a through-and-through lip laceration may not require suturing if there is good hemostasis and the wound edges are well-approximated.",
"     </li>",
"     <li>",
"      <strong>",
"       Tongue",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      The decision whether or not to repair a tongue laceration depends upon the extent of the laceration and the risk of compromised function after healing, but evidence suggests that outcomes for most tongue lacerations in young children are not improved by suturing. A more in-depth discussion of the indications and technique for repair of tongue lacerations is found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24309?source=see_link\">",
"       \"Evaluation and repair of tongue lacerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Scalp",
"      </strong>",
"      &ndash; The assessment and management of scalp wounds are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30872?source=see_link\">",
"       \"Assessment and management of scalp lacerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Eyebrow",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      The eyebrow should never be shaved, because regrowth of the hair is unpredictable. Debridement and excision of the wound should be conservative and parallel to the direction of hair follicle growth. The eyebrow is of major cosmetic significance and the wound edges should be carefully approximated. Closure of eyebrow lacerations is described in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=see_link&amp;anchor=H22537729#H22537729\">",
"       \"Assessment and management of facial lacerations\", section on 'Eyebrow'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Eyelids",
"      </strong>",
"      &ndash; Assessment and management of eyelid lacerations are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39045?source=see_link\">",
"       \"Eyelid lacerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cheek (zygoma)",
"      </strong>",
"      &ndash; Deep lacerations to the cheek, just anterior to the ear, have the potential to injure the parotid gland or the facial nerve (",
"      <a class=\"graphic graphic_figure graphicRef77364 \" href=\"UTD.htm?11/23/11634\">",
"       figure 8",
"      </a>",
"      ). If the parotid gland is injured, bloody fluid can be seen leaking from the parotid duct via the buccal mucosa at the level of the maxillary second molar.",
"      <br/>",
"      <br/>",
"      Closure of cheek lacerations is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=see_link&amp;anchor=H15489009#H15489009\">",
"       \"Assessment and management of facial lacerations\", section on 'Cheek'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Ear",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Wound closure on the ear can proceed in standard fashion when the cartilage is not involved. The cartilage should not be sutured if at all possible because of the risk of infection. If suturing is necessary, the perichondrium must be included in the stitch in order for it to hold. The goal in repairing a wound with exposed cartilage is to cover it with skin as completely as possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     GUIDELINES FOR CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with a plastic surgeon or other surgical specialist may be required in some circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Closure of large defects that might be more practical to close in the operating room or that might require grafting",
"     </li>",
"     <li>",
"      Severely contaminated wounds requiring drainage",
"     </li>",
"     <li>",
"      Tendon, nerve or vessel damage that requires repair",
"     </li>",
"     <li>",
"      Open fractures, amputations, and joint penetrations",
"     </li>",
"     <li>",
"      Laceration over the site of a fracture (even if contiguity seems unlikely, this is still technically considered an open fracture)",
"     </li>",
"     <li>",
"      Compression between two rollers (eg, washing machine, industrial), which can cause delayed, extensive soft tissue and muscle damage [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Paint and grease gun injuries, which can initially appear as benign puncture wounds but later develop widespread tissue injury due to high-pressure injection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Strong concern about cosmetic outcome by either the patient or family",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lacerations in some areas of the face may also require surgical consultation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=see_link&amp;anchor=H3940557#H3940557\">",
"     \"Assessment and management of facial lacerations\", section on 'Indications for subspecialty consultation or referral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     AFTERCARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Dressing and bathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most wounds should be covered with an antibiotic ointment and a nonadhesive dressing immediately after laceration repair. Evidence for this approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of 426 patients with wounds that received care within 12 hours found that treatment with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      zinc (eg, Bacitracin&reg;) or combination ointment containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      sulfate, bacitracin zinc, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      sulfate (eg, Neomycin&reg;) significantly reduced the rates of wound infection when compared to a petroleum ointment control (5 to 6 percent versus 18 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A crossover trial in four adults evaluated reepithelialization for wounds to the upper dermis on the inner aspect of the arm. Occluded wounds had 1.4 to 3.8 times increased new skin growth at five days. All wounds were 100 percent reepithelialized at seven days [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A crossover trial in 10 adults evaluated epithelial coverage in full thickness wounds to the lower extremity between occluded and air exposed sites. Occluded wounds had significantly increased epithelial coverage than air exposed wounds at seven days (62 versus 39 percent), but there was no difference in coverage at 14 days [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A nonadherent sterile gauze (eg, Xeroform) from which most of the grease is wrung, followed by cloth gauze, is ideal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/22\">",
"     22",
"    </a>",
"    ]. A simple Band-Aid will suffice for many small lacerations. Scalp wounds can be left open if small, but large head wounds can be wrapped circumferentially with Kerlix.",
"   </p>",
"   <p>",
"    The dressing should be left in place for 24 hours, after which time most wounds can be opened to air. Wounds closed with nonabsorbable (eg, nylon, polypropylene) suture may be gently cleaned with mild soap and water or half-strength peroxide after 24 hours to prevent crusting over the suture knots. An antibiotic ointment can be applied to the wound as well, with instructions to apply the ointment two times per day at home until suture removal. In contrast, absorbable sutures rapidly break down when exposed to water and should be kept dry.",
"   </p>",
"   <p>",
"    Patients with nonabsorbable sutures (eg, nylon, polypropylene sutures) may be allowed to shower or wash the wound with soap and water without risking increased rates of infection or disruption of the wound based upon the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of 857 patients who underwent minor skin excisions found that allowing bathing more than 12 hours after suture placement without antiseptic or dressing use was not inferior to keeping the wound dry and covered (infection rate 8.4 versus 8.9 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational study of 100 patients who underwent primary excision of a skin or soft-tissue lesion or local flap closure and began washing their wounds twice daily within 24 hours of surgery found no wounds developed infection or dehiscence [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not well studied, prolonged soaking of nonabsorbable stitches including swimming in chlorinated water should be avoided because of the theoretical risk of premature loss of suture tensile strength with wound dehiscence. Patients with sutures should also not swim in natural bodies of water because of a potential increased risk of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper wound preparation is the essential measure for preventing wound infection after suturing simple lacerations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"     \"Minor wound preparation and irrigation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that healthy patients with sutured nonbite wounds NOT be prescribed prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/25\">",
"     25",
"    </a>",
"    ]. A meta-analysis of seven trials (1701 total patients) found that prophylactic antibiotics in healthy patients with nonbite wounds were associated with a 16 percent increase in infection relative to control patients (95% CI 23 percent reduction to 78 percent increase in infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylactic antibiotics may decrease the risk of infection in some animal and human bites, intraoral lacerations, open fractures, and wounds that extend into cartilage, joints or tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, some experts advocate prophylactic antibiotics in patients with excessive wound contamination (eg, soil or water contamination), vascular insufficiency (eg, devascularized wound, peripheral artery disease), or immunocompromise [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial management of animal and human bites\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link&amp;anchor=H12#H12\">",
"     \"Soft tissue infections following water exposure\", section on 'Empiric antibiotic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Suture removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of suture removal varies with the anatomic site [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18553/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eyelids &ndash; 3 days",
"     </li>",
"     <li>",
"      Neck &ndash; 3 to 4 days",
"     </li>",
"     <li>",
"      Face &ndash; 5 days",
"     </li>",
"     <li>",
"      Scalp &ndash; 7 to 14 days",
"     </li>",
"     <li>",
"      Trunk and upper extremities &ndash; 7 days",
"     </li>",
"     <li>",
"      Lower extremities &ndash; 8 to 10 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Follow-up visits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clean wounds do not need to be seen by a physician until suture removal, unless signs of infection develop. Highly contaminated wounds should be seen for follow-up in 48 to 72 hours. It is imperative that clear discharge instructions are given to every patient regarding signs of wound infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     UNIQUE PEDIATRIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Anxious parent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A parent is an important advocate for his or her child, and his or her concerns need to be addressed with patience and understanding. It is inevitable that we will encounter some parents who demand a plastic surgeon for simple laceration repairs or sedation for a laceration that easily could be managed with patient distraction and topical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    injectable anesthetics. The best approach is to listen first and to suggest reasonable alternatives later. In some instances, there is no choice but to call a plastic surgeon. At other times, parents will listen to the explanation that the cosmetic outcome will be no different if repaired by a surgeon in the case of a simple, clean laceration. At times, it is also an issue of plastic surgeon availability. Often their viewpoint changes when the parents are truthfully told that it will be two to three hours before a surgeon can see their child.",
"   </p>",
"   <p>",
"    In cases where a parent demands sedation for a simple laceration, he or she must understand that sedation has risks that are unnecessary if a reasonable and safe alternative exists. The use of distraction methods and the use of topical anesthetics should also be explained to the parent. Child life specialists, if available, can provide invaluable assistance in this scenario. The child life specialist can adequately distract many patients by reading books with the patient or providing visual imagery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Anxious and uncooperative patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anxious and uncooperative patient is a challenge that at times can be managed with similar methods of distraction and imagery, but at other times leaves no choice but to sedate the patient to repair the laceration. Sedation choices vary depending upon age, mechanism of injury, and time required for repair.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is most commonly used for laceration repair in children. Other reasonable alternatives include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , midazolam alone, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/51/6962?source=see_link\">",
"       \"Patient information: Stitches (The Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wound irrigation, foreign body removal, and necrotic tissue debridement are the main preventative measures against tissue infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Wound preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classically, absorbable sutures were only used for deep sutures. However, absorbable sutures are now advocated in some cases for percutaneous closure of wounds in adults and children. In particular, fast-absorbing gut is ideal for skin closure of facial lacerations in patients in whom suture removal would be difficult or tissue adhesives are not an option. Chromic gut or Vicryl are recommended to close lacerations in the oral mucosa, and Vicryl Rapide or Chromic Gut is ideal for closure of lacerations under casts or splints. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Suture materials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutting needles are ideal for skin sutures that must pass through dense, irregular, and relatively thick dermal connective tissue. Standard skin needles (FS series, CE series) are suitable for the scalp, trunk, and extremities. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Needles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The simple interrupted suture is the standard technique used for the closure of most uncomplicated wounds (",
"      <a class=\"graphic graphic_figure graphicRef60681 \" href=\"UTD.htm?9/34/9775\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef74454 \" href=\"UTD.htm?35/31/36340\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Percutaneous skin closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deep sutures should be avoided in highly contaminated wounds (",
"      <a class=\"graphic graphic_figure graphicRef75042 \" href=\"UTD.htm?31/22/32097\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Dermal closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A running suture is used for rapid percutaneous closure of longer wounds. It is best reserved for wounds at low risk of infection with edges that align easily. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Running suture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vertical mattress suture is appropriate for wounds under tension and for wounds with edges that tend to fall or fold into the wound (",
"      <a class=\"graphic graphic_figure graphicRef69848 \" href=\"UTD.htm?19/1/19473\">",
"       figure 5",
"      </a>",
"      ). A horizontal mattress suture can also be used to achieve wound eversion in areas of high skin tension (",
"      <a class=\"graphic graphic_figure graphicRef51901 \" href=\"UTD.htm?9/52/10063\">",
"       figure 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Vertical mattress'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Horizontal mattress'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The timing of suture removal varies with the anatomic site. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Suture removal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/1\">",
"      Hollander JE, Singer AJ. Laceration management. Ann Emerg Med 1999; 34:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/2\">",
"      Kanegaye JT. A rational approach to the outpatient management of lacerations in pediatric patients. Curr Probl Pediatr 1998; 28:205.",
"     </a>",
"    </li>",
"    <li>",
"     McNamara, RN, Loiselle, J. Laceration repair. In: Textbook of pediatric emergency procedures, Henretig, F, King, C (Eds), Williams and Wilkins, Baltimore 1997. p.1141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/4\">",
"      Robson MC. Disturbances of wound healing. Ann Emerg Med 1988; 17:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/5\">",
"      Moy RL, Waldman B, Hein DW. A review of sutures and suturing techniques. J Dermatol Surg Oncol 1992; 18:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/6\">",
"      Lober CW, Fenske NA. Suture materials for closing the skin and subcutaneous tissues. Aesthetic Plast Surg 1986; 10:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/7\">",
"      Guyuron B, Vaughan C. A comparison of absorbable and nonabsorbable suture materials for skin repair. Plast Reconstr Surg 1992; 89:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/8\">",
"      Webster RC, McCollough EG, Giandello PR, Smith RC. Skin wound approximation with new absorbable suture material. Arch Otolaryngol 1985; 111:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/9\">",
"      Shetty PC, Dicksheet S, Scalea TM. Emergency department repair of hand lacerations using absorbable vicryl sutures. J Emerg Med 1997; 15:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/10\">",
"      Start NJ, Armstrong AM, Robson WJ. The use of chromic catgut in the primary closure of scalp wounds in children. Arch Emerg Med 1989; 6:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/11\">",
"      Andrade MG, Weissman R, Reis SR. Tissue reaction and surface morphology of absorbable sutures after in vivo exposure. J Mater Sci Mater Med 2006; 17:949.",
"     </a>",
"    </li>",
"    <li>",
"     Ethicon wound closure manual, Ethicon, Inc. 1998-2000.",
"    </li>",
"    <li>",
"     Trott, AT. Special anatomic sites. In: Wounds And Lacerations: Emergency Care and Closure, 3rd edition, Elsevier Mosby, Philadelphia 2005. p.153.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/14\">",
"      Bang RL, Mustafa MD. Comparative study of skin wound closure with polybutester (Novafil) and polypropylene. J R Coll Surg Edinb 1989; 34:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/15\">",
"      Rodeheaver GT, Borzelleca DC, Thacker JG, Edlich RF. Unique performance characteristics of Novafil. Surg Gynecol Obstet 1987; 164:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/16\">",
"      Austin PE, Dunn KA, Eily-Cofield K, et al. Subcuticular sutures and the rate of inflammation in noncontaminated wounds. Ann Emerg Med 1995; 25:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/17\">",
"      Mehta PH, Dunn KA, Bradfield JF, Austin PE. Contaminated wounds: infection rates with subcutaneous sutures. Ann Emerg Med 1996; 27:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/18\">",
"      Jones JS, Gartner M, Drew G, Pack S. The shorthand vertical mattress stitch: evaluation of a new suture technique. Am J Emerg Med 1993; 11:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/19\">",
"      Dire DJ, Coppola M, Dwyer DA, et al. Prospective evaluation of topical antibiotics for preventing infections in uncomplicated soft-tissue wounds repaired in the ED. Acad Emerg Med 1995; 2:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/20\">",
"      HINMAN CD, MAIBACH H. EFFECT OF AIR EXPOSURE AND OCCLUSION ON EXPERIMENTAL HUMAN SKIN WOUNDS. Nature 1963; 200:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/21\">",
"      Agren MS, Karlsmark T, Hansen JB, Rygaard J. Occlusion versus air exposure on full-thickness biopsy wounds. J Wound Care 2001; 10:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/22\">",
"      Phillips LG, Heggers JP. Layered closure of lacerations. Postgrad Med 1988; 83:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/23\">",
"      Heal C, Buettner P, Raasch B, et al. Can sutures get wet? Prospective randomised controlled trial of wound management in general practice. BMJ 2006; 332:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/24\">",
"      Noe JM, Keller M. Can stitches get wet? Plast Reconstr Surg 1988; 81:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/25\">",
"      Cummings P, Del Beccaro MA. Antibiotics to prevent infection of simple wounds: a meta-analysis of randomized studies. Am J Emerg Med 1995; 13:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18553/abstract/26\">",
"      Capellan O, Hollander JE. Management of lacerations in the emergency department. Emerg Med Clin North Am 2003; 21:205.",
"     </a>",
"    </li>",
"    <li>",
"     Selbst, SM, Attia, MW. Minor trauma - lacerations. In: Textbook of Pediatric Emergency Medicine, 5th edition, Fleisher, GR, Ludwig, S (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.1571.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6319 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-7288C09AE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18553=[""].join("\n");
var outline_f18_7_18553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WOUND PHYSIOLOGY AND HEALING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WOUND ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31004258\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31004266\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WOUND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUTURE MATERIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Absorbable sutures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Catgut",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Polyglactin 910 (Vicryl)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Poliglecaprone 25 (Monocryl)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Polglycolic acid (Dexon)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Polydiaxanone (PDS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Polytimethylene carbonate (Maxon)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonabsorbable sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NEEDLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUTURING TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Percutaneous skin closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dermal closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Alternative suture techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Running suture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Subcuticular running suture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Vertical mattress",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Horizontal mattress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SPECIFIC WOUND SITES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      GUIDELINES FOR CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      AFTERCARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Dressing and bathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Suture removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Follow-up visits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      UNIQUE PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Anxious parent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Anxious and uncooperative patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6319\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6319|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/34/9775\" title=\"figure 1\">",
"      Wound eversion A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/31/36340\" title=\"figure 2\">",
"      Wound eversion B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/22/32097\" title=\"figure 3\">",
"      Technique for deep suture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/28/19908\" title=\"figure 4\">",
"      Subcuticular suture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/1/19473\" title=\"figure 5\">",
"      Technique vertical mattress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10063\" title=\"figure 6\">",
"      Closing a corner of a flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/14/35055\" title=\"figure 7\">",
"      Lip laceration through the vermillion border",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/23/11634\" title=\"figure 8\">",
"      Cheek structure lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6319|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/22/33132\" title=\"table 2\">",
"      Absorbable sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/14/37099\" title=\"table 3\">",
"      Nonabsorbable sutures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=related_link\">",
"      Assessment and management of facial lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30872?source=related_link\">",
"      Assessment and management of scalp lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33124?source=related_link\">",
"      Closure of minor skin wounds with staples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24309?source=related_link\">",
"      Evaluation and repair of tongue lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39045?source=related_link\">",
"      Eyelid lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/51/6962?source=related_link\">",
"      Patient information: Stitches (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=related_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=related_link\">",
"      Superficial wound repair with tissue adhesives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=related_link\">",
"      Wound healing and risk factors for non-healing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_7_18554="Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults";
var content_f18_7_18554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18554/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18554/contributors\">",
"     Reinhard Lorenz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18554/contributors\">",
"     Stefan Endres, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18554/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18554/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/7/18554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/7/18554/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/7/18554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;By convention, acute hepatitis C virus (HCV) infection refers to the presence of clinical signs or symptoms of hepatitis within six months of presumed HCV exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/1\">",
"     1",
"    </a>",
"    ]. While acute hepatitis C virus (HCV) infection is estimated to account for 15 percent of symptomatic cases of acute liver disease in the United States, the majority of patients with acute HCV go undetected [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This is due in large part to the fact that patients with acute HCV are typically asymptomatic. In the United States, the Centers for Disease Control and Prevention estimated that there were 17,000 new cases of HCV in 2010, but that only 2800 patients (16 percent) presented with symptoms of acute hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/4\">",
"     4",
"    </a>",
"    ]. If acute HCV is diagnosed (either because of symptoms or screening high-risk patients), early treatment is appropriate for patients who do not spontaneously clear the virus, and is associated with high sustained virologic response rates. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will review acute HCV in adults. Issues related to the transmission of HCV, screening for HCV, and managing patients with chronic HCV are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H495128408\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hepatitis typically develops 2 to 26 weeks after exposure to hepatitis C virus (HCV), with a mean onset of 7 to 8 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/5\">",
"     5",
"    </a>",
"    ]. In patients who experience symptoms, the acute illness usually lasts for 2 to 12 weeks. Symptoms may include jaundice, nausea, dark urine, and right upper quadrant pain. However, most patients who are acutely infected with HCV are asymptomatic. Patients with acute HCV typically have moderate transaminase elevations, though they may go undetected in asymptomatic patients. Fulminant hepatic failure due to acute HCV infection is very rare but may be more common in patients with underlying chronic hepatitis B virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164593365\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the majority of patients with acute HCV are asymptomatic, some develop symptoms of acute hepatitis. In a review that included five studies from the National Heart, Lung, and Blood Institute Study of Transfusion-Associated Non-A, Non-B, and Type C Hepatitis, more than two-thirds of patients with acute HCV were asymptomatic during the acute episode [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Jaundice is a common symptom reported among patients presenting with symptomatic acute HCV. In a study that included 51 patients with symptomatic acute HCV, patients reported jaundice (68 percent), dark urine and white stool (39 percent), nausea (34 percent), and abdominal pain (25 percent, predominantly right upper quadrant pain) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/9\">",
"     9",
"    </a>",
"    ]. Additional symptoms reported in other studies include fatigue, low-grade fever and chills, loss of appetite, pruritus, muscle aches, mood disturbances, joint pain, dyspepsia, and confusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164593372\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminotransferase levels are often greater than 10 to 20 times the upper limit of normal in patients with acute HCV, but can be highly variable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In one of the largest series that included 254 patients with acute HCV, the mean alanine aminotransferase was 1174",
"    <span class=\"nowrap\">",
"     unit/L,",
"    </span>",
"    with a range of 5 to 5185",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     microkat/L,",
"    </span>",
"    range 0.09 to 88",
"    <span class=\"nowrap\">",
"     microkat/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/13\">",
"     13",
"    </a>",
"    ]. Among patients who develop symptoms, the aminotransferases start to increase shortly before the onset of clinical symptoms.",
"   </p>",
"   <p>",
"    Patients with acute HCV may also have elevated total bilirubin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/10,13,15,16\">",
"     10,13,15,16",
"    </a>",
"    ]. In the study of 254 patients, 51 percent had a bilirubin level above 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (51",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/13\">",
"     13",
"    </a>",
"    ]. In a second study with 28 patients with acute HCV, the mean bilirubin concentration was 4.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (75",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hepatitis C virus (HCV) infection should be suspected in patients with clinical manifestations of acute hepatitis or with possible exposure to HCV (eg, from a needle-stick). Such patients should be tested for the presence of HCV RNA and antibodies in the serum. The timing of testing is influenced by when HCV RNA and antibodies become detectable in the blood (",
"    <a class=\"graphic graphic_figure graphicRef68723 \" href=\"UTD.htm?22/31/23038\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60223 \" href=\"UTD.htm?20/39/21118\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A newly positive HCV RNA polymerase chain reaction (PCR), usually followed by the development of HCV antibodies within 12 weeks, is generally considered definitive proof of acute HCV infection. However, this requires documentation of a recent serum sample with a negative HCV RNA PCR and HCV antibodies. In the absence of such documentation, the distinction between acute HCV infection and newly discovered chronic infection is not straightforward, since in both settings patients may have detectable HCV RNA, HCV antibodies, and elevated serum aminotransferases. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Distinction from chronic infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For a patient presenting for the first time with acute hepatitis (eg, elevated transaminases and jaundice), we obtain the following tests:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Testing for HCV RNA by PCR immediately",
"     </li>",
"     <li>",
"      Anti-HCV-antibody testing by enzyme-linked immunosorbent assay (ELISA) immediately and at week 12",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For a patient presenting following a known exposure to HCV, we obtain the following tests:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Testing for HCV RNA by PCR immediately and at week 4, week 12, and 6 months",
"     </li>",
"     <li>",
"      Antibody testing by ELISA immediately and at week 12",
"     </li>",
"     <li>",
"      Serum aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) immediately and at weeks 4 and 12",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Baseline testing following an exposure to HCV is performed to determine if the patient has previously undiagnosed chronic HCV or to prove subsequent new seroconversion. Within one to two days following an exposure, a patient without prior infection should have negative HCV RNA, negative antibodies, and normal aminotransferases. These recommendations for postexposure testing are similar to those suggested by the National Institutes of Health, with slight differences in testing intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64908705\">",
"    <span class=\"h2\">",
"     Testing for HCV RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV RNA is first detectable in serum by PCR within days to eight weeks following exposure, depending in part upon the size of the inoculum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In a series of 14 needle-stick injuries, a negative HCV PCR at two weeks postexposure had a high negative predictive value (100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the minimal interval following suspected exposure after which a persistently negative HCV PCR test excludes infection has not been definitely established. We typically test patients at baseline, at week 4, at week 12, and at 6 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link&amp;anchor=H1987511#H1987511\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\", section on 'Quantitative tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCV RNA may remain detectable in the liver even in patients in whom it is undetectable in serum, although its clinical significance is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64908712\">",
"    <span class=\"h2\">",
"     Testing for HCV antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-HCV ELISA tests become positive as early as eight weeks after exposure, with most patients seroconverting between two and six months after exposure (",
"    <a class=\"graphic graphic_figure graphicRef68723 \" href=\"UTD.htm?22/31/23038\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60223 \" href=\"UTD.htm?20/39/21118\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/14,19\">",
"     14,19",
"    </a>",
"    ]. Approximately one-half of patients with symptomatic acute infection have detectable antibodies to HCV by ELISA when first presenting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the development of HCV antibodies may be delayed up to several years in patients who have subclinical infection.",
"   </p>",
"   <p>",
"    Delayed seroconversion was seen in a study of 19 patients who acquired HCV from injection drug use and had low levels of HCV RNA detected in their blood or peripheral blood mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/22\">",
"     22",
"    </a>",
"    ]. HCV antibodies developed an average of 41 months (range 13 to 94) after HCV RNA was first detected. Because of this, patients with suspected acute HCV or with known exposure to HCV must have HCV RNA testing by PCR, since a negative antibody test does not rule out infection.",
"   </p>",
"   <p>",
"    A positive anti-HCV ELISA does not distinguish",
"    <span class=\"nowrap\">",
"     acute/early",
"    </span>",
"    infection from chronic infection or from a prior infection that has spontaneously cleared. In addition, some patients with prior infection may have negative antibody testing because HCV antibody levels may eventually drop below detection limits in patients who have cleared the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. As a result, population-based studies that estimate spontaneous resolution rates of HCV infection using the prevalence of anti-HCV ELISA positivity and HCV PCR negativity in untreated patients may underestimate spontaneous resolution rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64908719\">",
"    <span class=\"h2\">",
"     Measurement of serum aminotransferases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminotransferase elevations of greater than 10 to 20 times the upper limit of normal are often seen with acute HCV (with an ALT up to 5185",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    [88",
"    <span class=\"nowrap\">",
"     microkat/L]",
"    </span>",
"    in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the levels often fluctuate and may normalize [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/10,26,27\">",
"     10,26,27",
"    </a>",
"    ]. Thus, not all patients will have elevated aminotransferase levels at the time of presentation, and normalization of the serum aminotransferase concentrations after acute infection does not necessarily mean that the infection has cleared. (See",
"    <a class=\"local\" href=\"#H164593372\">",
"     'Laboratory tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Distinction from chronic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing acute from chronic infection has important treatment implications since patients with acute HCV who do not spontaneously clear the virus should receive treatment with an interferon-based regimen. Treatment decisions in patients with chronic HCV are more complicated and take into account factors such as the HCV genotype and the degree of fibrosis. In addition, the treatment regimens are different for patients with acute and chronic HCV. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A newly positive HCV RNA PCR, usually followed by the development of HCV antibodies within 12 weeks, is generally considered definitive proof of acute HCV infection. However, this requires documentation of a recent serum sample with a negative HCV RNA PCR and HCV antibodies. In the absence of such documentation, the distinction between acute HCV infection and newly discovered chronic infection is not straightforward, since in both settings patients may have detectable HCV RNA, HCV antibodies, and elevated serum aminotransferases. In some cases, there is suggestive circumstantial evidence for new infection, such as a history of a recent high-risk exposure, new clinical features of acute hepatitis, consistently normal aminotransferase levels on prior testing, and absence of risk factors for HCV infection in the past. Although the presence of symptoms compatible with acute hepatitis can also be informative, most patients are asymptomatic during acute infection with HCV.",
"   </p>",
"   <p>",
"    The pattern and timing of the appearance of serologic markers, including HCV RNA (usually positive within two weeks after inoculation), serum aminotransferase elevations (usually preceding anti-HCV seropositivity), and HCV antibodies (usually several weeks after exposure) can help differentiate acute from chronic infection (",
"    <a class=\"graphic graphic_figure graphicRef68723 \" href=\"UTD.htm?22/31/23038\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60223 \" href=\"UTD.htm?20/39/21118\">",
"     figure 2",
"    </a>",
"    ). As examples, acute HCV is more likely in a patient with positive HCV RNA and high ALT concentrations but with negative HCV antibodies, whereas chronic HCV is more likely in a patient with positive HCV RNA, HCV antibodies, and low or normal ALT concentrations.",
"   </p>",
"   <p>",
"    Fluctuating low levels of HCV RNA are suggestive of acute HCV, whereas higher HCV levels that do not fluctuate are suggestive of chronic infection. In one report, low HCV RNA levels (&lt;10",
"    <sup>",
"     5",
"    </sup>",
"    int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    were seen in 17 of 21 patients with acute HCV (81 percent) compared with 81 of 623 patients with chronic HCV (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/26\">",
"     26",
"    </a>",
"    ]. Viral load fluctuations during a 10 week period among those with acute HCV were &gt;1 log in 18 patients (86 percent). By comparison, other studies have found that viral load fluctuations in chronic infection tend to be less than 0.5 log int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, evidence of hepatic fibrosis may suggest chronic infection. Acute HCV is diagnosed serologically, so liver biopsy is not required for making a diagnosis, but it may help differentiate acute HCV from chronic HCV in cases where there is doubt. Alternative noninvasive methods for detecting hepatic fibrosis are also being developed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link&amp;anchor=H15#H15\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\", section on 'Liver biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=see_link\">",
"     \"Noninvasive assessment of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164593400\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to acute hepatitis C virus (HCV) infection, the differential diagnosis of patients presenting with an elevation in aminotransferases, with or without symptoms of hepatitis, is broad and includes other liver diseases such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      toxicity",
"     </li>",
"     <li>",
"      Drug-induced liver",
"      <span class=\"nowrap\">",
"       injury/idiosyncratic",
"      </span>",
"      drug reactions (including herbal supplements and illicit drugs)",
"     </li>",
"     <li>",
"      Alcoholic hepatitis",
"     </li>",
"     <li>",
"      Nonalcoholic steatohepatitis",
"     </li>",
"     <li>",
"      Hepatitis A virus infection",
"     </li>",
"     <li>",
"      Acute or chronic hepatitis B virus (HBV) infection",
"     </li>",
"     <li>",
"      Chronic HCV infection",
"     </li>",
"     <li>",
"      Acute or chronic hepatitis D infection (in the setting of concurrent or pre-existing hepatitis B)",
"     </li>",
"     <li>",
"      Hepatitis E virus infection",
"     </li>",
"     <li>",
"      Hepatitis due to herpes simplex virus infection",
"     </li>",
"     <li>",
"      Hepatitis due to Ebstein-Barr virus infection",
"     </li>",
"     <li>",
"      Hepatitis due to cytomegalovirus infection",
"     </li>",
"     <li>",
"      Ischemic hepatitis",
"     </li>",
"     <li>",
"      Budd-Chiari syndrome",
"     </li>",
"     <li>",
"      HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome",
"     </li>",
"     <li>",
"      Acute fatty liver of pregnancy",
"     </li>",
"     <li>",
"      Wilson disease",
"     </li>",
"     <li>",
"      Autoimmune hepatitis",
"     </li>",
"     <li>",
"      Hereditary hemochromatosis",
"     </li>",
"     <li>",
"      Alpha-1 antitrypsin deficiency",
"     </li>",
"     <li>",
"      Toxin-induced hepatitis (eg, mushroom poisoning, carbon tetrachloride)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevated aminotransferases may also be seen in patients with disease such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Muscle diseases",
"     </li>",
"     <li>",
"      Thyroid disease",
"     </li>",
"     <li>",
"      Celiac disease",
"     </li>",
"     <li>",
"      Adrenal insufficiency",
"     </li>",
"     <li>",
"      Anorexia nervosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Differentiating among these entities requires a thorough history to identify risk factors for and symptoms of the various disorders as well as laboratory tests. Rarely, liver biopsy may be required if no cause for a patient's elevated aminotransferases can be determined noninvasively. The approach to the evaluation of a patient with abnormal liver tests is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164590471\">",
"    <span class=\"h1\">",
"     SPONTANEOUS VIRAL CLEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients infected with hepatitis C virus (HCV) may spontaneously clear the virus or go on to develop chronic infection. The estimates of how often patients spontaneously clear the virus range from 14 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/9,19,23,31-40\">",
"     9,19,23,31-40",
"    </a>",
"    ]. Several more recent studies of acute hepatitis C report spontaneous viral clearance around 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. As a general rule, most patients who are destined to spontaneously clear HCV viremia do so within 12 weeks and usually no later than 20 weeks after the onset of signs or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/9,27\">",
"     9,27",
"    </a>",
"    ]. As an example, in a study with 27 patients with acute HCV who were not receiving treatment, 8 patients (30 percent) spontaneously cleared the virus, 88 percent of whom did so before week 12 (with the final patient doing so at week 14) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/46\">",
"     46",
"    </a>",
"    ]. Whether spontaneous clearance can occur after longer follow-up (as in the case of chronic hepatitis B) is unclear, but it is unlikely when considering long-term follow-up studies in patients with post-transfusion hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The wide variability in estimated clearance rates may in part be related to the patient population, mode of acquisition of HCV, and risk of reinfection by continued exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/44\">",
"     44",
"    </a>",
"    ]. As an example, HCV RNA clearance rates of approximately 50 percent have been described in children and those infected after Rh immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/23,39,40\">",
"     23,39,40",
"    </a>",
"    ], whereas in injection drug users, rates of 20 percent or less have been seen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Reports suggest that reinfection must be considered, especially in patients with ongoing injection drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/44,48\">",
"     44,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic acute HCV infection appears to be associated with a higher rate of spontaneous clearance than asymptomatic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/9,39,49,50\">",
"     9,39,49,50",
"    </a>",
"    ]. In a study of patients with acute HCV, spontaneous clearance occurred in 24 of 46 patients (52 percent) who were symptomatic and in 0 of 9 who were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that may be associated with spontaneous clearance include a rapid decline in HCV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/27,32\">",
"     27,32",
"    </a>",
"    ] and certain polymorphisms in the IL28B gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Host and viral factors that have an influence on rates of spontaneous viral clearance remain a topic of intensive investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\", section on 'Risk of chronic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who appear to have cleared HCV RNA should have subsequent HCV RNA determinations to ensure that clearance was sustained. Our practice is to measure HCV RNA at three-month intervals for one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated, the majority of patients with acute hepatitis C virus (HCV) will develop chronic infection. However, if treatment with an interferon-based regimen is initiated during the acute infection, sustained virologic response (SVR) rates appear to be high (greater than 80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discussion that follows is generally consistent with guidelines issued in 2009 by the",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/Diagnosis_of_HEP_C_Update.Aug _09pdf.pdf\">",
"     American Association for the Study of Liver Diseases",
"    </a>",
"    (AASLD) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/55\">",
"     55",
"    </a>",
"    ]. However, in many instances the AASLD guideline provides guidance but does not make definitive recommendations. In such instances, we have provided recommendations based upon the available data. Specifically, the AASLD guideline does not make definitive recommendations regarding the choice of interferon, the optimal duration of treatment, or the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58732302\">",
"    <span class=\"h2\">",
"     Treatment overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use the following approach in the treatment of patients with acute HCV:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Who to treat &ndash;",
"      </strong>",
"      Patients with acute HCV are candidates for treatment if they have a high-likelihood of being adherent to treatment and do not have any comorbid illnesses that are contraindications to treatment. (See",
"      <a class=\"local\" href=\"#H58733829\">",
"       'Treatment candidates'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link&amp;anchor=H9641724#H9641724\">",
"       \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\", section on 'Patients in whom therapy is contraindicated'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       When to treat",
"      </strong>",
"      &ndash; The initiation of treatment should be delayed for 12 weeks from the time of suspected inoculation (or diagnosis if the time of inoculation is unsure, such as in patients with ongoing injection drug use) to allow time for spontaneous clearance to occur. Possible exceptions are those who are infected via a transfusion who typically receive a high inoculum and those with asymptomatic acute HCV, because chronic infection appears to be highly likely in such patients. In such patients we offer immediate treatment upon diagnosis. In addition, we offer immediate treatment to patients who are not willing to wait for additional testing during an observation period. (See",
"      <a class=\"local\" href=\"#H64910840\">",
"       'Influence of the timing of treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       What to treat with",
"      </strong>",
"      &ndash; Patients should receive weekly pegylated interferon alfa (either peginterferon alfa-2a 180 mcg per week or peginterferon alfa-2b 1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week). Treatment with standard interferon (5 million units per day for the first four weeks, then 5 million units three times per week for the remainder of treatment) is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H64910848\">",
"       'Influence of the treatment regimen'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Patients who are not co-infected with HIV should receive peginterferon monotherapy since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      does not appear to be beneficial in patients who are not co-infected with HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/41\">",
"       41",
"      </a>",
"      ]. However, based upon its efficacy in patients with chronic infection, we will add ribavirin to the treatment regimen if it is not clear if a patient's infection is acute or chronic and in patients who are HCV RNA-positive at the end of a course of treatment with peginterferon or standard interferon.",
"      <br/>",
"      <br/>",
"      Patients who are co-infected with HIV should receive peginterferon as well as weight-based ribavirin (&le;75 kg 1000 mg, &gt;75 kg 1200 mg, divided into two daily doses), provided there are no contraindications to using ribavirin (eg, impaired renal function). (See",
"      <a class=\"local\" href=\"#H58732862\">",
"       'Addition of ribavirin'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Anemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H14#H14\">",
"       \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       How long to treat",
"      </strong>",
"      &ndash; We treat patients with HCV genotype 2, 3, or 4 for 12 weeks. For patients with genotype 1, we treat for 24 weeks, but 12 weeks of therapy is a reasonable alternative in patients who achieve a rapid virologic response (negative HCV RNA at week 4) and are not tolerating therapy. (See",
"      <a class=\"local\" href=\"#H58732907\">",
"       'Influence of treatment duration'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58733829\">",
"    <span class=\"h2\">",
"     Treatment candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute HCV are candidates for treatment if they have a high-likelihood of being adherent to treatment. Not all patients with acute HCV are candidates for treatment. It is important that patients have a high-likelihood of adherence to therapy, as nonadherence is associated with significant decreases in SVR rates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In addition, patients may not be candidates for treatment if they have certain co-morbid conditions, such as major, uncontrolled depressive illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link&amp;anchor=H9641724#H9641724\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\", section on 'Patients in whom therapy is contraindicated'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79210547\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors influence treatment efficacy, including when treatment is initiated, the HCV genotype, and the duration of therapy. A meta-analysis of 1075 patients suggested overall SVR rates for patients treated with interferon-based therapy starting 12 weeks after diagnosis of greater than 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64910840\">",
"    <span class=\"h3\">",
"     Influence of the timing of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with symptomatic acute HCV, treatment is typically delayed for 12 weeks from the time of suspected inoculation (or diagnosis if the time of inoculation is not known) to allow time for spontaneous clearance to occur. Patients with asymptomatic acute HCV and those who acquired HCV through blood transfusion are at increased risk for developing chronic infection, and in such patients we initiate treatment at the time of diagnosis. (See",
"    <a class=\"local\" href=\"#H164590471\">",
"     'Spontaneous viral clearance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Delaying treatment for 12 weeks avoids unnecessary treatment in patients who are destined to clear the virus spontaneously and does not appear to decrease the likelihood of an SVR. In a meta-analysis of 22 studies with 1075 patients, patients treated within 12 weeks of diagnosis had higher SVR rates than those who initiated treatment between 12 and 24 weeks, or after 24 weeks (83 versus 67 and 63 percent, respectively), though the authors do not report whether the differences were statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/54\">",
"     54",
"    </a>",
"    ]. A second meta-analysis of 12 trials concluded delaying the initiation of therapy by 8 to 12 weeks did not decrease the SVR rate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Starting treatment earlier than 12 weeks has also been examined in randomized trials and generally does not appear to be beneficial provided patients are not lost to follow-up while awaiting treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial included 129 patients with acute HCV who had not cleared the virus by 8 weeks and were assigned to treatment with peginterferon starting at week 8, 12, or 20 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/46\">",
"       46",
"      </a>",
"      ]. On intention-to-treat analysis, an SVR was achieved by 95, 93, and 77 percent of patients, respectively. Subgroup analyses found that SVR rates were lower in patients with genotype 1 compared with genotypes 2, 3, and 4 (SVR rates of 72, 100, 93, and 84 percent, respectively). There was no benefit being seen with starting treatment at 8 weeks compared with 12 weeks for patients with genotype 2, 3, or 4, though a higher SVR rate was seen in patients with genotype 1 who started treatment at week 8 compared with week 12 (approximately 75 versus 50 percent).",
"      <br/>",
"      <br/>",
"      However, the number of patients who were nonadherent or who dropped out of the trial due to side effects was extremely low (one patient), so this trial may overestimate treatment responses. If these data are confirmed in subsequent trials, it may be reasonable to initiate treatment at 8 weeks for patients with genotype 1, though doing so would result in treating some patients who would have spontaneously cleared the virus without treatment.",
"     </li>",
"     <li>",
"      A second trial with 108 patients with acute HCV compared SVR rates between three groups: symptomatic patients who were treated immediately, symptomatic patients who were treated after a 12 week delay, and asymptomatic patients who were treated immediately [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/56\">",
"       56",
"      </a>",
"      ]. Preliminary results from the trial suggest acceptable SVR rates for all groups, provided patients who receive delayed treatment are not lost to follow-up prior to initiating treatment. Among symptomatic patients, the SVR rate was higher with immediate treatment than with delayed treatment (78 versus 54 percent). However, the lower SVR rate was mainly due to drop-outs during the 12 week observation period. Per-protocol analyses found SVR rates of 87 and 100 percent for the immediate and delayed treatment groups, respectively. Among the asymptomatic patients, the SVR rate on intention-to-treat analysis was 69 percent when treated immediately (100 percent on per-protocol analysis).",
"      <br/>",
"      <br/>",
"      This trial suggests that immediate treatment may be the preferred strategy in patients who are not willing to wait for additional testing during an observation period, provided they are otherwise suitable candidates for treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64910848\">",
"    <span class=\"h3\">",
"     Influence of the treatment regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported efficacy of treatment for acute HCV ranges from 22 to 98 percent with standard interferon given daily or every three days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/9,11,15,60-68\">",
"     9,11,15,60-68",
"    </a>",
"    ], and from 57 to 95 percent for pegylated interferon given weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/15,46,69-74\">",
"     15,46,69-74",
"    </a>",
"    ]. The majority of studies, regardless of the type of interferon used, report SVR rates of 70 percent or higher. Peginterferon may be preferable because it is easier to administer and may be better tolerated. However, studies directly comparing standard interferon with peginterferon are lacking. The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    may increase SVR rates among patients with HIV, but it does not appear to improve outcomes in patients who are HIV-negative.",
"   </p>",
"   <p>",
"    Our approach is to treat with peginterferon (either peginterferon alfa-2a 180 mcg per week or peginterferon alfa-2b 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per week). Treatment with standard interferon (5 million units per day for the first four weeks, then 5 million units three times per week for the remainder of treatment) is an acceptable alternative. In addition, provided there are no contraindications, we give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    to patients with HIV, to patients in whom it is not clear if the infection is acute or chronic, and to patients who are HCV RNA-positive at the end of a course of treatment with peginterferon or standard interferon.",
"   </p>",
"   <p>",
"    Using peginterferon instead of standard interferon is consistent with the 2009 practice guideline of the",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/Diagnosis_of_HEP_C_Update.Aug _09pdf.pdf\">",
"     American Association for the Study of Liver Diseases",
"    </a>",
"    and preliminary data from the German HEP-NET acute HCV III study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70774814\">",
"    <span class=\"h4\">",
"     Studies of standard and pegylated interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of studies have been performed with standard interferon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four randomized trials involving 141 patients with acute transfusion-acquired HCV compared patients treated with standard interferon monotherapy with patients who were treated with placebo or who received no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/75\">",
"       75",
"      </a>",
"      ]. Patients treated with standard interferon monotherapy had a greater likelihood of having an end of treatment virologic response (42 versus 4 percent) and a sustained virologic response (32 versus 4 percent). While the SVR rates with treatment in the meta-analysis were low, more recent studies suggest higher SVR rates.",
"     </li>",
"     <li>",
"      Some of the best results with standard interferon were seen in a study of 44 patients with acute HCV using a regimen that began initially with 5 million units subcutaneously daily for four weeks, followed by 5 million units subcutaneously three times weekly for 20 more weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/11\">",
"       11",
"      </a>",
"      ]. The SVR rate with this regimen was 98 percent.",
"      <br/>",
"      <br/>",
"      A subsequent report included 31 of the patients who were followed for a median of 135 weeks, during which HCV RNA remained undetectable, suggesting that the virologic response was durable [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/76\">",
"       76",
"      </a>",
"      ]. The induction strategy and the use of a relatively high dose of standard interferon therapy may have been important factors leading to the high SVR rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A growing number of studies have evaluated peginterferon in the treatment of acute HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/15,46,69-73\">",
"     15,46,69-73",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial included 129 patients with acute HCV who were treated with peginterferon starting at various times following diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/46\">",
"       46",
"      </a>",
"      ]. The overall SVR rate was 94 percent and was higher for patients with genotype 2, 3, or 4 compared with genotype 1. (See",
"      <a class=\"local\" href=\"#H64910840\">",
"       'Influence of the timing of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An open-label trial treated 89 patients with acute HCV [",
"      <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/69\">",
"       69",
"      </a>",
"      ]. Most of the patients were identified following surveillance after a known exposure. Patients received peginterferon for 24 weeks beginning when acute infection was detected. Treatment was initiated a median of 76 days after infection. An SVR was observed in 71 percent of patients on an intention-to-treat basis. However, only 65 of the 89 patients (73 percent) adhered to therapy. An SVR was more likely in the subset of patients who were adherent to treatment (89 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58732862\">",
"    <span class=\"h4\">",
"     Addition of ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence in support of combining interferon or peginterferon with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in the therapy of acute HCV is scarce, but the available data suggest it does not provide a significant advantage over monotherapy with peginterferon or standard interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/41,71\">",
"     41,71",
"    </a>",
"    ]. However, based upon its efficacy in patients with chronic infection, we use combination therapy if it is not clear if a patient's infection is acute or chronic and in patients who are HCV RNA-positive at the end of a course of treatment with peginterferon or standard interferon. In addition, we also use combination therapy in patients who are HIV-positive, since there appears to be a benefit in this population. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Distinction from chronic infection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=see_link&amp;anchor=H3#H3\">",
"     \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\", section on 'Combination therapy with interferon alfa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of combination therapy with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    was evaluated in a prospective study that included 40 subjects with acute HCV who were treated with peginterferon plus ribavirin combination therapy (n = 20) or peginterferon monotherapy (n = 20) for 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/71\">",
"     71",
"    </a>",
"    ]. SVR rates were compared with a group of 14 untreated controls. All patients were infected with genotypes 1 or 4. Treatment was started after an initial 12-week observation period. An SVR was observed in 85 percent of the combination group and 80 percent of the monotherapy group (p = 0.3). By comparison, only 5 of the 14 untreated patients (36 percent) spontaneously cleared the virus.",
"   </p>",
"   <p>",
"    One group that may benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is patients who are coinfected with HIV, who have SVR rates as low as 0 to 10 percent with monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Some studies suggest that the addition of ribavirin may increase SVR rates in co-infected patients to 47 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/79-82\">",
"     79-82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79210515\">",
"    <span class=\"h4\">",
"     Addition of a protease inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of a protease inhibitor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    to the treatment regimen of patients with chronic HCV genotype 1 is now standard of care. However, it is not yet known whether there is a role for protease inhibitors in the treatment of patients with acute HCV genotype 1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the high SVR rates seen with interferon-based monotherapy, the risk of additional side effects, and the lack of studies in acute hepatitis C, we are not currently recommending adding a protease inhibitor to the treatment regimens for our patients with acute HCV genotype 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58732907\">",
"    <span class=\"h3\">",
"     Influence of treatment duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longer treatment durations are associated with higher SVR rates in patients with genotype 1, but they appear less important for patients with other genotypes. Based on the available data, we suggest 12 weeks of treatment for patients with HCV genotype 2, 3, or 4. For patients with genotype 1 who do not achieve a rapid virologic response (RVR, negative HCV RNA at week 4 of treatment), we suggest 24 weeks of treatment. We also suggest 24 weeks of therapy for patients with genotype 1 who do achieve an RVR, but 12 weeks of therapy is a reasonable alternative in such patients if they are not tolerating therapy.",
"   </p>",
"   <p>",
"    The duration of therapy was evaluated in a randomized trial that included 102 patients with acute hepatitis C who were treated with peginterferon for 8, 12, or 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/72\">",
"     72",
"    </a>",
"    ]. Overall, SVR rates were 68 percent with 8 weeks of treatment, 82 percent with 12 weeks of treatment, and 91 percent with 24 weeks of treatment.",
"   </p>",
"   <p>",
"    As with chronic HCV, the optimal duration of treatment may vary with the genotype. In the study of 102 patients, the benefits of treatment durations of longer than 8 weeks were observed primarily in patients with HCV genotype 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/72\">",
"     72",
"    </a>",
"    ]. Among patients with genotype 1, the SVR rates after 8, 12, and 24 weeks of treatment were 38, 60, and 88 percent, respectively. By comparison, for patients with genotype 4, the SVR rates were 77, 93, and 100 percent, respectively, and all patients with genotype 2 or 3 achieved an SVR, regardless of treatment duration.",
"   </p>",
"   <p>",
"    In addition to genotype, another factor that may influence treatment duration is whether the patient achieves an RVR. Among the patients with HCV genotype 1 who achieved an RVR, SVR rates were 46, 75, and 92 percent with 8, 12, and 24 weeks of treatment, respectively, whereas response rates were 0, 0, and 33 percent, respectively among those who failed to achieve an RVR. Similarly, among patients with genotype 4 who achieved an RVR, SVR rates were 92, 92, and 100 percent, respectively, compared with 0, 50, and 50 percent, respectively for those who did not achieve and RVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55013931\">",
"    <span class=\"h2\">",
"     Influence of comorbid illnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with HIV-negative patients who achieve SVR rates of greater than 80 percent with interferon-based therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/54\">",
"     54",
"    </a>",
"    ], lower SVR rates are seen in patients with HIV. In HIV-positive patients treated with monotherapy, SVR rates are approximately 0 to 10 percent. However, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    may increase SVR rates (up to 80 percent) in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/77-83\">",
"     77-83",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H58732862\">",
"     'Addition of ribavirin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Lower SVR rates are also seen in patients on chronic dialysis. Interferon-based treatment of acute HCV in patients receiving dialysis increases SVR rates from approximately 10 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64911143\">",
"    <span class=\"h2\">",
"     Complications of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon-based therapy is associated with numerous side effects, including hematologic side effects, flu-like symptoms, and psychiatric side effects, including suicide attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/7/18554/abstract/69\">",
"     69",
"    </a>",
"    ]. The side effects of interferon-based treatment as well as their management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link&amp;anchor=H9641724#H9641724\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\", section on 'Patients in whom therapy is contraindicated'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of patients with acute hepatitis C virus (HCV) infection is uncommon since most patients are asymptomatic. Occasional patients with acute infection will be recognized because of symptoms or during surveillance following a known exposure. (See",
"      <a class=\"local\" href=\"#H495128408\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A newly positive HCV RNA polymerase chain reaction (PCR), usually followed by the development of HCV antibodies within 12 weeks, is generally considered definitive proof of acute HCV infection. However, this requires documentation of a recent serum sample with a negative HCV RNA PCR and HCV antibodies. In the absence of such documentation, the distinction between acute HCV infection and newly discovered chronic infection is not straightforward, since in both settings patients may have detectable HCV RNA, HCV antibodies, and elevated serum aminotransferases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Distinction from chronic infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For a patient presenting for the first time with acute hepatitis (eg, elevated transaminases and jaundice), we obtain the following tests for acute HCV (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Testing for HCV RNA by PCR immediately",
"     </li>",
"     <li>",
"      HCV-antibody testing by enzyme-linked immunosorbent assay (ELISA) immediately and at week 12",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a patient presenting following a known exposure to HCV, we obtain the following tests (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Testing for HCV RNA by PCR immediately and at week 4, week 12, and 6 months",
"     </li>",
"     <li>",
"      HCV-antibody testing by ELISA immediately and at week 12",
"     </li>",
"     <li>",
"      Serum aminotransferases immediately and at weeks 4 and 12",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients infected with HCV may spontaneously clear the virus or go on to develop chronic infection. The estimates of how often patients spontaneously clear the virus range from 14 to 50 percent. As a general rule, most patients who are destined to spontaneously clear HCV viremia do so within 12 weeks, and usually no later than 20 weeks after the onset of symptoms. (See",
"      <a class=\"local\" href=\"#H164590471\">",
"       'Spontaneous viral clearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our approach to the treatment of patients with acute HCV is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We discuss treatment with patients who have acute HCV if they have a high-likelihood of being adherent to treatment and do not have any comorbid illnesses that are contraindications to treatment. (See",
"      <a class=\"local\" href=\"#H58733829\">",
"       'Treatment candidates'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link&amp;anchor=H9641724#H9641724\">",
"       \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\", section on 'Patients in whom therapy is contraindicated'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest waiting 12 weeks from the time of suspected inoculation (or diagnosis if the time of inoculation is unknown) before starting therapy to allow time for spontaneous viral clearance to occur rather than initiating treatment immediately (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Immediate treatment is a reasonable alternative for patients who are infected via a transfusion and those with asymptomatic acute HCV because chronic infection appears to be highly likely in such patients. Our practice is to offer immediate treatment to such patients. In addition, immediate treatment is a reasonable alternative for patients who are not willing to wait for additional testing during an observation period. (See",
"      <a class=\"local\" href=\"#H64910840\">",
"       'Influence of the timing of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that HIV-negative patients with acute HCV who fail to spontaneously clear the virus and are treatment candidates receive treatment with an interferon-based regimen rather than being followed expectantly (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Patients who fail to spontaneously clear the virus within 12 weeks are unlikely to do so, and treatment is associated with SVR rates of greater than 80 percent. (See",
"      <a class=\"local\" href=\"#H164590471\">",
"       'Spontaneous viral clearance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest that HIV-negative patients receive monotherapy with an interferon-based regimen rather than combination therapy with interferon (pegylated or standard) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Ribavirin does not appear to be beneficial in patients who are not co-infected with HIV. The addition of ribavirin is a reasonable alternative if it is not clear if a patient's infection is acute or chronic and in patients who are HCV RNA-positive at the end of a course of treatment with peginterferon or standard interferon, based upon its efficacy in the treatment of patients with chronic HCV. (See",
"      <a class=\"local\" href=\"#H64910848\">",
"       'Influence of the treatment regimen'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We also suggest that HIV-positive patients with acute HCV who fail to spontaneously clear the virus and are treatment candidates receive treatment rather than being followed expectantly (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Among patients who are HIV-positive, we suggest treatment with weight-based ribavirin (&le;75 kg 1000 mg, &gt;75 kg 1200 mg, divided into two daily doses) in addition to interferon-based therapy, rather than interferon monotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). SVR rates among patients with HIV who receive interferon monotherapy are low, and ribavirin appears to increase SVR rates in this population. (See",
"      <a class=\"local\" href=\"#H58732862\">",
"       'Addition of ribavirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who are being treated receive pegylated interferon alfa (either peginterferon alfa-2a 180 mcg per week or peginterferon alfa-2b 1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week) rather than standard interferon (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The two regimens appear to have similar efficacies, and peginterferon is easier to administer and is better tolerated by many patients. Treatment with standard interferon (5 million units per day for the first four weeks, then 5 million units three times per week for the remainder of treatment) is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HCV genotype 2, 3, or 4, we suggest treatment for 12 weeks rather than 24 weeks (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Among patients with genotypes 2, 3, or 4, SVR rates approach 100 percent with 12 weeks of treatment. (See",
"      <a class=\"local\" href=\"#H58732907\">",
"       'Influence of treatment duration'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with HCV genotype 1 who do not achieve a rapid virologic response (negative HCV RNA at week 4), we recommend 24 weeks of treatment rather than 12 weeks (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Increasing the duration of treatment in patients with genotype 1 is associated with higher SVR rates, though even with 24 weeks of therapy, only approximately one-third of patients will achieve an SVR.",
"      <br/>",
"      <br/>",
"      For patients with HCV genotype 1 who do achieve an RVR, we also suggest 24 weeks of treatment rather than 12 weeks (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). While SVR rates with 12 weeks of therapy in such patients are approximately 75 percent, the SVR rate increases to over 90 percent with 24 weeks of treatment. Treating for 12 weeks is a reasonable alternative in patients with genotype 1 who achieve an RVR and are not tolerating therapy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/1\">",
"      Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology 2008; 47:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/2\">",
"      Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/3\">",
"      Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31:777.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/hepatitis/hcv/StatisticsHCV.htm (Accessed on September 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/5\">",
"      Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/6\">",
"      Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/7\">",
"      Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut 1999; 45:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/8\">",
"      Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26:21S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/9\">",
"      Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/10\">",
"      Loomba R, Rivera MM, McBurney R, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011; 33:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/11\">",
"      Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/12\">",
"      Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008; 372:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/13\">",
"      Deterding K, Wiegand J, Gruner N, et al. Role of BMI, age and sex for disease severity in acute hepatitis C: Analysis of 254 patients from the German Hep-Net acute HCV cohort. Z Gastroenterol 2008; 46:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/14\">",
"      Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis 2010; 14:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/15\">",
"      Corey KE, Ross AS, Wurcel A, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 2006; 4:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/16\">",
"      Vega Palomares R, Planas Vil&agrave; R, Dur&aacute;ndez Lazaro R, F&aacute;bregas Puigti&oacute; S. [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin]. Gastroenterol Hepatol 2002; 25:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/17\">",
"      National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology 2002; 36:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/18\">",
"      Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26:15S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/19\">",
"      Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/20\">",
"      Wang TY, Kuo HT, Chen LC, et al. Use of polymerase chain reaction for early detection and management of hepatitis C virus infection after needlestick injury. Ann Clin Lab Sci 2002; 32:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/21\">",
"      Haydon GH, Jarvis LM, Blair CS, et al. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 1998; 42:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/22\">",
"      Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999; 94:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/23\">",
"      Wiese M, Gr&uuml;ngreiff K, G&uuml;thoff W, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol 2005; 43:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/24\">",
"      Nikolaeva LI, Blokhina NP, Tsurikova NN, et al. Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat 2002; 9:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/25\">",
"      Wawrzynowicz-Syczewska M, Kubicka J, Lewandowski Z, et al. Natural history of acute symptomatic hepatitis type C. Infection 2004; 32:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/26\">",
"      McGovern BH, Birch CE, Bowen MJ, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis 2009; 49:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/27\">",
"      Santantonio T, Sinisi E, Guastadisegni A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003; 35:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/28\">",
"      Nguyen TT, Sedghi-Vaziri A, Wilkes LB, et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/29\">",
"      Gordon SC, Dailey PJ, Silverman AL, et al. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998; 28:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/30\">",
"      Fanning L, Kenny-Walsh E, Levis J, et al. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. Hepatology 2000; 31:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/31\">",
"      Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/32\">",
"      Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/33\">",
"      Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000; 32:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/34\">",
"      Rodger AJ, Roberts S, Lanigan A, et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/35\">",
"      Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/36\">",
"      Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/37\">",
"      Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/38\">",
"      Alter HJ, Conry-Cantilena C, Melpolder J, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26:29S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/39\">",
"      Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/40\">",
"      Vogt M, Lang T, Fr&ouml;sner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/41\">",
"      Nunnari G, Montineri A, Portelli V, et al. The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Eur Rev Med Pharmacol Sci 2012; 16:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/42\">",
"      P&eacute;rez-&Aacute;lvarez R, Garc&iacute;a-Samaniego J, Sol&aacute; R, et al. Acute hepatitis C in Spain: a retrospective study of 131 cases. Rev Esp Enferm Dig 2012; 104:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/43\">",
"      Morin T, Pariente A, Lahmek P, Investigator Group of ANGH, SPILF, FNPRH. Favorable outcome of acute occupational hepatitis C in healthcare workers: a multicenter French study on 23 cases. Eur J Gastroenterol Hepatol 2011; 23:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/44\">",
"      Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2012; 55:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/45\">",
"      Ferreira Ade S, Perez Rde M, Ferraz ML, et al. Acute hepatitis C in Brazil: results of a national survey. J Med Virol 2011; 83:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/46\">",
"      Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/47\">",
"      Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/48\">",
"      McDonald SA, Hutchinson SJ, Cameron SO, et al. Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow. Int J Drug Policy 2012; 23:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/49\">",
"      Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/50\">",
"      Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/51\">",
"      van den Berg CH, Grady BP, Schinkel J, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One 2011; 6:e27555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/52\">",
"      Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/53\">",
"      Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/54\">",
"      Corey KE, Mendez-Navarro J, Gorospe EC, et al. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010; 17:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/55\">",
"      Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335.",
"     </a>",
"    </li>",
"    <li>",
"     Deterding K, et al. Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV III study &ndash; a randomized controlled study. 44th EASL meeting, Copenhagen 22-26th April 2009, Abstract 1047.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/57\">",
"      Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/58\">",
"      Broers B, Helbling B, Fran&ccedil;ois A, et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005; 42:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/59\">",
"      Licata A, Di Bona D, Schepis F, et al. When and how to treat acute hepatitis C? J Hepatol 2003; 39:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/60\">",
"      Vogel W, Graziadei I, Umlauft F, et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996; 41:81S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/61\">",
"      Lampertico P, Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994; 19:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/62\">",
"      G&uuml;rsoy M, G&uuml;r G, Arslan H, et al. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001; 8:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/63\">",
"      Delwaide J, Bourgeois N, G&eacute;rard C, et al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004; 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/64\">",
"      Rocca P, Bailly F, Chevallier M, et al. [Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients]. Gastroenterol Clin Biol 2003; 27:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/65\">",
"      Nomura H, Sou S, Tanimoto H, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/66\">",
"      Calleri G, Colombatto P, Gozzelino M, et al. Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial. Ital J Gastroenterol Hepatol 1998; 30:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/67\">",
"      Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology 1994; 107:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/68\">",
"      Hwang SJ, Lee SD, Chan CY, et al. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994; 21:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/69\">",
"      Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/70\">",
"      Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/71\">",
"      Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/72\">",
"      Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/73\">",
"      De Rosa FG, Bargiacchi O, Audagnotto S, et al. Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users. Clin Infect Dis 2007; 45:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/74\">",
"      Broers B, Helbling B, Fran&ccedil;ois A, et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005; 42:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/75\">",
"      Poynard T, Regimbeau C, Myers RP, et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2002; :CD000369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/76\">",
"      Wiegand J, J&auml;ckel E, Cornberg M, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/77\">",
"      Serpaggi J, Chaix ML, Batisse D, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/78\">",
"      Danta M, Dusheiko GM. Acute HCV in HIV-positive individuals - a review. Curr Pharm Des 2008; 14:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/79\">",
"      Laguno M, Mart&iacute;nez-Rebollar M, Perez I, et al. Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses 2012; 28:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/80\">",
"      Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/81\">",
"      Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/82\">",
"      Piroth L, Larsen C, Binquet C, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology 2010; 52:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/83\">",
"      G&ouml;tz HM, van Doornum G, Niesters HG, et al. A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS 2005; 19:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/7/18554/abstract/84\">",
"      Fabrizi F, Dixit V, Messa P, Martin P. Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis. J Viral Hepat 2012; 19:784.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3650 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18554=[""].join("\n");
var outline_f18_7_18554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H495128408\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164593365\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164593372\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64908705\">",
"      Testing for HCV RNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64908712\">",
"      Testing for HCV antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64908719\">",
"      Measurement of serum aminotransferases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Distinction from chronic infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H164593400\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H164590471\">",
"      SPONTANEOUS VIRAL CLEARANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58732302\">",
"      Treatment overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58733829\">",
"      Treatment candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79210547\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H64910840\">",
"      - Influence of the timing of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H64910848\">",
"      - Influence of the treatment regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H70774814\">",
"      Studies of standard and pegylated interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H58732862\">",
"      Addition of ribavirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H79210515\">",
"      Addition of a protease inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58732907\">",
"      - Influence of treatment duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55013931\">",
"      Influence of comorbid illnesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64911143\">",
"      Complications of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3650|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/31/23038\" title=\"figure 1\">",
"      Serology acute to chronic HCV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/39/21118\" title=\"figure 2\">",
"      Acute HCV clearance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=related_link\">",
"      Noninvasive assessment of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=related_link\">",
"      Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_7_18555="Contraindications bronchoscopy";
var content_f18_7_18555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications to bronchoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Life-threatening arrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refractory hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor ability to cooperate with procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent myocardial infarction or unstable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum creatinine &gt;3.0*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelets &lt;50,000*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncorrected coagulopathy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superior vena cava obstruction*&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary hypertension*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable neck or cervical spine immobility&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limited motion of temporo-mandibular joint&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy&Delta;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Relative contraindication for biopsy, but not inspection.",
"     <br>",
"      &bull; Contraindication to rigid bronchoscopy only.",
"      <br>",
"       &Delta; Bronchoscopy is possible during pregnancy, however medications must be assessed careful for potential maternal and fetal toxicity.",
"       <br>",
"        &loz; Relative risk of bleeding with biopsy in this setting is not well-defined.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18555=[""].join("\n");
var outline_f18_7_18555=null;
var title_f18_7_18556="ACCP Rx mechanical valve";
var content_f18_7_18556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ninth ed: ACCP evidence-based practice guidelines: Antithrombotic therapy in patients with mechanical heart valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        &nbsp;&bull; In patients with mechanical heart valves, vitamin K antagonist (VKA) therapy is recommended over no VKA therapy and over antiplatelet agents&nbsp;for long-term management.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <ul>",
"         <li>",
"          In patients with&nbsp;a&nbsp;mechanical aortic&nbsp;heart valve, VKA therapy with a target of 2.5 (range 2.0 to 3.0) is recommended over higher targets and is suggested over lower targets.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <ul>",
"         <li>",
"          In patients with a mechanical mitral heart valve, VKA therapy with a target of 3.0 (range 2.5 to 3.5) is suggested over lower targets.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <ul>",
"         <li>",
"          &nbsp;In patients with mechanical heart valves in both the aortic and mitral position, a target INR of 3.0 (range 2.5 to 3.5) is suggested over a target INR of 2.5.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        &bull; In patients with a mechanical mitral or aortic valve at low risk of bleeding, an antiplatelet agent such as low-dose aspirin (50 to 100 mg/day) is suggested&nbsp;in addition to long-term VKA therapy (over not adding such an agent).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        &bull; For post-operative bridging immediately after mechanical heart valve replacement, unfractionated heparin (subcutaneous prophylactic dose) or low molecular weight heparin (prophylactic or therapeutic dose) is suggested over&nbsp;intravenous therapeutic unfractionated heparin until the INR is stable on VKA therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The most commonly used vitamin K antagonist (VKA) is warfarin.",
"    <br>",
"     <br>",
"      Note that the&nbsp;above&nbsp;INR ranges&nbsp;relate mostly to bileaflet and newer generation tilting disk valves.",
"      <br>",
"       <br>",
"        For older valves, the 2012 guidelines refer to the 2001 guidelines. The&nbsp;2001 guidelines recommended a target INR of&nbsp; 3.0 (2.5 to 3.5) for patients with (older) tilting disk valves. A combination of a target INR of 3.0 (range 2.5 to 3.5) plus aspirin 80 to 100 mg/d&nbsp;was recommended for patients with caged ball or caged disk valves.",
"        <div class=\"footnotes\">",
"         <p>",
"          &nbsp;",
"         </p>",
"        </div>",
"        <div class=\"reference\">",
"         Data from Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.&nbsp;Chest. 2012;141:e576S.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18556=[""].join("\n");
var outline_f18_7_18556=null;
var title_f18_7_18557="Educational resources for developmental-behavioral concerns";
var content_f18_7_18557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Educational and informational resources for health care providers and families of children with confirmed or suspected developmental and behavioral disabilities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Resources for parents and health care providers",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         American Academy of Child and Adolescent Psychiatry: Facts for families",
"        </p>",
"        <p>",
"         www.aacap.org",
"        </p>",
"       </td>",
"       <td>",
"        Provides handouts on topics such as divorce, disaster recovery, and how to choose a psychiatrist. The handouts are available in multiple languages and can be downloaded for free.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         American Academy of Pediatrics: Healthy children",
"        </p>",
"        <p>",
"         www.aap.org",
"        </p>",
"       </td>",
"       <td>",
"        Provides information for parents about health, development, and behavior of children at various ages.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         British Columbia Council for Families",
"        </p>",
"        <p>",
"         www.bccf.bc.ca",
"        </p>",
"       </td>",
"       <td>",
"        Provides articles, online questionnaires, and links to resources on a variety of parenting and family topics (eg, child development, family cohesion, adolescence, marriage). Individual and bulk copies of books and brochures can be purchased.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Children and Youth Health",
"        </p>",
"        <p>",
"         www.cyh.sa.gov.au",
"        </p>",
"       </td>",
"       <td>",
"        Provides information for parents on a range of psychosocial issues in teens and young children.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Early Childhood Connections",
"        </p>",
"        <p>",
"         www.rch.org.au/ecconnections/",
"        </p>",
"       </td>",
"       <td>",
"        Provides information for parents and professionals interested in developmental and behavioral issues in early childhood. It includes parent information sheets in various languages including Arabic, Bosnian, Chinese, Croatian, Somali, Spanish, Turkish, Vietnamese, and English. (Adobe Reader is required.)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         First 5 California",
"        </p>",
"        <p>",
"         www.ccfc.ca.gov/parents/",
"        </p>",
"       </td>",
"       <td>",
"        Provides child-rearing guidance for parents in a variety of languages including Spanish, Chinese, Korean, and Vietnamese.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         First Signs",
"        </p>",
"        <p>",
"         www.firstsigns.org",
"        </p>",
"       </td>",
"       <td>",
"        Promotes early detection of autism and other developmental disorders through routine screening and collaboration among medical and non-medical professionals. Provides an information kit for clinicians that includes a video demonstrating the behaviors of children on and off the autism spectrum.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Kids' Health (the Nemours Foundation)",
"        </p>",
"        <p>",
"         www.kidshealth.org",
"        </p>",
"       </td>",
"       <td>",
"        Provides information on health and safety, emotional and social development, and positive parenting.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         PEDSTest, LLC",
"        </p>",
"        <p>",
"         www.pedstest.com/Translations/HelpforSpanishspeakers.aspx",
"        </p>",
"       </td>",
"       <td>",
"        Provides downloadable handouts in Spanish for parents and professionals on topics such as promoting speech and language, promoting motor and self-help skills, promoting social development, getting ready for kindergarten, death and dying, discipline and behavior, marital problems and divorce, parents, and careers.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Reach Out and Read",
"        </p>",
"        <p>",
"         www.reachoutandread.org/parents/",
"        </p>",
"       </td>",
"       <td>",
"        Provides parenting handouts on how to share books, literacy milestones, etc.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Selected Patient Information Resources in Asian Languages (SPIRAL) (maintained by Tufts University)",
"        </p>",
"        <p>",
"         spiral.tufts.edu",
"        </p>",
"       </td>",
"       <td>",
"        Provides downloadable Asian language on health, child-rearing, and disabilities.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         United Kingdom Department of Health",
"        </p>",
"        <p>",
"         file://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH_107303",
"        </p>",
"       </td>",
"       <td>",
"        Provides book on parenting and child-rearing on its Web site.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         US Department of Education&mdash;My child's academic success",
"        </p>",
"        <p>",
"         file://www.ed.gov/parents/academic/help/partnership.html",
"        </p>",
"       </td>",
"       <td>",
"        Provides information for Spanish-speaking families on how to promote child development, help school-age children, etc.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Frances Page Glascoe, 2011, Nolensville, TN: PEDSTest.com, LLC, www.pedstest.com. Adapted with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18557=[""].join("\n");
var outline_f18_7_18557=null;
var title_f18_7_18558="Effect on dyspnea";
var content_f18_7_18558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of pulmonary rehabilitation on dyspnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 271px; background-image: url(data:image/gif;base64,R0lGODlhpQEPAeYAAP///4CAgAAAAP+ZMyBzOQAzmcDAwEBAQP8AABAQECAgIFBQUDAwMNDQ0KCgoPDw8ODg4HBwcEBms//MmbCwsGBgYJC5nP+fQFiWa5CQkC58RRBAn//mzf+zZvL38//58/+AgP8QEPDz+f+mTcjczoCZzDyFUv/s2f/z5v/AwP/fwOTu51Bzuf/Gjf+sWf+5c//w8P/Zs2afdyBNpsDN5v/TpkqNXv9AQP8wMDBZrHCNxnSohNbl29DZ7KzLtbrUwv/Q0JCm0/+/gLDA34KwkJ7Cqf9QUODm8/8gIP+goP9wcP+QkP+wsP/g4P9gYKCz2WCAv9C5zO/T2a+gv4+Wwt+2w1Biqd+Wo49Wg4CJvO/j6VBmk69Qb+/Dyc9pfO4jKb98lo92o3J3c+9jaT9Wot9WY+DW4++jqe8yOcC81nB8tb+dtu9zel9QjwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAClAQ8BAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+SQBucGsQsLDwDoBu2ZFAEBFI4RB4gOB/bl/uICAgpI4MBVAAHpAAgcmLDSAwYCDkAM0OiAgEQLEsT7x5FbQAAQIBpoECCdgQANAGQ4cCAChJMG1qU8SaECP0ExW7bLeSBDoQcJKgz6GEEARQAUFvQU5CAAhAwQAARoGaDgoIMRBDWwBwHfAnv4DlRIaVEQBJtjzRrtyFbbRwAO/wQsgCAXwAIBZwVECMDgZMQACRJIHWgRLwW5RRdIrTBVgFVBhxsG5Ksg6uEFRbNaTIAw8cF8g+L+TQk0QQCbABQEiJBAAYCyEBIwACxYkMS2uK29NRDxNd66dxeUHJyuqN/iCO/SU3DxQYYFEwkdJBTwAHOKd9sxEGwxngDXCkFf5RzQQQbHZt3h4+xbpQDGFhNOz00/2tu4QuNCtPegAkQB8yBE3EHpEGgRPfQAsF0G5x0lyHyCvPVRWe1RGF6E4gEQTwNFHUDgIJdRAFF7BzFGT1SD1aeiMwEZ4EBgUQE1kCAVZGBAURkclAEFgRFH3HkLGFCTQgrcuFZoAqQUIf9C57nW4GXtCbJfXBlO5YABFRjVgAB9OSCcURQw196WDFBwo5ILgLfimsgstICSAGSZlVScJZDVQcwpkNKHfDJXl2gHEkKXgwsdoCRrcrVjYQPMWZShAYWpBtl/ATz0nZgUihgQAzEGxeanz0CEoiEfclJBAqNKIqRfc4ZyUKqgxmrMlhkWUuomQDGwUSSiBbWrJ3E5KOuwxBZr7LHIJqvsssw26+yz0EYr7bTUxnJOtdhm+6Cw2nb7bILehussuOKWmyy55qZLLLrqtvspu+7GWx+88tbLFr325lsOvvr2Cw6//ga8DcACF2wNwQYnPMwDTXFrq8MKRzxMA5xZpwj/whJnnAtzcCaCscYgz7KlAswpRshJCHoY8sq88NYXRI+5g+BUELNscyy0DlazVDvf7DMrzGnaEKk9/2z0KQ1ARNDFRR/tdCwfPy21KlFPbXUpVV+tNShZV5PC1ynAUEkSNwABwA1KbC1O19Qg4DYCIaRACQgIyA1CEmqHw/Y0bgOgBAIgAJCCETfcsIQgQDhxgxF4wwDC4kwAQLfdeKcAAhOKRy444UqInXc0e0vjNgg4INGE5E48jkASTSCAAwhOGAEADiGQjgAQkwOAwA2Sw32D200wgYARf8v+OTShR+P2DUgADgAMSxiBA+BAIICEEkvAUP0NsAOe++69y/33/+DeN3888k1r07fuCMwewhJLOM/EDSG4nsLuIORved2685775L/LX/7O94zkQcNtKYgfEnSHhBT8DQQpcAITUhCCEACggklIYBK+5z/+TS5+RkgB5gjoDAM+4227M1sSlge4JkzPdWYDghHchgQmcDB8OARB84ZHwmaYsIdAlE762uKE9QVRb0PsyApdxwkaOJEGItiEDiSQCAnoAABTBEAPJPCEI0rih90AQv1CcLpNFOCMBdgADTQhgQIkogBUfEIJAECDAszxEHD04iHAuA0YvFBzZnSjDuwIADkeIQhHAEAQJMCCIQhCjkNgAQt68EgWWFEEbYzkJAVRAglAIf+PcqQjIWlgSQkEoZAFmEEJEhlJUz5ylYgUwRQlcMer8VEbRURA2jpxxhLkYAaJbOMGCkCDQeqABQVwZBtnkINUAqAEBWBBCWZAg2U2cwZYjCY0qdhGUc6xBFDoZAGeMMgNSKAHQ4imMQEgTGLOYAMl0AE2tXZLbCwRByiryq8ocUYJzICQbYwiADaQAwCIIJrsdCMAmjnQeYoAkwpl6Abmmcdu1nGOIggCC5o5xzwCAJlRzMEGEirQDWwgnImkZxLJIUa4NSGfwUFQPyAQM0acURA37SZOqQiAiiq0mx4VhE6BylOfenOhGwhCEAjp0aG6UadaZME/N5BSq9WzGn7/dBsgB8EwBNlJQUl6xBlpsFRsQhWZQ4DmKZ360QIEgZTV/OlTk/kEo160p9QcZEepeUg7ppMFCR0EF+NKSVuuVBy53KUiQkIejTgCjXCkJFRFgMwNXDGwgRUBFIYJTLb24J9t5KYb71pXOBISmgWgpA6GyYIonvWMM+hisZ4SAKjs4qrTuKcjDiMQBuiRV985AHtW8Y6hEU1FLSVjI2KzEL389hEBicdR9rEUkpgEJe5QSgTa0ZSnQOABU/lKI5rLtPpkFQFbXeypmlvT5yIiTxVwQDsycxeoAMcwiKnLZhCyHb6EdREtutbJZqYy+iQ2Egz7z0A65t5DNKAwXAKK/2o+4xug5EM5AcCUANpBq9McSRHVCVIh8kkz+uiWEg1YrwL2CYoVWMACPmgFETBwrHY8IEwI+Q6CCoIf9BwIQVHijYfoYdxDCCdLqPLYYbmR3DI6xAEMMFkjetBMhULCBwQwgQ0IYAMPmIIEBLCAIDBAgGPZSUiBeYByXESRBwTEsUASklAsFJgrZaC9iYiPknFz3vRaogGwQgRqC3DZR6wgy14uAgF24AELFAEAjS4CDyxAAgCQwAI8AMAPMLCDFwuCBDLAABG8DOMicNrLg9gBATAgZjL/QAYyyDQAfIABDDwaADCe9KxrLYMfWJrSsM50EcSM61tbowJ+epOG1v9rGhq95yrJjhIAGnCX7/QjEQaYDZJZvC3cHBgVR6gyNSWhaCIIwgME0ACuCeADVfPg0DIAgAwIsIIfcNkCJiizvWVABALEmwBczvcOCLFlE9CYzFrOMgD6TYR5PzrdAJc3EfBNbwus2gIaULe7ebBoaoVkUwx+WFtOfIogDLMAUBBoJCxObABEXN4aIMCtyQxvANDc5mWe94vz7XIao5vGgwAzscksiC0DQAMmePGqXW6DQbgYA/m+NAEq3W8SgJkI/Za1u3C7jCafAqJpdCQl9i0Ijjd91gBfgSCwvGVfEx3nOH+xp5fec0IIfcxlhnuW5R5juq9AAzZo99QtXmn/wgPABEg/e7y4ngwY7NDPoRjCyVuLkyI3YssW+EHbAcADDWAA8F72QMzVvfAw/4DnipYBCX4wcLrT/dP+dnveia5zEvhAzHQHs+rJLPUi/CDjgrC4zOvFeGTM0HmloOwZN7AFelDgAQpIQMgZ4YEdxNwGvvaADTTgATAPHACqNjekEc5zXOfb33VP/yDIrO63E736o8c90MGf7i1LPd8mkPWhCYDqxS/ZGvEDPqVAAycnAUeAMq3xZtyWCVumdgCwAj5ge4AHC4ZHCPb2ffJSfMVQPXDjOaIgS2h0SoTAW5uygJbAcfPXeQAXaxQ4dYUwb5VGfP83DY6HQKTwWWeU/wOFxVV+0luQ0Ggxl3enwAFESISZcAIdEAOhEAMdcAKI0AEt8C4zKA3HFzijMGi1JCjVthBCwQgroGoAZwIxhgoDUIZlmAkoMAEcEAkTMABryAgcMAEogAgToIRsooHCEIC8IwpUBltrlAgMs4XOlQgkQGYAhwG+pgplWIQAUAMT8AGN+IgAwIQdUAOCUIcnMAEA8AE10AGVmIZr+AEt4Ima+AET0AEvoAKEgAIdMABCEAOgqAJKOIodIAROGIcokIYqMIqaCAB1OIkToAIv8AJOCAAqUIsT0IvkgIfAwIEh4IGfsFRnpAMqtwiBWB6H4APnt2hap4gDkIxKyAGuGP8DA2CJLTAALfAC5QgAA3ABZ9iKLdACFyCOmjgCFzABLTACAOAC9+gCA1CMAHACIzAALtAC4uiOHQAAI4CPF6CPbUiEZdgB7qiEA5CQrTgC/qiPKkCQEzCQ/sCMvlCD/AMKR9BGafSHCLYP1waEAKcBFuCArWCGFSkINdCOLyAIDZmMM0mQgnACrigIKECPAHABFyAEcuiTHTABQvCNhPCQACCOUSgIHDCK7uiLbiiUG6mJM9mKguCPANCKc8iV+zKFzlCFofAEk1eNlfCFAJdlPtB/rnCGq1iGdjgACwmO7JiQT8mUUsmUJ/ACA3kB5JiUyfiGl+iGe9mLG5mKXvn/kEIplFs5AILAlWIplstIlsygh6CgfGGXCYXYloiICD7hjclYivwokU6ojmoYA1qpl0N5ASqgAi4glEnIAa14AkQZAxxQA3Z4mGoolFYZjB7pmEwJmRYpmV8pmeconMh5meHgjNC4CZLXT1VVCdrYljsgayRWD1kymqCgAkLgjs0pk5K5lBzwARfgAh/wAeHZjq05CH8ZkUKpjnaphPFpl6o4CCgwkC8AnB+QkcN5lcXJlJE5mZL5ARfpkWMJDiIpN52gWcsngpXAkun2kgOGIEWhgJ5wAu1Zhi/Qm9eAAroZA+n5kZiZDGbZCTTwTwWQA9UpCV8YhGIIl4eQJQLR/4VHmI9mmISQuA246aEAOQ4gmQua2QmD1EuWAGqgOYaLIBoLMX2QgAI14I9l6AI1MIfPNaS3AJ2c0IctuoOS4ANbBnA7EIOO4AA92BuT8AExQKV22QJY2mBaWgsNygmDRo2T0GjnpwFEAJOQAF4LcW2NwKb02Y4tEKQNxjPdkKKZEG5+OAkxGoZFQKOSAAHVpiaLAJ5mWJT5magitw10I4CZYHJnlHKSoKSHyKSZkG0fdggc0KEDkIqeumfacD/WE52UAHYbIHZXNqaLZqadgKaBdgI66qEx0KPP1QAGEGhCpA0wUD+3kwnTGU1quQh62pJ9OgoPMCpSOpBVeqWeSv8xrXpc2fA7CHA4l8CZSQUJkZplk3oKUuqmCxmnnkop5YUNoWo8lrCi1PkIJACGq6aqo0CoZjgChzqr0mEn40piBWYNtooEuAoJIIikjkBrbal6pyCMmyoEhomwWgEgB8EtDHuiv/CsbmM2lYCDX9oIHlAEe7oDfioK4CmertipHisdzbUzc+oK5oqulICFjbACRCCjFkCpn0Cs3hqrx3qziPASWPIezNpt1ZCvKStuKEmIABt4pZCGSWulyMq0FzOunzoNDxuxjUCqhFathWCxKwisoBCvBQuuYLsJO6sKJhutklCSy8erh9CyLxuznsCmrViGBouoc5sJdZsKPTv/CWh5RpSHCEJLtEbLCTFQqEVpuIerCYl7ClQbCerKt4Xwr22ptTLboZyauaKwuaVQtpEwrQaICJt2sW7bCcRKsx/6taj7Cao7CneLso4wsetqCB5wnWQKuJuAtGboAkubu6Swu6KwuI/ArytbCC4WhC45uZgAt99Kr8w7Cs4LCp3rCEdKSIXAAwArhqDApvIKp92bCt/rCaw7ZVWmg4UQu4c4u5lAsGV4AQfbvlRDsrXQBNDqu4twpyo3vNsIs58ws/srBDbrv+4LwLTwQnjDCHqbSihZvS1ZtBsKqx8Kwa/wvpvwNwjgBGeblmV3vgKbo0nLoyAMCyKcCcLjOmY7/wi6Knb2u2r4awndmrxy+8IwLMGwIMBwQ8CHMK2UR7yLZryVwInyKodATAsxfAkUrAjqeko8MKbXuwn6+6aYG8UhLMSuQMImnAjS+7rCRwDipwma2sAPDMazMMWUMMM4YLYTS0hZHIY7LAkM7KFvDMdSLMarQMQhYMSDoLL0q2gAN2qYgLzGiruAbAtyLAlVfAhAuwKGqAF77Ahc68OQHMm3MMmQQMaH4KXjVgRBKAPYywjaa5c/DLbKiiIvAaWE0BK5IMqOQMe4irbU6AGZnIiS0MWFy7wWYTKNwghqGgm8MYMNkCPyda/DQMhGfMG7qmmpvMqJoLEN3LG5WxgQwP9boJEUS/EgYqGm1DWaVUESABAWaZElKgNeByBeyCwQtTK2wlDJg4DEIuAB85ZuxvYIfVyzL2wRChABadIbl5EZ6ywXFEZfAuATA/ERqsEargERCpAP/QURtBwaIPEWiIDLi0DKNoxMadRFv3eITIwItWuGtxvFFpEBnHEeF7ZhCiIYrYEhANAa9NAbXDIINyJcF7HM0/YXWZI+RiKyBCbIpaDL+VyAR+AB/ebPj4ACxUqQywvG3cElQhYlZaGmPD1hVXEhSCEXmuIOayFkCGJ5hrAPg+jTSS0M0iwIwHtKJHB+NtCNidDKVsq9WH0RgLbVT6JfAEIldmEUbCbWIYv/Y2YtXnVmAHf2CHr20Uo9CpUsvToI1W3ZcokguAXbv6BsGxeBE2qKKOwwbY3SG/1RJxShppZCMqG9GdN2qYJ6CNm2GgERtYr6C0DwQmUMtHnMZXhdCF18uZ9dDB9nbdDMCwGoS1okbpSUxmuMCBzgradb3Acz2Z0AA+YaN8+ERtT42yawyaJohspo3dfNC0wArUYAAxc8btC9ytNdpV9s3qCD3ZkAAyT8PoqUlpisx4ow3mVY3vR93riw226DA0DwuQCAyisI397qAvM94PWNC8udNq4rAv2dbsB8CADOlxKeDXKs3W4TN1dszQ2uCPFNkBH+4RNOC+ntNut9xk/d/88asMKE0OECzuLXIML4PeJLcMdzdNKrltLGKJ4QruPc8L4GDkNeetlgqAH/bAgfQJ8XYIlInuT2/QgV3t3TaGl2TeQqIJ4dwNdXvuNZzghNsN0pYMo0gNkAp9lSTuVWXuZY7govPjwwwMsiwAN2HdyEEOYRSeZ0buasAAO5FAJJQM2OlMZwLtxyPujfULdAsEM40AT6DN6bDOgVKeiQTuipEKqAo65d9N55/eidHulnTghpTkMp4LpHkOHhrQg1IOacfuqevtTqrQVHuq4M7m/Yy4r7+8e2rg3MaOgjngSW3QMZrgEbbgiz7qGfPOzEfuaTfuBNALQ+cM15PbiwKf/ta5PloA4CptwD/NySzV4Izx6r0e7t0x4Kq249KSCNaSvkGJDSwN6Ows7uzEBbGWCCXHfnRmAGJqlG5S7ViZDuL7Du+r4MEOZbtMoJMHB8iI62rVXXKJ0ISBjsC18Nzwd9AiLZnZACO3QDUkDSu+rmYaYIbViGQqDwG+8MzJEqI8sJ4X7hFg/cGE+lI8DNLz8N59EqOPHWmeBCNNQFn5RGp8ToKm+GLeDyPc8MRYGjII8JSQCtTpAGLOqi4O3nPanzPP/00XAXE6bWuV0JET/iZzC+c0TqdMj0Tg/2y5CzDz8JIr88UTC/yj6msa7SXg/3/xA64X6nCx6EjJYIK4//jm/v9+0uCURvPVVgtct+7oOQ4juv+BzRNVXvNk5ABSeXctl+4hx+jgGe+Ja/+I5w9nBzBQM/BAXP7ImQ4kde+pefRHW/O1OQlvTOxDgu+/cyRCSMAGxg8k/Q+lFOCLC/4ryP6oyw5DiwBk5NAkFY74iw+8nf+4uwBNA6BmoQgihf/JP/4Mhf/cqPCKgfAmCQ9T1w83c9/aLv4eLfEfhCQcuTBWg0R1Gd8oig6bH//tYPCACCg0oIhl45BQUzPTw2BAQ2PIOUAB8vAwMXNZWdnp+goaKjpKWmp6ipqqusra6vsLGypQEBlUA4hjhhigU6IhaQBEQenyoXmR0os8zN/87P0NHS09TVq7WUSyGGZWSKGzSOkCYkn5eZm9bq6+zt7u/w79gAMEaGIVgbiiwiRRqQxIwhG6AsnsGDCBMqXDgNW4ptCNBY+TZkBQZIGn6Yw6SJE8OPIEOKHGmwViFDXPQVkNDvHwEZxTwdS7aMpM2bOHPqJFXL0Jc234J4kIFRoycUHNPtXMq0qVOE2GjMUJTjyA+XGGJ2qjGw4NOvYMOKjVVLR68SQzEW+YSiAzoVY+PKnUuXUi2qPUhgXfGJa6YXH+oKHkxY5zwPRIStPepWE9zCkCNLfmDAwKDKDwAciAAgwoFKDg40kIWNhAlIkvoOBCy5teu6BgQIGO1Atv/lAA40C6gUQIBlUgZGhwogJjEkC2wbX3j8urnzr7EFVADAwDYA3LoFNVhw4IDvUQ16fx4eAPUkT34HsH7Ovr3O2Ap8C4hvWcBn7wAgJEgQwPvvUN7ZJ8o8n5ygHHPuJaggSLEFsB933wmIXwYC5Nbbf6HENh4lBtRSywG2fDJBJgMIEdiCKKaIUIMRCECBfwBIuNuF1303ioaddOghiJ6c4EImI3Cg4pBEutMgZbrVd99usS1gAIw3CkheJyNm0sKJRWapZTQNDgKjjIK0mEB1GH7SAIUMGJDZJwQC4COQQm4p55w4BWgdmyECUOUAV9Lp559PYfPmAEECauihOdX/smefiDbq6Ee1wPnopJQe1GalmGaqzqWaduppM5x+Kuqo1+RJ6qmo0mJqqqy2ateqrsaKaqiy1uoprbbmWimuuvbaKK++BvsnsMIWuyWxxiY7JLLKNqsgs85G+xy00lbbGrXWZksYttp2m9MDDuC2Jp7elhtXdd4xMKW57D5FgQALALCAi6Bw2+69UAlgS2+m6vghiB4GLPDABBds8MEIJ6zwwgw37PDDEEcs8cQMlykqvzX2G3B3FBvMcccDfwzyxgCP/K/JAouMcn8lr6yyyTyiSiFnLWZQL6xk4fyKvaPwvC6oOu8ctCs+/0wqBPMZEB8ENz9TdNNAR+3M01BL/80M1X46EJ8CuVV99dCsYN2J2K86DXbYZ5c6ddquks0b26i4PYjc18Edt92n0C2I3no/WtkzfzcTODODy1L4LIcbbnEsicPSOL6QRy755JRXbvnlmDcHrrjMQJBBABmMK0sDBjA9y+Z4h7J56IgLB8DmDoi+SnCDeA667KrQTgnpprOiuyCo64quAOrOYmfxoyeg7ywNKH+AArE8MHwCuKsSnpTU2Ud8K9dveDz34u2ufOqDdF++89Db+m6881IwCwUPPEDfLNUtL0t8rju+PZSuBDje+vKi1yr8Nwj4yc9GqiDgIOpHPkEoEAD46xXGMNaMpZEmAS1qoCcaMJ/4xP8LFtIjngKmwzgpTdB+s8PeICzoO+w5KIOtwBEAOKgAD+bqhBoExcxG5yIK6i9N1emaKx5QgQTEhwHVy50Jl+dDJW5IEDuMoZQ4SIEmpkKGsQFihWy1w5oxo0UkJItsxpjD3QnIiqugkC3mVcbLSKmLArBZC58IxlfIsDdjROEVp3hGPboKaQpQmgB6B4t5KaAWi1MFBCpTAekQ0hXxoQCZYFEbLQqRe2hSEyAF+chTnIl4agrgIQOQSFJ8Mk0PWKQBGlmBTpbilKGM5CRtpbX5XBIWefTjznTJveok4JatiIDyDhkLO32nllxrhTHrk0cNLnNuvCzFMxvgS2Bm7pr/2MymNrfJzW5685vgDKc4x0nOcprznOhMpzrXyc52uvOd8IynPOdJz6VU5p6jCE3+muKZYD7xGfqs50Jy2TMEOiVcqZASQqXRIVeyyaACbYZt/tYhClTgAO6bIXf8AwFS5oeUHTUABXLjmQNUYDQVvWhGV2lSlHInArIzwEvjB7rX1RQCFz0pADrUAAdYhqUnXSgFuFMBy+C0pZSozSEhsFDc9McB21nAmkJzADl6IlwvgulFURoApuEmAybNDHau4wAIeKcCuTmqTgEA1s04NKKikE0tLCSABAQIAvrhj3+61KDYOA+CARAm9HpjV9ksknj9CcD6WvRBQSwWXjVy/0AjG6AfBjgoATUaXxYTi5/aLCAAn63sZSkhJtHgJ0bEG2Z1ptOiCMzLqpXwTg3rKtsaMZMB8ZmOlOzTgCNGQLT7AUAjIxCANME1oWP8DI1aZAAK0bUyy+urADgjCAN4Rnm27Yxv5mU6CLAxAPGhxHfDKy/l2YxCFeiPb3qTUe4Kwqy7QRN20KteDEnptH1UEgCMWAsVUgI/XcIPjQT0AAHtVrnfoa9/5vXZUh4XFLKxy3cuRKML8VVfXQLA+iQ5own75rQO1JeH/iviedRmkDVKby06aiMQZ+c6ASKudDxEyPvuJkYI1u98PGTN7AS4w/rFsZCFXOEZr5iI9cvog+ZLIVdsFBm6TvIPB/WKYfvxiwLhfTJ6dUQhJ1mUEl0W6XSad4AxPYCDDKCAda/3my1/KL4RMIBn0azmCOQvafAVRH6FzEY5r5F6JN7p8gQcofEISHkRaCSCSUnnNVcgA9aN45JNQdAna3dM32nRCKscohDONrsVjk8C3Ade2TR2b/GBl/SoF5vpcJh4LP5PqUeNHyybOjOvZgAh8dgA/OZYyERUHn/2G8YQC9oWhA6ygBywnxZ9BgI2zHVHhU3dSReLg2+1tjirqO1ue/vb4A63uMdN7nKb+9zoTre6183udrv73fEMBAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of exercise training on dyspnea compared with bronchodilators and oxygen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Am J Respir Crit Care Med 1999; 159:321.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18558=[""].join("\n");
var outline_f18_7_18558=null;
var title_f18_7_18559="Subcostal view HCM";
var content_f18_7_18559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcostal long axis view in hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 216px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADYAQ4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VyaXJptFPmYC5PrS7iKSimpMBwakz1ptFPnYrDs0uabRTU2Fh2TRmkoq0wHbjSl802imKw8tkUbs53Uw5FPQZPqaLCshx/LFaOqaLqWlQ2c2oWksEN7Ctxbu3KyRt0IIr1H4H/CpvFs41fWQ8ehwPhQOtyw6qPYdzX0v4n8KaV4j8PNo95bJHahQsRiUAw46bfSlzJOzCzZ8IWNjeX7slja3F1IoyVgjZyB9AKbeWl1Yy+Ve209vKOSksZQ4+hFfVXw607S/hJqes6d4ivre3N5sntb+T5VliXgpnswJyR7157+0f4u8OeIb3T49DnhvbmGM+bdRHKkE8Lnvjn86d9bCseIA80uabnnoOvWm5GeuM0XYWJM0ZpoOeOtKMdqLsVhQeKUMR0JFNoo5mA7cT1J/OlDtj7x/OmUU+YRIJD6+1SLKc8moKUHFJtMaJ9/y46/WlSUA9D9agzS9KWhXKiczdhnjpTlnJOCPpVegcGqe1gcUWUk45z+H8qUOGOO3vUKOOjZz60hIAwRk+nTFSRymdRRRWBsFFFFABRRRQAUUUUALS5ptLTTsAuaAfem0oqlJhYlQd8V6d8Fvhtc+M9ZjuryB00G2cGeQ5Hm4/wCWa+ue9eeaPZNf30Nv5ixiVtod/u59zX1z4A1w+GvCVlb6kY/s9uCn7hcgLnhiB0962jFtXRm2r2Z6bp9la6dZw2dhbx29pCuyOKMYVRVmseDxBZTXKwLJmVxkKB0HvVqLVIZJjE4eOTsHHX3FYuEupqmil4v8MaZ4s0eTT9YtkmjIPlOR80TEY3Ka+L/iR4NuvBuvzWMqXD2uT5FzLAY1lA6ke2a+6t3PpxnmuP8AiLoOm+K9JGkatOsce8TABwJFIzgqD6jIyeKqD+yTJdUfC5GcgDik5PWt7xtoMvh3Xp7MoywZ3wEyCTKE8ZYDBPrXP7jVO6JWo5ep65p31PWoixJyTS72HelcLEv86WodxxgUoZs0xcpJ3paj3NQWOORxRYLElFMDHHTNOyeO1INhwp1NBpRSKQ6j6daSg9eKu+lxkqDORj3FIcZJLYpokZRx3oEh9vyqbk2dyhRRRWJYUUUUAFFFFABRRRQAvekpaKACruj6fLql/FawKSznnAyQO5xSaTp02p3YgtwN2Mkk4AFe23Xh7Q7TR9IuPDF3bnULdgJLe4UpcBiOSecFc/zrelT5tWROVtjnp7KDT/CMRszd/Zo5yDMI8EYOGYZHPPaup0LxC+pWE8l9qslzPboE+zyps83aMjAA5+nes+DSNRXUIodcvEe0VzLGN+Y1YfeAwOQ3AxXTCPStE0Max4h01JhLPuSFCUmIJwdvTpwfwrr21MFqb1tp2oqlpeOM3AHn72bLJnBCmtjS5LjS9cmknviyP+9kV3Vvmxxz6dRWHqGuaReeGpdT0MubO4ZY/wB7cZuBJ6eXnp+NctrkiQT2t3p0UjWDLulDybcuOoIPPWnfmQ/hZ6x4x1uW20yG4064uGlk5R2j3RFsfdbA6968SufEV5aeLL+W5SZppVUO27B+buc8Y9qr678UH1Lw3/ZcaTi4Qlo1WMbE9cnP5GvNbybUbuKOVpQ4YbdwkG8/73NZpqCshyvJnouv6ja3lxZ2Wvac92YpAp3NsRjjIG9egxxxXlOu2hstWuoCkabZDhI33qoJ4APfAresr1IoAksjTXSYIiYgxY75OetWNXOl24jeXSvOjlt2VQJipWUjIckdcHtSmuZXFBuLscVS9qdLE8RxIpU9eRTK5zoFpR2pBSjj+dMQD9KUenejp/gaXHrTEKMHkZxTqQcHBxSg9+1SIM04Him96ce2KAQfhxS0lL6UdCgPBoFB5oH0oDqU6KKKxKCiiigAooooAKKWimAlPjXe6ruC5OMscAU1QScDqa39Fj05oHivpIxlgwZgQyMO3uDVQhzMmUrF3TILTTbq2uRNJc2m0MZYeDFKPUdwDiuk0jWorq4N/qsbvcRzBpLhgMKcYDMAM46cVmeHdJ0u4FxdaoJo7My+XuhJCpkcE1nxTz6devc2VwgWJmKNKdynHYqeufQ11q8TB6nR+MNUnsZXj0m5aC1OJQFw6MxIJYZzgZrB1Xx/rurKo1a6S5KEY3RKOPw4H4VhanqkmoEySpEkpOWaFAgOfYcVl55rOVS7ui4w01Po79nb+ztWv9Te+gsZ3KL5cblQ0eD24ySc123xW8LaVfeGb4Wnki/t+YttwI/LHUgjPPf3FfI2mX1xp97HdWcnl3EZykg6qfUVuzzat4lkUahepLIHJzIecnv+NCk5Mb0VjIu45IXZA+9QTja+TjPSmQK2PkhEgfjrz+ddnpXh+SK4WNdKeQx5LSj5gxHfOOnt3rQuPAt5dGa5itypmfjfbGM/8AGetaeye5nzo86gnSHeGiLk9ADgA1LZTTpMTEcnB4ZuB689q3r7SYdO+2W1w265hT5TGuFznkNnPIrm1Vncqqu+ewHWs2nEq6ZPDftbwXUTW1vO9xH5ZknTe0fOcoT909s1nsMdau+VF9lDKxa4LYKAfdH9adHd3cFldWcblLa6KmVMDDlDkfkTUstMz6O1WBZ3DWhuxBKbUP5ZmCnYHxnbnpn2qDHPPFIq4dc0uMfX0oH64oHTJ70wFGT1zT6YCcgmn554+tIlhmne5pop3rSBB2peM0A5oFHQpCGgGg9aBzQLqVKKKKxLCiiigAooooAKKWgUwLFuyAMrHaeqv3BFbrbLmD7Vc6haGd8RtEI/mb3+vvWAwhMalCwfoyn+YqWW6kmhhiYRnZwpCgNW8ZWM3G50UGuz6X9qsbuGNllQLuixuQ9j7/SsFr5nuJHnUSKxJ2j5QW9SKuaLol1q10LWB1DtyDjOT7muo1H4UeKrSGGSTTpZFcfKYhu/PHStOWcldErlRwKo8zny0JJ7KKkt7ZprhImYRlm2kt2rvvDHw58R3s2YdImuArkKjZVcjruPavRtD+DMmvW0hvbePT7mKUB0diWGOoBHBFJUrK70Hzt6JHkQ8KTLeWtsZ7Z3nPBWUfMPp2r3X4KfD5I5bqXV9PVbbH7slch+ehJ6jvxXXaB8N9O03yovsFkQT84ALGIdxk5/Ouq1TxJoPhhLeC9ujBCylEcIzp8vYsOAfaiU0tIbgoveexZXw3pa3Eksdsq7hgx4+QfQVS1vwhb6nOkjapqVrHGCFihlVUT3HHFZ7+PNMvI/L06+ggmlG+KS6BRdo6kg81594v8Ai7Npl5LDpOq6fqMrLjykt3KKfTd0rNe076l3glsej6d8NPCVtGG/smG8lPzG4uD5jtnvnpVu78B+Gp4Wi/se2hEnBaFNrfmOlfOOpeJviBqkkdvYxtBLcj92IWKHAPO3LYFX7/RfijaW9pe63rE+m2a4Vp5bhf3IPqAck+1XyVL6tk3g1setN8KfBNkjIVkR8kp5kw+Rvbiss/DrQW1SHZYmFUgYRPvBVix6AH+I14F4qvZ1la3fxKtykL7gUZ8ux7+2az7fxIkCRefqOp3MkYLIwlIVWPoDzVKTjo2Q+V9D6F8deCtLXwJBpMumRRXBy8O2XEiydNwA6j1r5s8UeE9R8PCOS+8hoJZGjjljlVt5Xr8ucj8aY/iTVZbppvtt3LcMdqtJKXbHp/8AqqprVxqF3dLNqZYylflzxtHpUtpxv1Hs9DMx6jg/zox6CruoacbK1s5Tc28puUMhjjJLRYOMPkcE9eM1QBOeOoqS9x+BnHGff0p3f3pgz0xyKcDnFSJi04U2gdP6UAh3ApRTeemD9KUe1HQaA9aO3NIaB9aBFWiiisTQKKKWgAorqPAXh3TvEd3qMOq6zBpEdtZvcJNMMqzAj5fXv25rmp0WOeREkWRVYgOucMAeoz607Cv0GUlLU1rbyXUwihXc56D1oSvoPYgp6cMCRkA816novwwutStYbd7qyjM6F4pWyHVv7jetWoPhu2kWC6lrtj9p03cYLhrdjviP8L49K6Fh2nuZe0XY6L4R+JtN0c27TaCfJchYriL5yxPXdnpXuet6vdrrcFjp7xwl4xJls/MD+h/Cvn7wdpvhZtKntLmK6jv4ZA0EsEzbZgTwWX9K+htE0ZLXSLOa2lnmnRN+58EnI+5g9BVystZBDsjFsdD1G+1ue+nvZVngChVtdscb56hvWukZ7PQkD3czQsQWAdshvb1z703XtRl07SHnjkt7K4Cb1jmwAcdRnv8AhXkmvfEHSm1CeTW0FxaGASQQrKwlHrgrxjPvUq9TfRFNqPqdj4813Tz4eneK/uNOmdwW2JlHYdQ3fGPSvANd8cJb2c+m2t2t7G8vnMwVgiN6oG9a5XXPFD6jFJZw/aHtHkMkaStuaMHsD1xWZoeg614gunsdB027v7pEMxht4i7qmQCxA5xkqM+9Dkor3SbOT1Hya1eT3rvE7sZDll4X8AR0qx4d1ZrLUpJnngs2I4eWIzYI7gc81WvvCniKwXUjfaNqFuNN8trzzYGU24kOEL5HAbsehqhfaXfWEVpLf2s1vHdwie3aRSPNjJIDL6jIPPtUKo76DcDsYfiXq9tftfo0NxqBUp580KlV9CqYwPyrB8QeLte8RknWtVursbi213+UH/dHFYKKDmvpH4IfBXRfE+g2us6ml3LdxOUutPuG8uNgeUdSozjaRwepB5HSh3er6Dsloj51t7S4uw/2aCWbyxufykLbR6nHStDTNCubx4WYrBC7hDLIeFHcn6V9p3mgQ+H45tIgtdM0rTrseWHhixKyAYxgD5j7k15ZfeENJ8Q6zeWlhqyWFrZqkUZih8ySRt3QqMBvc1pCCauRJs4bU7bwT4e8PuNAu5rvVP8AVvezpjce/lr0C++M+9eYXV2pdhG0kozkM/JPvXuvif4SWEPiG20bWfEV5BqtzcJZxXH9lSiykndQ0cQmxjcQV4Gcc+lY+g/CFNX1e78Pabq0E+rQXc1pNcfYbnyI5YgS6GXy9gIxxk85HqKTmnomLla1aPGZWdx+8JyeRmrd/YQBLc6a9zct9mE1zmHAibJzjGflHHJxXul9+zZqelt52qeK/D1uuN4+0zNGCAQMnK9MkfnXSeAvhr418Hw+IE0/WvAN4kyhLo3F1ITBkfLuxH8oIP3TwazbRaufK2PyNLgA4J/Cvdr39nXWLvUETTvF3hK5Nw7Ioa7ZGeZRmRFVUbO3PQc46gV4V3BHHFLRlCAHIAHBpwOAck/40Y4Izmj07YpiBsYGDSp1NNbGacg69qfQLink0oNJS0iblWiiisTUWprW3lu7mK3tkMk0rBEUdSTUFenfCrS54y2r6Vsub62OJrSRMt5Z6slaUoc7sTOXKjp9O+A91qfhD7VaTsurgFwkhAXcOsJHY+jdK8V1PT7vS76ay1CCS3uoW2vG4wQa+2fBHi6zulS3nuIkkIG3J259Mj1+tP8AiT8OdJ8c27JqMCwXqj9xfxKN6n+6/wDeFaVEuazVhRva61PhmtvwdA83iC0CozIHG8qM7R6+1dz4t+Cnifw9unaCO7sAwDTWzbtq5646123gf4davoduNQh0z7UGUPFMp2uB/dde4p0qWvM9iZT0seg6pYwweFJ57uGG8EcO6C5thtmXA6OO+PUV4g/j3UL+O3TUbiZ3hYhhANrsnbcOhA/OvonS7CLW/CD21xbRRSzAlowcFc8HB7GvEda0PTPDOp31qlu9qwO6B7o/vUx1Ibpito6vfYmei0L/AIV0SfXYZr+zvNOt7mBw0dx0Ax/eHeprrxRrN1rEYXUgt3DLtlmswQkvbGz/AArz2z8Qz3V/MHlMkoG1VgUEN7nHard9rFlpht58NatCASiHcbh/U46VV09WQm1oj2a4/szx1ZJoOvw6tbXqKXSUAuuB/EM42/SvDviN4Xi8P6gI4kuLhcfJdElUkUdjnofpWhbfFZRaXEa2rWc7TiRLiCVhIUHVWPOc0zxf8Wj4l0ltPuNKgKqQY55DmRfxrPnjsi7N6nmJumWZ3iUKG4APzED616H8E/FOj+GrzxVL4kYSW134eu7KK1cSYuZXMZERaMZUMFI3cY9RXB3yb7jcLdbZXAKqvI+tUZF2sR1xWEkzSNmfQd18QvC918TJnl1eR/BWu6Euk3MH2aQSaYoj+RCNv7xkcZDru++euOfNfilq8Pinx3O+lny9GtY47DTRKdgS2iXYh56ZwWwcctXC1KgG3khj/KpilccjrbaxstIBnaeGW4UhQikOPck9K9i+AXxEuofiTZWFxNENJvYjZ7QwADdYmI9d3y59HrzbRZrKPTfLvzLFcSKFje3gJFuD3z0NONnbeGr+D+xdRXWbyVQxaK3x5LdQVZuM11yjdW6HOm73Ps/4keJLCy0q/wBKiu4RrEtqzKgHmPbow2iZkBDbQSOR069AxHzh8Nrm28Nanqg8QW90twjhEmiY7/NU8hT3z+oqH4T313qPju1igjjk129lZWe6k3C3ABLSE/xtgH5e+cd6+sNQ0WGPR7tNNtoFvTETG5QZLgZUEntnj2FYpqlp3NNZ6nn/AI38Oa54i8c6HqX9oeHLPS9KvY7yC8FxKbryVHzxmI/ujklhvzwCPx5zT9M0/S/irF4ivPEngnQ7OGe6uJxYao4m1EzE489JGCLjO44J5HGBjHlHib4geNby1uLjVHXT4C3lLbRDy3I+h5z7Vy+sanaW0dld3kckkRIIhkAJJ7lvWlGhp7zsN1ex9J/Euy8OeNtes7+PxH4RuLO00m/tSt1fRvslmRRHIByAFI5bqO2a4G88MeH08M6rplh408A2st94dsNMfZqsaK93DIGllfA5DYOGwWJ6gV4144+Is2tQxWWlW62FhGoU7QAz/XHauBJLksx6n8TUOEejKUn1PrWfQPBsfiebU9L8UfD+0iHiSw1W38rUIY2itYVAljG0fKWOSFB2nuRXybdCFrqY2iSJblyYkkIZlXPAJxycUsCxspaYkKvQDqx9K0/DBthrkM1/aR3dopPmQvna2Rx93mhRE5GOQTwT7c0AflWt4j8P6l4fuIF1S0ltVuU86DzOC0ZPH0rIC85/SnYBW9zz2oXvjpTSeQeM0DkjnvTCw+lpAMUUhFekpygsQFBJPQCu18CaHaS6xbf2soe3kYKMHKNnsT2NTCDmy5SUTD0zQX1M2yWdzA1xMdpiY7Sp7V2+gReJfAWrFbq0eCdF3RyEZDj2PevW7L4K6ba3H2zT/Pntz8wiJG5T6A/1r0XT/DtvqWhJYarFcT2Y/wBV9pH76Aj0PWui0IK5naUtDyax1jSfGpt49YsotG8QS/KLqP5Yp/r6GvRfDEHjXSdOns2S3vDbHbB9ok5dOw3d/rWdrHwuYWjJp8lvdKrho4bhdpH/AAIdDXR+EYNahvntrxZYraBQMStuH0U9x705OLjo07dxxTvrowsvEGr3EN3Fc6V5dyiMPsr/AHj7jswrxK7+OviHRr2402TT4IZIZCu2UH5QD0FfTpALBiAWHAPcfjXkPx5+HA8SWD6xpsKtf26ZlRQFaRB7+tYxcZe7axck0rnhXij4veINZlla3mNoswxKqdT6YPpXO3Xie91LTYrXU9QedUB2lvvD2JrBu4fs8hWMk7SeowQe9VXbccnqetDk4k8qkaRlsBbs6yXRvCeMHAH41pQeDvFeq6L/AG3a6Fqt1pW1nF1Hbs8e1SQxyB0BU5PbBrmfevorwB8R/CGmeAPCGj3199k1u0sdWt/7TEE0n9lyTy5jJQDbIrr1wGKlR0yazlJspRSPB7bQdVudDutZt9Ou5dJtXEc92kRMUTHAAZugPzL+Y9azK+ifB/jrwFo3g/TvBF7qN5Jpt9ptymqXsMDfZ0uZ8MGMZTzHePy41VgMfMetfPDqFdlVg4BwGXOD7jPNQUG48e3enAFyPmGfc1s+H/CmveIcnRdJvL1QcF4oyVB926CtR/BfirRrvyrnSbmB2OxgUVv58VvCnN9CHJLqY1tpM7xme2eKZE+9tIJ/75612vh3wTqF5Al/pV3byIOJCEAeP1+Vuv4Vpa34M8T2ul2cnlSLb4AXAiMyn32HgfWotM8LXem6nA+t649qZMFYtk35naMYFdMYW6GDlfcpX3g7xAdRnSJLiS6hJCEjaZE7Njpj6VFKt9BiTWbRIxCgKQoy/MR3fByK9L1G30qxtVms9Xu7sZBEjTLFub1XcQ20e4rhTp+la1qM0cc8UxOS8lzcrGQ3cqc4YfWm+VapisSWni3Q9D0aSLTtPgOrSSCUTXXzlD1+Vl4HtXo3w7+NnibSIi/iHOp6T/Cbn93KPZJD94f72fqK8uXxjoPhizns9G8P6Zfamcr/AGjcr5ir/uoRj8a4vV/E+p6vbrbX04a3VsrGqgKv0A6VjOcXo9S4xluj2T47eLPC+uXen634fVvtExzcwSKVkB557rnjqMggj3rxDVdSm1C4aSQbVB+VASQtUGYseck9qVcn3qLtqxpy21YLjuev6U4suPkB4HNIB6flVqG1Jga4kSQwg44HU+lLcG0FvaTTxl1XEa9XPQV6P8H7HTrXVxqGoRLdTo3+iwP93d/fI7gVwVr50xW0RWAY5CZ4/GvR/hvo8+p30sEVx5ECL+9mVcttHXn+EVrTir3M5NkPxF17UT4lv5kmgnluo2gYzosnyHglQeEx2xXmjWsoV3jR5YY8b5UUlVz0ye1et+P9D02GEadoeHu5nBdmYtI59/Qe1cfrNsdE0+506K+dRKFF1HC/7tyOQhH8RFFSHUcX0OMb0/Q+lCdO34VaXTruXTptQigZrOCRYnl4wrN0B+tVBjPfA7VkWPpKKWkSdZ4MSLRXtNZuY4L22lJjkjB+aLn9DXu3wz8I6fe+drmgubqB3KXWl3qYVh2ZG7H0PSvmiBCLZmtpmED4Eo9D7+3vXqnw78aa94aktrNVLRcbF6kr7etaxcrWQna92fV1kscMIECGOMYyh6oat9etchpnjJNUtoWs7YySuQsgVvuexHUV09rI7LiRQGHb0+tYSi1rI6YtdCV3CyKhzls444/OmXUBuIwu9kIPDL1H0qwGz97io5CVV3hHmMo+4DyfaoQzitSv9V8K3YdbF9S0mQ/PMj/OjepFb+h+ItM1uMfY5sykfNDIuGX1B9aj1m+t7jRpwJGtpWBUgj5kb3HevnDxDPf+GtZMt/e3DzI26K6tJiFPvt9R6VuoKau9GZOTh6Hd/E/4X2y3V3q2l6dDcpNy9vypVj2XHr614Rrvhf8As66eNrQRzbTutPM+YejAntXvvhL4nG/t4RqUyajHErefc2/ySRA9mTv9RVnx/oPg7xfpDXdnqdtb30Sbo7gS/KP9lxmtVJ2tP7zNxT1gfJN/Y3FjIEuYyjEZAPcVVOTzXSanpxivXtpNRhnkQ43ZL/gCauWGhNZNBLrMEL2MhG19+3OTjqOlZOld6DVTTU5AqR1FWrSwuLvf5ETPs+8AORX0Dpug+CtIWObUPC2oQyrh45TMZ4ZeOo46Vx/jXWtHvElbT7c23lnia0t/Ldz/ALTZ/pVqglqxOo3sc/4NvtdtZja6drWrWEX8QtwwXj1GRXrEdhqGsWKS3PimOe5tBuUXTOjZ9wAc/nXiGlazNHfR3E+p3EEaH7qud2P613No2v69NHJY6rqN1bsfkVo0Vcf3c5rSDj0WpLvszprjWdS0q1ml0eC4l1KVNsuImeHHqq4/U1wGp3PizWImu1/tACLKnbF5ap68k8V6f4ksvGWq6dbafpvhO+tVhUK0nmlC+OhV1P6V5zr3hfx5Z27HUor62tG+byJrvg49Kcmm9EJI8+uorgSOblmZx3Lbv61TPWr1xe3SPJFPgsOPmAJH41U8xihBVTz1I5rllbobRv1PQfgx4esPEUvjSLULL7ZLZ+Gb28tEG7K3CbNjAKeSNx4569K6X4afDqz8deEpdMFibHxNperW73kshKO+ny8MSrd05bPpj1FeXeHtR1nRZ3vNE1G80uZ4zG1xbXDQMyEgldykEjIBx7CrVtr3iW91mea01fWZ9X1BBbTyx3EjT3KEAbGIOXGFUYJxwKnlY+ZEHje60y68XavL4dtls9HNw62kKMSBEDhTySckDJ9zWlb+Erm50/Qp7ITz/wBoW0txLhPlh2TSR4z34QH8a1L34d2+mbF1vWZNMnaPzPKubQBh7EeZ19q6nwz8W4fBvhGLQdGt/t80O9UvZ4woVWdn4TJ7ue9VGLi7yE2pLQ881TTWs5ha+UIYVwzbz88g9T7elXofFzx2Uen21hAI4xtjJG8r6n3NY2s6nc63qs13K/72Y5Znb1rWtri00fSmhUCe5m++VXg+27uPpWql1WiMmu4kDmWNbe1VIZJ3xLO4+YA9cn+lfU3ww0CO28OQWFlpptNOwHluZRiW7b+8R2FeB/DfT7pb6PUJ7CKd8gwLKPkB/vY7mvrjQmvP7KgbUVCXG35gOMe2KJtxjcdNXZxnje18NeF9JeZ9NhE8zEiYLkqccszV8peKFTUdQa/l22tlIxEK/wAUg/vY7CvUPjrb+KrzVTJq06/ZQSLSyhB6Z6t/UmvDtQM5uiLmTzJBxwcgewqW5KNmVZN6EVwU3MsBYRZ6E8GnGwu006O/a3YWckjQpN/CzjkrTJIpAiswwh6HsaYJGMYTc2wEnbk4z9KljGjp0oqzdWT21paXBmt5BcqWVI5NzJg4w4/hNVqQi5p6tbb5UJ8xRyh5WRO4r1Lw7bWk2k201lLIY4zvi3jLxHuufT2NcTYaF9psTc6eftFs3WJm2yRt6VvaBr9hZ27R3q3VldRnal1ApKn2lXpmuimuTczl7zPa9MvbWwuLXUTBLC1wqo8sPKynsR7+xrsdK8RXRvkjaSK+tSdpdRtng/3l7j3r540fxrNZXcskVwqW8xwyOuYJiO4/uNXeeFPG2m6tqMD6kGs8/ulvEHCt2Vj2FOXLPcqMmj3q4u4reASzSJHHwA7cLz6ntXIeI/Gv9l2lxc2VrFc+WfmVXAbj+YrmPiJrGoaHp5bT9QglgkXIjfDpKp6jHavnLxLfWly7zW1/d2j5y9puJUe6N3HtWCpqKuzV1NbI9f8AHvxctdR05DZQW5uD8pyxV0J6qfT+teWa1q0mpxrPdExyA5jZnC7h2U/4VyMFpFczH/T4/m5y/B/H3rY8LX2m2169nqfl3GnzYB81clT6g9quDtp0MpO44eIbyOcC2s4oJ4wPmgba2fU/4UmpeI7iSWePUdPRGlALhPl3sOhP/wBaovEWmaDFPN/ZepPuHIikXIx/vdz7VzsgcKreaH4yMHJH1qZSkuo4xTO4stcsZYobjUdMhvbh22gNN5QTHoMc/WtdZW0+7OpCw0gWrj5IJZ/NcH/Z7Vwek6sIYXtbu1hubV/4GyGUnup7Gu503wTqT6U82nSzGxkUGSN0JIHoOP1raEpS1REly6F+48U+PPEtlNBbXRFjCM+WdsaAAdB6/nXlGoNMbmRZRKrbiSrtu5re1p30cSWcJljjfrE+4EY9+Ko22lateWYnhhkkt/uluB+tZSjfSKKi7asxav6Rq9/pE/nadcPBJ6jnP510kHh2HyoZoNRs7aQD51mmXOe/PSobLTX8R+N9F0WW+DQ317DZi4QK+wSSKhbgDOM5qHT5Fe5ampO1ipfeMfEl5L5t1rF82f4RMVBHpgGor7W11KFPt0c7TLxuWY4P1BzW9pngI6h8Wb3weL4x21ne3ME980f3IIC++Urn+6hOM9SBUXjXwavhLx22im7+1WZEU1te7CqzQyKGV8DOOuPqDUQ3sipbalTw/wCHLXVpfLjnuJZW/wBWkMDNuP8Adz2NejQfCbUbiyxpulW8twUBUyXSRvG3+7kkn6gV3nwx8F+ZP9qursSyFAIvKXyzEMdR05969JGkWWhwKLaC3Fy+QWuSS8zeuQc11S5Ye71MYpy1Z8majpOkeHp7iy8V293cajDz/o8ny5/u5/qKq23juTSiX8OaVZ6dKyGIzAeY5B75PQ+9en+IfBl1NFf3WpQ3EJaUmEpEZFXnnkjIUeprzLWbLTdLvY0crfTKNxWOPIb0PFOcZLZ2/r7xJraxy13eXur35ku55Li6lblpXySfxp8unSxMd7Kdv3tucD6Hv+Fdp4du1tpnudQ0g2lmwyJFt/mH+6W6VY1uW1mKzWds9pCpD+UWG8+7E8ZPtUKmkhubucvPocqaX9v+wTpbjGJHYKG9wDya1PC2htezxT3REMZYFWJBP1PoPetjVNdi1h7UXFnBFp8OAtusp3zEd3JPFev/AA2+HyXcX9q3cAjeUgJEF/dog5xzyeO9UlFa9CdXodR8Lfh5a6Iker3t3JqF7KN0RfhIge4HrjvXoN3dGIlEXLBSxY8Ko9TViJBHEqDoowMDFec/FfXVs9Fmt5Vm82ZSIoEbbuz/ABMw5wPQVza1JHQkoI8f+LuqajqWrywrqsCoxKjYw6D39PavIpbbTYLnZLcs6Ly7KMk+w967DxKZLGCOEJbrLMAHnbDFV/2R6+9cPqsloGEVpGSF6uepNb1EkzKN3qV9UvUu5tsEXk26fLHHn7o9SfWqgUAY6kU2Q/5xSKRkc/nWT7l200H8KCauapaxWU0KRTvMskKyEvC0W0kcrg9ceo4NV7Odre5hnjCF4nDgOoZSQe4PUV1nir4jeIPFMMEesyWUqwH92VtEQqMYxkDp7VIGSpuEtka1ujKqnckiHBHswrs/Bfiu0tra5j8SaWLmzmBV54wCAT3I7V5fDNJC+6JypxjjvXR+F9alivdjLC/mAho5R8kvsfQ+9aU6mvYmUWjq9H0pr7UZRpEVrcWcT7oVaQZdPT3+les+H49Cis5IiiWUjrtaGQAYb2J9/WvFrnU9Ohy8elS20sR+Z4XIZPqO2PWr2p3w1yG3UXRF6FDQyOcJOo/hf39+9dClZWTM1vqavi+6ubCSa2kuLS+gjOfKmQp8o9+30rzvW9QtLuVZILaW0fuMh1rS1m5milU3kN3ZzDAKSjfG4HXa1VHt11IMLQQHI3KYzhh7MD1/Cold6IatuZM0lndW6osTpdqMBk+6/uR1FUJY3jIWSNkbGcMMGtQaHdGNmaKWN1xwVyDz+lVLiWTaI7iUyDPO8Hcv4nn8KwlF/aNYtbIrBhtwy5PYg800AHjOD69qklWPOYn3DsCMGmeWcA8DPTms3consoopZtk0vlj+/wBh9a3NNk1FjJHYeIJYI4h1Nw8a49uawFeWDJBK7htPuKuRakXWOC4gt2gXqFjCn65xmri47Mlp7otazfapfW8aanez3JQ4j835sj1Dd6gs7LV72BhZ291JCOCIw2B+FXb3SleGMQ6iJtwykO7O32HOKyIry+sy0cN1cQYPISQrz+Bqpe69fzFHVaF5NBuIi41JLmywMgyW7EH8RUOhanP4f8Q6dq1mIpbjTrqK6iEqkozxuGAYZBxkDPIp0etarLKobVLtiOB5kzED8zVrV9NMNpHc3WpWNxI/SOCTLj3IxS5VKOg7tPU62f4xasupalqelaH4e0jV9QjljuL+xt5VmbzHV3b55GG4leuP4j61naz8S9b1y70TUNTNq+qaTCbeK78rLzpuLDzckqdpJxgDqetcfaWgumcLPFFtGf3hIz9OK1Y/DjCy+1T31rEmRgFuT71MISvdDlJbM7zSfjX4lhuHl1G4N+jKQsbhYlQ+20Zqxpvxs1bTZ/OWKKeQnkTEyFQfQmvKryG0iOy2nkmx1bbhfw55qqI2YkLzxmru1oLfU9X8WfGDVNesZYGur1Ek4Ma7Yl/8d61ymgeL5dHEnlwlpHQLvBAKkd/euVA9f5V0Xh7wjrXiCVY9GsLi7fqTGvC+5Jpxcvskyt1NXUPHMmowSrdxFlZQFjAAVD/eFZnhfw9rnjHUls9LR53ZsMzNhU+p7V3+kfAnxVLPv1G2QLkHAlUZ+p/wr6M8E+AdK8NaVFClpbm72jzZkXBY+1OTVrzYorojzb4YfC610vWE+3WlrqLQ8yzOSQr46DscGveI0WNAqAKqjACjAA9hTYIYoE2QoqL6KMZNOkdY1LOcAVjUqc702NYx5Rs8nlQu/GFGck4ArwL45+IYBpaOk6XE8n3HVflUegr2HWHXU9NmjmEiQj78YbbnHqfSvnHX9Q0t/E0lz4jeOWO1JWOythuQEerdMVtRhZXZNR6WPK5rtbktcXgmmlf7gPGf/rVUvX84iK1gCIPvFRwT9a2vFer2mq6g9xa2/kQqe2MKPRR2rnLu8MwCqvlQjog/qe9KT6ERRWePaSC4OD1HOTTFwAf1zSOcnihMc55qehp0HAdeOaOOppR8o5PSj6E1IivS0lFZGhc/tC4ITdIzFeM55I9Ce4rXTV7VvLHlsoU52nnH+IrnKUHHSrjUaIcEzvgtzczINMvy1u//ACyuPnRD3xnoKy9S0O60u9JvYA+TlHtWw3+8BWVpesyWboJUEsYIPXDYHbPce1dnpE1rf3Sz2kgZQMuryYkBPYf4V1RlGehi1KJj3Wq6jFbI1rcC6QOFR9pEmR2K9/rWHeS3moTA3du7zeqJhj9fWvQ4bG8i1FJBqdlESw220sYG3J6e31r1XQ/C0erWojtrzT11SH5SGTAYnqAw5P1qnC61Y4vsj5Ykj2sAFdT2DDBp8PlI7C6idz/stgivqjxH8PrjVNIuLa+0yyWeCICAY29OpEnrXjur+E7Gx1G3sJo5Y7kjbJFJIAyHqCPUVHsezL531Rwn9lXFyvm2cDNFgfxhj9KsReFtXkgeVbRgE+8DwRXtbfC7Sr7Q5byP7RFdLHlZg32eFT9TnNeS+IJde05H0y5v2urYHKiKXen6UpU4rdCUpHLyoYZSpIJHpWgL2K6hxfscoMII4l/U8VKhdLJ1vbNUU8LKYcEGq+maVJqUxSCWCPHeaUKKhJp+6O6e5UdFbLKyKOwzTEZkHoD7Zr23wv8ACS0bS3udUeG8JHy/Z7tV/L1rG1b4ba3cH/iV+GbuO2UnD+YGz9ap0nvcOc87BsGhBBu5bjuoUKv4YzWnpuj3N+0YjsH95GOMD8etamh+EdRsNVLakkdosZIImbBP0Het/UNang1XyL3T7Q20CgrviZmkX3INXGHWREpdEVNH8F2F3cJDHcTC9LYzIoMQPuRXY2/wP1W5lMMdvEof5jcrLsi+mMZ/KqHhj4lWei3/APxLPCNsIuSzSOcs3qM8D6V6GPjdPet5djpS2ny8zy/vRn2UEfzpt9IISt9pkmi/s9aHB5UmpXU0pGC8SdCfTcecfhXr2g6JpugWK2uk2sdvCvGFHJ+p715PbfEy9eziM00TCSTaxkxC2PUDk12tje6jqEqQg3MaSj78EOI9pHXcc/pWcoTa1ehpFx6HZSTIisWONoyfpTIZfPUlARGQNrevuKpaXpcNggUz3FzL133L7m//AFVNcX9pasVmuoUYdUZxkZ9utc7S2RsW1QJkjP4msTxBriaZZTTMm8x4+VT1z79Kvy6nCiMVWWUgE4WM8/nXP+KZUl0959TS3tbWMb0aaQBvqueM+1XCOt5bCbPLPEviO61OR1lnSGwywd2OcsP4ePbtXlnjgWv2dXjRrWE/d8ziRx67e1TeMviM39q3S6THavDnCylMk44yfevNNS1K51G5ae7maSQ85J/lXROrFLlRzqLk9SO5mU/LDnYOm7qfeoMljTaM/lXLzXNkrC4x1oopQeeRWjdkMcOnI49aUMQflBJ/Wmoe/GR60hO3p9Ki5NiOiiisywooooAKUEqQVJBHcUlFAGzZ+IL2FEimk8+FSCA/LLj0PUV6B4J8a2a3UCXE7Wc5k3EniIgdAff3ryaitYVpRIcEz7Q8I+P7K/Zra5vGS7PyxRH94hz3OO1XfHmk2ep6XNPCLSWYIWa7ikVHB9COpHsK+LtN1G6026jubKZopkOVYHpW7eeO9fulRWvnjAGH8r5fM92q1Ujfm2Bp2sz0DQ/iBqfhG7e1juYrOJ2I+dDJERjqyfeBrD+IHxBvvEgt447W3hRHJae1h8sTe+OtY/gnVdJS+uJfELRmOU4bzVdyfcYFeh3HhjwXPYjUdJuLO78xdyRvfLCVPptYjFaaS1TM7taM43w3r+i2sxm1SxivJQfuzo74/LivQ7DxF4F1uNJJPCGnpdRjjbPt3H6Ka8Q16DZqLRRmEse0TKQPbIODVrwvBpLSn+2HuoGB+WWIcChSbdmLlSVz3GXxDYRlbdPA1sIc/N5gkKkexJxXLeLdT8AXsksNlpesWN+vBNrPtiz/ALpNcBrmsEFoYNTmuYDwPnYFRWTaTXdhIL2xcIw4DPtY/kacpK9v+CCTsdG2swXMZ08WmQOEe8umVeO5Ga3fDkFv4huItPf7LaPuwXDvKhHqDn9K4VvEF7c3G+doPM/vNGMV2nhm+tI8XE0nhuOYEAfaZ5zk+uAcU4STd7ilG2h1Go/Du+u9Rt9MW6WHTEbLTumxCM9s8/rXZD4f6H4eW3kg1i2njUbZYy6IoHcgnJJ9hXBeKfEWoX9kkc/iOC8gjGVstNgKAD13nB/OvPtS1kqY4Et5FZRuBu5y+0+oAOPzpylZ3BJPSx65401jw1Zratb6ff3Eu4gzRBMjHp1/lUPh74qrp6S20FjeW43ZWV3d2b2I6A/lXikN4Wnnmlv3t5Cc/uUzu+hHSpbLXpNOmE1kZWlJy5mbcGP0qHVT3Y+V9D6j8E6xJdw3l1qGj6jdzl90M08mFIxwODx1qzpHiqK1uJr7xE3h/QrVXKKWk8y4z3BGTXzNqfxI8VajaLaS6tLFbKwYRW4EQ46fdAJrlbm4muZnluJXllc7mdzkk+pNZzqp/CaRi1ufUHjb9oLRrRJIfC1tLf3R+7cTgpEhz1C9T6189eLPF+teKr17nWb6acs2QhbCL9F6CufJpKw5mWLmikopDClpKWgBaDQOlIetaN6CHDp0FB6YFJjim1IBRRRUjCiiigAooooAKKKKACiiigBaKKKYCU8OwUgMwB7A0UUANpyOyHKHB6UUUAN60UUUgAGkoooAKKKKACiiigAooooAKKKKACiiigBwpD1oorV7CF7UhooqFqM//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The subcostal view from the two dimensional echocardiogram shows extremely hypertrophied and asymmetric septum which is 35 mm in thickness. The subcostal view often provides images from which the interventricular septum is most easily measured.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_7_18559=[""].join("\n");
var outline_f18_7_18559=null;
 